Chemical studies of selected chromone derivatives by Nchinda, Aloysius Tchangwe
CHEMICAL STUDIES OF SELECTED 
CHROMONE DERIVATIVES 
THESIS 
Submitted in fulfillment of the requirements 
for the degree of 
DOCTOR OF PHILOSOPHY 
of 
RHODES UNIVERSITY 
By 
ALOYSIUS TCHANGWE NCHINDA 
MSc (Yaounde) 
December 2001 
ABSTRACT 
This investigation has been geared towards several aspects of chromone chemistry. Selected 
2-(N,N-dimethylarnino)chromones have been synthesized via 2-hydroxyacetophenone boron 
difluoride complex intermediates, and potentiometric analysis of these compounds in ethanol-
water has been used to determine the influence of substituents on their basicity. The pK. 
values have been found to lie within a narrow range (1.92 - 2.52), and the observed 
substituent effects have been rationalized with the aid of semi-empirical and ab initio 
molecular orbital calculations. 
An efficient route has been developed for the synthesis of the naturally-occurring chromone, 
"granulosin" [7,8-(methylenedioxy)-2-propylchromone], and several C-2 side chain 
analogues in good yields, by condensing 2'-hydroxy-3',4'-(methylenedioxy)acetophenone 
with a range of ethyl carboxylate esters. These compounds show significant cytotoxic 
activity against the brine shrimp, Artemia salina, and two of them, the 2-ethyl and 2-benzyl 
derivatives also show 100% activity as pesticides on Beet army worms (BAW). Another 
naturally-occurring chromone derivative, 5-hydroxy-2-isopropyl-7-methoxychromone, and 
four C-2 side chain analogues have been prepared in moderate yields. These compounds also 
show significant cytotoxic activity against the brine shrimp, Artemia salina, and it is apparent 
that the presence of the hydroxyl group at C-5 is critical for such activity. The electron-
impact mass spectra of both series of chromone derivatives have been investigated, 
permitting the elucidation of characteristic fragmentation patterns. 
In work directed towards the synthesis of potential HIV -1 protease inhibitors, five novel 
chromone-containing analogues of the clinically useful drug, ritonavir, have been 
synthesized. The design strategy has involved the coupling of substituted chromone-2-
carboxylic acids with a specially prepared, hydroxyethylene dipeptide isostere to afford 
ritonavir analogues containing chromone termini. An interactive docking procedure has been 
used to explore the docking of ritonavir and the novel chromone-containing analogues into ' 
the active site of the enzyme, and has indicated the capacity of the ritonavir analogues to 
form hydrogen-bonds with the HJV-l enzyme receptor. 
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Various substituted cbromone-3-carbaldehydes, which have been synthesized from the 
corresponding o-hyclroxyacetophenones using Vilsmeier-Haack methodology, have been 
examined as substrates for Morita-Baylis-Hillman reactions, using 3-hyclroxyquinuclidine as 
the catalyst and arcylonitrile and methyl acrylate as the activated alkenes. Optimization of 
the reaction conditions has permitted efficient conversion of the cbromone-3-carbaldehydes 
to the Morita-Baylis-Hillman products and, in some cases, dimeric products, within 24 h. 
Heating of the Morita-Baylis-Hillman products, arising from reactions with methyl acrylate, 
at 80 DC for 3 h in the presence of DABCO as catalyst, has been shown to effect 
transformation to the corresponding dimers in good yield. 
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Introduction 
1. INTRODUCTION 
Chromones constitute an important class of oxygen-containing heterocyclic compounds, 
many of which are widely distributed in plants, and possess useful medicinal properties. I The 
name "chromone"was first used by Bloch and Kostanecki I to describe coloured, naturally 
occurring compounds known to contain the benzopyran-4-one structure 1. Chromones are 
benzannulated derivatives of y-pyrone 2a, and their systematic nomenclature is based on the 
pyran analogues 3 and 4.2.3 In this thesis, the chromone structure will be denoted simply as 
chromone rather than the systematic name, 4H-l-benzopyran-4-one. Chromone 1 is isomeric 
with coumarin 5. 
0' 
56°' 3 
6 1 12 ... -~. 6 
° ° 1 + 1 2a 2b 
chromone 
(4H-l-benzopyran-4-one) 
(benzo-4H-pyran-4-one) 
(4-oxo-4H-chromene) 
y-pyrone 
(4H-pyran-4-one) 
• 0: 
° 1 3 
4H-pyran 
:ct): 
• 1 4 
4H-chromene 
( 4H-l-benzopyran) 
(y-chromene) 
1.1 Properties of the chromone nucleus 
~ ~oAo 
5 
coumarin 
(2H-l-benzopyran-2-one) 
Many properties of the heterocyclic ring of the chromone nucleus follow the pattern 
established by y-pyrone, and can generally be explained in terms of the aliphatic dienone 
structure 2a rather than the aromatic pyrylium betaine structure 2b.4 However, certain 
1 
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properties of the y-pyrones and chromones, such as lack of normal ketonic behaviour and 
their tendency to form salts with acids, has been rationalized in terms of the pyrylium betaine 
structure 2b.5 These properties reflect 1t-electron delocalization in the pyrylium betaine 
structure, and it was Arndt in 1924,5 who flTst suggested that the ether oxygen in the y-pyrone 
could interact electronically with the carbonyl group, thus modifying the properties of the 
latter. This was, in fact, the first explanation of the theory of mesomerism, affording y-
pyrone an important place in the history of organic chemistry.5 
Studies of the molecular orbital delocalization energy (DE), dipole moments and IH_ and llC 
NMR data have shown that pyran-4-one and chromone possess some degree of aromaticity.2 
Nevertheless, certain spectroscopic properties of chromones may be rationalized in terms of 
the aliphatic dienone structure 2a, rather than the aromatic pyrylium betaine structure 2b. 
The IR carbonyl stretching frequency for chromone (Vrnax 1660 cm- l ) is a little higher than 
that ofy-pyrone (vrnax 1650 cm- l ), but is much lower than that of coumarin 5 (vmax 1710 cm- l ). 
Hence, IR spectroscopy can be used to distinguish chromones from the isomeric coumarins. 
The UV spectra of chromones are characterized by two strong peaks at ca. 225 and 290 nm; 
chromone itself exhibits electronic absorption bands at A.max 245 nm (10000) and 297 nm 
(6460).3 
In the IH NMR spectrum of chromone 1 in CDCh, the 2-H and 3-H nuclei resonates at 8 7.9 
and 6.3 ppm respectively. These values are very close to . those found for y-pyrone 2 (8 8.0 
and 6.5 ppm respectively),l suggesting that the ring current in the heterocyclic ring is not 
significantly affected by benzannulation. In the llC NMR spectra of chromones, carbonyl 
carbon (C-4) signal is always at lowest field and is relatively unaffected by substitution in the 
system. Of the remaining nucle~ C-2 resonates at lower field and C-3 at higher field than all 
of the other carbon atoms. However, substitution at C-2 or C-3 of the chromone nucleus has 
a marked influence on the chemical shifts ofthese carbon atoms. For instance, both methyl 
and phenyl groups induce a downfield shift of the carbon to which they are attached, but 
upfield shifts of the adjacent carbon atoms.2 
When SUbjected to electron-impact mass spectrometry, chromone 1 fragments via two main 
pathways, involving either loss of carbon monoxide or ring cleavage by a retro-Diels-Alder 
2 
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(RDA) reaction as outlined in Scheme 1.6 The base peak (m/z 146) is due to the molecular 
ion 1a. Loss of acetylene by the RDA pathway gives the radical cation 6 (m/z 120), which 
decomposes further by subsequent losses of carbon monoxide. Substituents may, however, 
divert the fragmentation pattern.6 
o i+ -:It 
</0 it eD -CzHz• a c -co ()=c=o • :::,.. 0 RDA :::,.. 0 
18 6 rnlz92 
rnlz 146 mlz 120 
\ + t-
co 
,- ex)' + ~ I 0 C5~' 
7 rnlz64 
rn/z 118 
Scheme 1 
1.2 Review of chromone chemistry 
The chemistry of chromones has been extensively reviewed l •l and, in this introduction, 
particular attention will be given to the more recent literature on synthetic and naturally-
occurring chromone derivatives, which exhibit interesting pharmacological properties. 
1.2.1 Occurrence of biologically active chromone derivatives 
Naturally-occurring chromones, like the 2-phenyIchromone derivatives (flavones), often 
contain hydroxyl or methoxy groups at C-5 and/or C-7 and a methyl group at C-2. One of the 
simplest chromones illustrating this substitution pattern is eugenin 8, long known as a 
constituent of the wild clove Eugenia caryophyllata L. Thunb.l The continuing interest in the 
chemistry of chromones is largely due to their pharmacological importance. One of the most 
3 
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useful naturally-occurring clu:"omone derivatives is khellin 9,7,8,9 a natural furochromone 
isolated from the seeds of Amni visnaga, Extracts of this plant have been used for the 
treatment of bronchial asthma, 7,8,9 but unpleasant side effects, such as nausea and vomiting, 
have limited its clinical use, Khellin 9 also exhibits lipid-altering, antiatherosclerotic 
activityIO and may thus provide a valuable therapy for reducing the risk of cardiovascular 
disease, The bronchial spasm of asthma is caused by antigen-induced release of histamine 
from mast cells, and, bronchodilators have been used to provide symptomatic relief of this 
condition, However, prophylactic treatment is now possible with disodium cromoglycate, 
which is marketed as "Intal" or "cromolyn sodium" 10 and which blocks the release of 
histamine and other substances which mediate hypersensitivity reactions, 1 1 This drug, which 
was developed from the lead given by khellin 9, has to be administered by inhalation as a 
powder, and research has been focussed on developing analogues that may be administered 
orally. 
OH 0 OMe 0 
& MeO""" 0 Me OMe 
OMe 
8 9 
Two new 5-methylchromones, 2-acetonyl-7-hydroxy-8-(3-hydroxyacetonyl)-5-methyl-
chromone 11 and 2-acetonyl-8-(2-furoylmethyl)-7-hydroxy-5-methylchromone 12, have 
recently been isolated from dried latex from the cut leaves of Aloe ferox Mill (commonly 
known as the Cape aloe). 12 Traditional medicine recommends the application of freshly cut 
aloe leaves to wounds, boils and ulcers, and the use of aloe leaves and roots to treat parasitic 
infestations in animals and people. In the old Cape, warmed aloe leaves were used to soothe 
aching teeth, and legend has it that aloes were used to embalm Christ's body. Today, the aloe 
plant is widely used in the cosmetic industry because of its medicinal properties,13 and bitter 
aloe is used as a bittering agent in alcoholic beverages. I4 Aloe vera has recently attracted 
attention as a health food although its chemical composition is far from being completely 
known. It is, however, rich in chromone derivatives,I4-I8 and several of these constituents 
have shown anti-tyrosinase activity.I6-I8 Robustaflavone 13, a naturally occurring 
4 
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biflavonoid, has been reported as a potent, non-nucleoside inhibitor of hepatitis B vrrus 
(HBV) replication. 19,20 
OH 
o OCHiHCH20 0 MM Na +'ooc)lov llAoJlcoo'Na + 
Me 0 
0 
HO 0 
R 
10 
11 R= CH2COCH2OH 
"':: 
OH 
12 R= CH2C-{) ~ 0 0 Q OH 0 
HO 
HO 
OH 
13 
In the phytochemical studies of Spanish medicinal plants, Martinez et al,21 recently isolated 
two anti-inflammatory flavonoids, 5,7-dihydroxy-3,6,4'-trimethoxyflavone (Santin) 14 and 
5,7-dihydroxy-3,4'-dimethoxyflavone (Ermanin) 15 from the aerial parts of Tanacetum 
microphyllum.21 An extract of this plant has been shown to exhibit significant antiedema 
activity on carrageenan-induced paw edema in rats and mice.21 A new xanthone, 6,7-
dihydroxy-l,3-dimethoxyxanthone 16, was obtained from the leaves and stem of Hypericum 
geminiflorum (Guttiferae) in Taiwan and was shown to possess anti-inflammatory activity.22 
OH 0 OH 0 
CH30 OCH3 OCH3 
HO HO p- I 
""-
14 
OCH3 15 
OCH3 
5 
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Natural 3-methy1chromones are rare and hormothamnione 17, isolated in small quantities 
from the blue-green marine algae, cryptophyte chrysophaeum taylori by Gerwick et al.,23 is a 
potent cytotoxin towards several human leukemia cell lines in vitro. Although the 
mechanism for its cytotoxic activity has not been completely established, it appears to operate 
via selective inhibition of RNA synthesis.24 Hormothanmione was the first naturally-
occurring styry1chromone to be isolated, and its biological potential has stimulated interest in 
synthetic analogues. 24,25 
0 OMe OH 0 
HO MeO Me 
~ OH HO OMe MeO 
OMe 
16 17 OH 
OMe 0 0 0 
m m ~ 0 ~ 0 
18 19 20 
Simple chromone derivatives such as 5-methoxy-2-methylchromone 18, 2-methylchromone 
19 and 2-ethy1chromone 20, have recently been shown to possess gastroprotective 
properties.26•27 Histamine induces various complex biological processes by interacting with 
specific receptors in the membranes of cell surfaces. The action of histamine on HI-receptors 
stimulates many smooth muscles to contract, including those in the bronchi. Histamine also 
increases the permeability ofthe capillary walls so that more of the constituents of the plasma 
can escape into tissue spaces, leading to an increase in the flow of lymph (and its protein 
content). The chromone derivative 21, in which the chromone moiety is connected to a 
(diphenyhnethoxy)piperidine via an alkyloxy spacer, has recently been found to possess 
antiallergic, antiasthmatic and antihistaminic activity?8 The chromone derivative, 3-acetyl-5-
7-dihydroxy-2-methylchromone 22, depresses the release of mediators (histamine, SRS-A, 
etc.) more strongly than 5,7-dihydroxy-2-methylchromone 23,29 the marked difference being 
attributed to the presence of the carbonyl group at C_3 30 - a structural feature which appears 
6 
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to enhance the antiallergic activity of a number of chromone derivatives.3D The presence of 
an acidic group at C-2 or C-3 of the chromone nucleus31.32 is also characteristic of many 
chromones which exhibit antiallergic properties. The majority of these contain a carboxyl 
group, but its replacement by a 5-tetrazolyl ring, as in compound 24, has been shown to result 
in systems with increased pharmacological activity.31.32 2-Aminochromones, such as 
compound 25, have recently been reported to display antiplatelet properties, and find use in 
the treatment of unstable angina and other thrombolytic disorders.33 The presence of both a 
diethylamino group at C-2 and an electron-donating group, such as ethoxy at C-7, appears to 
be an important feature for physiological activity.33 
0 
D~o 0 
21 
OH 0 o 
JYli HO~O~ 
23 24 
H 
I 
N 
I , N N __ ~[' 
H 
I 
NHVN, 
\\ 'IN 
N-N 
OH 0 0 
,p'l 
HO 
:::,... 
0 
22 
o 
~ EtO~O~NEt2 
25 
Miller et al. 34 reported that simple, non-hydroxylated chromones inhibit p561ck tyrosine 
kinase. Specific tyrosine kinases have been implicated in proliferative diseases, such as 
cancer and atherosclerosis, and selective tyrosine kinase inhibitors may be useful in the 
treatment of these diseases. More particularly, selective inhibitors ofp561ck could be effective 
in the treatment of T-cell leukaemias, lymphomas and autoinomune diseases such as 
rheumatoid arthritis, in which activated T -cells play an important role in the pathogenesis of 
the disease. Miller et ai., 34 also pointed out that the active non-hydroxylated chromones were 
as potent as the polyhydroxylated flavones in inhibiting p561ck. It is interesting to note that all 
7 
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the chromones (typified by the compounds 26 and 27), which act as p561ck inhibitors have an 
aldehyde group at the C-2 or C-3 position, the C-3 aldehydes being the more active. 
o o 0 
H 
~H ~oJ 
o 
26 27 
Natural products often exhibit useful medicinal properties and local populations may rely on 
these plants as a source of treatment for various maladies. This has prompted the 
phytochemical investigation of many medicinal plants. Recently, Huang et al.35 isolated 
capillarsin derivative 28, a 2-phenoxychromone, from the leaves of Epimedium sagittatum 
(Berberidaceae). This plant, called "yinyanghuo" in China, has been used for the treatment 
impotence, atrophy, neurasthenia, amnesia, and climacteric hypertension.35 Visnagin 29, a 
furochromone like khellin 9, was isolated from Pimpinella monica (Umbelliferae) and was 
found to be an active feeding deterrent.36 The production of feeding deterrents is one of the 
defence mechanisms that makes plants unpalatable to insect predators. It was suggested that 
the presence of an unsubstituted furan ring and an alkoxy substituent at C-5 of the 
furochromone is essential for feeding deterrent activity; both the heterocyclic (furan and 
pyrone) rings are also considered essential. 36 
OMe 0 
Me 
28 29 
5,7,4'-Trihydroxy-5'-methoxycournaronochromone (desmoxyphyllin A) 30 and 7,4'-di-
hydroxy-5' -methoxycoumaronochromone (desmoxyphyllin B) 31 have been isolated from the 
leaves of Desmodiurn oxyphyllurn.37 Although, the activity of these compounds has not been 
ascertained, their importance is due to the fact that they were the first reported 
8 
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cournaronochromones to be isolated from the genus Desmodium. The 2-hydroxymethyl-
chromone derivatives, 32 and 33 have been isolated from the aerial parts of Cnidium 
monnieri (L) Cusson, a plant called . Jashoshi' in Japan, which has been used mainly for 
treating the swelling of women's genitals, male impotence and ringworm.38 
OMe OMe 
OH 
HO HO 
30 31 
8-(2,3-Dihydroxy-3-methylbutyl)-5-hydroxy-7 -methoxy-2-methyl-chromone 34 has been 
isolated from the wood of Harrisonia per/orata (Blanko) Merr, a plant widely distributed in 
southeast Asia; the root of this plant is used in a folk medicine in China for the prevention 
and treatment of malaria and boils.39 5-Hydroxy-2-isopropyl-7-methoxychromone 35 has 
been isolated from the aerial parts of Baeckea frutescens L., an aromatic, low-growing shrub 
used in traditional Chinese medicine for treating rheumatism and snake-bite.4o 
OH 0 
ro HO ~ 0 CH20H 
32 
MeO 
HO 
OH 
OH 0 
o Me 
34 
HOH2C '<:::: OH 0 
HO 
9" 
"",I 
0 CH20H 
33 
OH 0 
MeO 
35 
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5,7-Dihydroxy-2-(l-methylpropyl)chromone-8-~-D-glucoside 36 is a chromone glycoside 
present in the aerial parts of Hypericumjaponicum Thunb., a plant used in Chinese medicine 
for the treatment of infectious hepatitis; this compound has shown good coagulant activity in 
vitrO.41 5-Hydroxy-7-methoxy-2,3-dimethylchromone 37 has recently been isolated, for the 
first time, from cultures of spore-derived mycobionts of the lichen, Graphis scripta.42 One 
characteristic of lichens, is their production of diverse secondary metabolites, some of which 
exhibit a wide range of potentially useful biological activities, including fungicidal activity.42 
OH 0 OH 0 
roMe 
:::,.. I I 
HO MeO 0 Me 
Glc 
36 37 
Stigmatellin 38, a naturally occurring chromone isolated by Hiifle 43 from a culture of the 
gliding bacterium Stigmatella auriantaca, as diastereomers 38a and 38b, has proved to be a 
potent inhibitor of the photosynthetic system It is, consequently, a useful tool for studying 
relevant electron-transfer phenomena.43,« 
OMe 0 
?' OMe OMe R2 
MeO ~ 0 
..-:;:; ..-:;:; ..-:;:; 
R1 
OH 
38a (Rl= Me; & = H) 
38b (Rl= H; R2= Me) 
Major efforts continue to be directed towards the discovery and development of new 
antibiotics to combat serious infections caused by resistant bacteria. 5'-Methoxyhydno-
carpin-D (5'-MHC-D) 39, a chromone derivative isolated from the plant H wightiana, has 
10 
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recently been shown to be a potent inhibitor of a Staphylococcus aureus multidrug-resistant 
efflux pump.45,46 The compound disables the resistance-conferring pump, permitting 
antibiotics to accumulate in the bacteria cells and thus kill them. It is said that this discovery 
could lead to the development of drugs to treat antibiotic-resistant bacteria including 
"superbugs", which exhibit resistance to multiple antibiotics.45 A new chromone, granulosin 
[7,8-(methylenedioxy)-2-propylchromone] 40, which contains a methylenedioxy group has 
recently been isolated from an ethanol extract of the bark of Galipea granulosa Kallunki in 
Costa Rica 47 This plant has been traditionally employed in the treatment of parasitic 
infections, particularly cutaneous leishmaniasis, by the Indians of Bolivia, and an extract 
displayed activity in the brine shrimp lethality test.47 
OH 0 
0B~ I OH 
,;r I OCH3 
:::,... 0 "",,,,,.,.....OH 
HO 
OCH3 
39 
11 
o 
'-0 
40 
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1.2.2 Synthesis of chromones 
The synthesis of chromones and their 2-phenyl substituted derivatives (flavones) has been 
widely explored and extensively reviewed.l•3 Here, a briefreview of the classical synthetic 
methodology will be followed by a survey of more recent methods. 
Two widely-used methods of chromone synthesis are the Simonis and the Kostanecki-
Robinson reactions.3 In both approaches, the general strategy involves building a side chain 
on to a phenolic substrate before cyclization to the desired chromone.! In the Simonis 
reaction,l a phenol 41 is condensed with a f3-ketoester to give either a chromone 19 or a 
coumarin 42 (Scheme 2). The reaction which leads to a coumarin is called the Pechrnann 
condensation, for which sulfuric acid is necessary as a condensing agent. Chromone 
formation is favoured when the phenol contains a deactivating group, such as chlorine, or 
when the f3-ketoester is a-substituted, and when phosphorus pentoxide is used as the 
condensing agent. 
o 
~ ~O~Me and/or 
~ ~OH 19 
41 
Scheme 2 
Reagents: i) Condensing agent (H2S04 or P20 S). 
In the Kostanecki-Robinson method, use is made of a Claisen-type condensation. In this 
case, an o-hydroxyacetophenone 43 is condensed with an acylating agent in the presence of a 
strong base to form a f3-diketone intermediate 44, which is subsequently cyclized in acidic 
medium to the desired chromone 19 (Scheme 3).2,48 The Baker-Venkataraman rearrangement 
of 2-acyloxyacetophenones 4S (Scheme 4i·3•49 involves intramolecular migration of an acyl 
12 I 
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group from oxygen to the carbon atom a. to the ketone carbonyl group, and provides an 
alternative route to the 1,3-diketone intermediate 46 encountered in the Kostanecki-Robinson 
approach. The migrating acyl group may be aliphatic or aromatic and, hence, this approach is 
useful for the preparation of flavones 47 (R=Ar)50,5] as well as chromones 47 (R=alkyl).50 
Catalysts (other than potassium hydroxide, pyridine or potassium carbonate) recommended 
for the Baker-Venkatararnan rearrangement include sodium, sodamide, sodium alkoxides, 
sodium hydride, and sodium hydroxide. 52 
~ ----=---. ~OH 
o 0 
Ii 
o 
~ ~oJlMe OH 
43 44 19 
Scheme 3 
Reagents: i) strong base, CH3C02Et; ii) W. 
0 0 
cC • 06 ~ OH ~ oj( 
R 
43 45 
lii 
0 0 0 
ro iii ~R • ~ 0 R ~ OH 
47 46 
Scheme 4 
Reagents: i) RCOCl, pyridine; ii) KOH, pyridine or K2C03 ; iii) W. 
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3-Methylchromones 49, which are used as fungicides, cardiovascular agents and in the 
treatment of allergic conditions or hyperacidity, have been synthesized by treating 2-
hydroxypropiophenone 48 with DMF, BF3-etherate and methanesulphonyl chloride (Scheme 
5).53 5,7-Dihydroxychromone 51,54 a flavonoid decomposition product found in some plant 
extracts, is also a germination and growth inhibitor and has been prepared by condensing 
2',4',6'-trihydroxyacetophenone monohydrate 50 with ethyl oxalyl chloride, followed by 
hydrolysis, acidification and decarboxylation (Scheme 6). 
+ Rk.)lOH o!J R 0 
48 49 
SchemeS 
~ HO~OH 
50 
OH 0 OH 0 
JYr HO~OJ iv JYr HO~O~COOH 
51 
Scheme 6 
Reagents: i) EtOOCCOCI, pyridine; ii) OH-; iii) W; iv) heat. 
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The facile elimination of the diazo group from a-diazo carbonyl compounds has made such 
compounds very useful in organic synthesis. Thus, substituted chromones 54 have been 
synthesized in high yield from 3-diazochromanones 53 by Lewis acid-catalyzed elimination 
of the diazo group from 3-diazochrornanones 53 (Scheme 7).55 
R'(Xj° ~I 
° 
o RWN2 
----'-_.. ~ I 
° 
ii 
o 
R~ ~oJ .. 
52 53 54 
Scheme 7 
Reagents: i) (a) NaH, HC02Et, Et20 (b) EhN, TsN3 ; ii) BfJ-EhO, CH2Ch. 
Chromone-3-carbaldehydes 55, which exhibit anti-anaphylactic properties have been 
synthesized in excellent yield from o-hydroxyacetophenones 43 by the Vilsmeier-Haack 
reaction (Scheme 8).56.57 This one-pot synthesis has been reported as the most convenient 
method of synthesizing chromone-3-carbaldehyde derivatives 55 in high yield. 
~Me 
RUOH 
.. 
43 
Scheme 8 
Reagents: i) (a) DMF, POCh (b) H20. 
The addition of substituted phenols 56 to dimethyl acetylenedicarboxylate 57 has recently 
been reported as a versatile, high-yielding reaction in a three-step synthesis of chromone-2-
carboxylic acids 58. Substituted phenols, deprotonated by triethylamine, add to dimethyl 
15 
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acetylenedicarboxylate 57 under mild conditions, the reaction tolerating a range of functional 
groups on the phenol. Moreover, the addition reaction is not stereospecific in the sense that 
both aryloxy furnarates and maleates are produced and can be cyclized to the desired 
chromones without contamination by isomeric coumarins (Scheme 9).58 This reaction thus 
constitutes a useful general synthesis of chromones. Recently, Zat6n et al. 59 have reported 
that the heterocyclic ring of chromone-2-carboxylic acids binds to human serum albumin 
(HAS); - a process involved in the distribution of a drug through the circulation system. 
C02Me Q 6 + III R OH C I 
56 C02Me 
57 
o 
~ 
RUOJlCOOH 
iv 
.. 
58 
Scheme 9 
Developments in organometallic chemistry have extended the range of methods available to 
the synthetic chemist. In particular, palladium is known to activate aryl halides towards 
functionalisation, and the palladium-catalyzed carbonylative coupling of o-iodophenol 59 
with terminal acetylenes 60 in the presence of secondary amine has been reported to be a 
convenient and efficient method for the synthesis of 2-substituted chromones 61(Scheme 
10).60 
0(1 I + ~ OH 
59 
Scheme 10 
R-O==C-H + CO 
20abn 
60 
Reagents: i) Pd-catalyst, Et2NH, 120°C, 2h. 
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2-Methylchromones fi3 (including khellin 9) have been synthesized in high yield by the 
reaction of t-butyl lithioacetate 62 with various polysubstituted o-hydroxyacetophenones 43 
and subsequent acid-catalyzed dehydration of the resulting hemiacetals (Scheme 11).61 2-
Methylchromone 19 has also been synthesized in high yield (ca. 85%) by hydrolysis and 
decarboxylation of compound 66, which was obtained by an unusual cyclization of the 
precursor 65 in the presence of p-toluenesulfonic acid (Scheme 12).62 Compound 65 is also 
an important intermediate in the synthesis of 4-hydroxycournarin, a potent anticoagulant.62 
o ~---, R~OH 
43 I, ii iii. ro 
R 0 CH3 + 
LiCH2COOBut -----' 
62 
Scheme 11 
63 
Reagents: i) Toluene, 100°C; ii) satd. aq. NaCI; iii) 20% HCI-MeOH, <IOmin. 
Scheme 12 
~OH ~OAC 
64 
o 
~ ~O~ 
19 
I, II 
• 
iv 
.. 
o 
~C02Et 
~f"\A~02Et OAe 
65 tm 
o 0 
~OEt ~O~ 
66 
Reagents: i) SOCh, urea, toluene; ii) CH2(C02Et)2, Mg, EtOH; iii) p-TsOH 
iv) 6M-HCl. 
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The furochromone moiety, present in the pharmacologically active khellin 9, has attracted the 
interest of several groups of synthetic organic chemists. Recently, the bisaminofuro-
chromone 70, a bivalent inhibitor of AcylCoA: cholesterol O-acyltransferase (ACAT), one of 
the major regulators of cholesterol metabolism, has been synthesized by Gammil et al. in 
good yield as outlined in Scheme 13.63 It has been suggested that ACAT activity increases 
when cells are exposed to cholesterol-rich lipoprotein. It has also been recognized that 
ACAT plays an important role in the intestinal absorption of cholesterol and that ACAT 
activity is greatest in the jejunum, where the majority of cholesterol absorption occurs. Since 
the intracellular accumulation of esterified cholesterol is one of the characteristic features of 
the atherosclerotic plaque, there is continuous interest in the hypothesis that regulation of 
ACAT activity is likely to be of great importance in atherosclerosis treatment. 63 
OMe 0 OMe 0 
i, Ii 
• 
OH 
OMe Me 
67 68 
OMe 0 7' 
OMe 
69 
OMe 0 tlV 0 
N N 
Me 70 
Scheme 13 
Reagents: i) NaIf, THF, CH3SCH2C02Et; ii) H30+; iii) CH3I, CH2Ch, 
iv) C13H26N2, K2C03, CH3CN. 
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The substituted 2-methylchromones 74, a rare class of chromone derivatives, have been 
prepared in overall yield (ca. 75%) by condensing the sodium salt of methyl salicylate 71 
with the bromocrotononitrile 72 to give the intermediate vinyl ethers 73, which are then 
cyclized by treatment with sodium hydride (Scheme 14).64 The vinylogous cyanogen 
bromide 72 reacts readily with the ortho carboxylated phenols 71 to give the 2-functionalised 
chromone derivatives 74, which are not easily obtained by other methods. 
o 
R~OMe_--, ~OH o 
71 R'CCI OMe 
1---'-- ..--s Et ~ o-C=C + 
I 'CN CH3 
73 
72 
Scheme 14 
Reagents: i) NaB, dry DME; ii) NaH, dry DME, reflux. 
o 
ii :~ ,SEt ~OJlCH 
6N 
74 
Many synthetic flavones are known to exhibit pharmacological activity. 5,6- and 7,8-
Benzoflavones have been shown to act as inhibitors of tumor induction by carcinogenic 
polycyclic aromatic hydrocarbons (P AHs). In contrast to most other types of tumor-
inhibiting compounds, many of which exhibit toxicity, mutagenicity, and other undersirable 
properties, the flavone derivatives tend to show minimal side effects.6s Recently, potentially 
antitumorigenic, polycyclic chromone derivatives 79 have been synthesized in excellent yield 
by the condensation of2-hydroxy-l-acetonaphthone 75 with cinnamonitriles 76, followed by 
cyc1ization and dehydrogenation as outlined in Scheme 15.6s 
19 
75 
79 
Scheme 15 
76 
r 
ii 
• 
• 
Introduction 
EtOOC CN 
e ' I COCH ... CH 
_ 2 ~I 
cer,CH -:y '<::, 0 'Ar ~ I .-& 
77 
78 
Reagents: i) Piperidine, EtOH, reflux, 6h; ii) DDQ, benzene. 
c{" 
R OH 
+ 
80 81 
Scheme 16 
morpholine 
EtOH • ~ R 0 CONHC02Et 
82 
Ellis et aZ.31 have shown that chromone derivatives containing a carboxamide group at C-2 
possess antiallergic properties. Substituted chromone-2-carboxamides 82 are rapidly 
produced in high yield (>90%) by reacting salicylaldehydes 80 with the enamine 81 in 
ethanol (Scheme 16),66 the reaction involving base-catalyzed condensation. 2-Trichloro-
methylchromone derivatives 84 have been synthesized in excellent yield (ca. 95%) by 
condensing 2-hydroxyacetophenones 43 with trichloroacetonitrile in the presence of N-
methylanilinomagnesium bromide to afford the intermediates 83, which are converted into 
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the 2-trichloromethy1chromones 84 upon treatment with concentrated HCI as shown in 
Scheme 17.67 This synthetic route also provides access to 4-hydroxycoumarins 85 via base-
catalyzed hydrolysis of the 2-trichloromethy1chromone derivatives 84. 
~ OH I Me • CCI3 R R ~ 
0 0 NH2 
43 83 
lil 
OH 0 
OCt .. iii ro ROO R 0 CC~ 
85 84 
Scheme 17 
Reagents: i) PhNMeMgBr, CChCN, 20°C, 3h; ii) HCI, Iday 
iii) KOH, MeOH, O.Sh, reflux. 
Recently, Morris and co-workers68 reported a convenient procedure for the synthesis of 
substituted 2-aminochromones 89, which exhibit antiplatelet activity, from substituted 0-
hydroxyacetophenones 43. Thus, the substituted o-hydroxyacetophenones 43, when treated 
with boron trifluoride etherate, afford the o-hydroxyacetophenone-BF2 complexes 86. 
Reaction of these complexes with the phosgeniminium salt 87 gives the p-chlorovinylogous 
amide complexes 88, which undergo methanolysis to afford the 2-aminochromones 89 
(Scheme 18). The initial protection of the phenolic hydroxyl group with boron trifluoride 
etherate is necessary in order to direct reaction of the phosgeniminium salt 87 to the methyl 
carbon of ketone group.68 
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Chromone derivatives 91 and 92, which are useful intermediates in the synthesis of 
fungicides and herbicides, have been prepared in excellent yield from 2,S,8-trimethyl-
chromone 90 as shown in Scheme 19.69 Thus, nitration of the compound 90 occurs 
selectively at C-6, and reduction of the nitro group with FelHCI affords the amino derivative 
92. 
Scheme 18 
~ ~OH 
43 
o ro .Ii 
R 0 NMe2 
89 
Reagents: i) BF3.OEt2, Et20; ii) MeOH, SO°C. 
Me 0 0 
-::? 02N 
I I • 
:::".. 0 Me 
Me Me 
90 91 
Scheme 19 
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Chromone derivatives bearing a furan (97) or thiophene (98) ring at the C-2 position have 
been synthesized by condensing substituted 2-hydroxyacetophenones 93 with 2,5-
disubstituted furans or thiophenes 94 (X=O, S) as illustrated in Scheme 20.70,71 The 
synthesis involves a crossed-aldol condensation, followed by epoxidation using alkaline 
hydrogen peroxide and, finally, cyclization of the a,~-unsaturated carbonyl derivative 95. 
These products (97 and 98) have been used to investigate the photochemistry of 3-
alkoxychromones bearing furyl or thiophenyl groups, since furans themselves are known to 
undergo phototransformations.70,71 
Scheme 20 
R~---' 
93 
94 
o 
97 (X=O) 
98 (X=S) 
III 
.. 
R1 
(R1=H. CH3) 
(R2=H. CH3. Ph) 
95 
96 
o 
~ 
X j 
!ii R1 
OH 
""" 
X j 
R1 
Reagents: i) NaOH, EtOH; ii) HzOz, KOH; iii) KZC03, Me2CO, DMF, R2CHzCl. 
Chromone derivatives bearing a carbonyl group at C-3 appear to exhibit significant 
antiallergic activity,z9,3o Moreover, Dean et a/.n have shown that a carbonyl group at the C-3 
position strongly activates the chromone ring by its electron-withdrawing effect, permitting 
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selective C-2 alkylation using diazo alkanes. Recently, 3-acetyl-4H-l-benzopyran-4-one 101 
has been synthesized by condensing 2-hydroxyacetophenone 43 with the dimethyl acetal 99 
to give the intermediate 3-(dimethylamino)-1-(2-hydroxyphenyl)propen-l-one 100 in 85% 
yield, which, on refluxing with acetic anhydride in acetonitrile, affords the chromone 101 in 
ca. 62% yield (Scheme 21).73 
~Me_-, ~OH 0 
43 f--'-~NMe2 ~OH ii 
o 0 
~Me ~oJ 
100 101 
99 
Scheme 21 
Reagents: i) DMF; ii) AC20, MeCN, reflux. 
The chromone derivative, 5-methoxyhydnocarpin-D (5'-MHC-D) 39, has been found to kill 
bacteria by first disabling their defence mechanisms; this is regarded as one of the two major 
discoveries in drug research in the year 2000,44,45 the other being the discovery of the first 
family of compounds capable of inhibiting human immunodeficiency virus (mV) integrase 
by Merck scientists. The compound, 5'-MHC-D 39, was synthesized by coupling coniferyl 
alcohol with 3,4-dihydroxy-5-methoxybenzaldehyde 102 to afford compound 103; 
subsequent crossed-aldol condensation, cyclization and dehydrogenation gave the chromone 
derivative 39 as outlined in Scheme 22.44 
Selenium dioxide has been recognized as an effective reagent for the incorporation of an 
oxygen functionality at allylic positions74 and, recently, chromone-2-carbaldehydes 109 have 
been synthesized in moderate yield (ca. 60%) by Se02 oxidation of2-methylchromones 108 
(Scheme 23).75 Previous methods for obtaining such products have involved base-catalyzed 
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condensation of 2-methylchromone and p-nitroso-N,N-dimethylaniline followed by acid 
hydrolysis to afford the chromone-2-carbaldehyde in low yield, 76 or the oxidation of 2,2-
dibromomethyl-3-methylchromone using aqueous ethanolic silver nitrate to afford chromone-
2-carbaldehyde derivatives in ca. 65% yield.77 
H &OH 
~OH 
o 102 
~~ 
10JI ::::,.. OH 
i 
-
°xaOH OMe .J!L H &oX(XoH OMe 
o 1 ~O 1 
::::,.. OMOM 0 104 ::::,.. OMOM 
OMe 
MOMO 
I"" 
OMOM 
-9'1 
,,:; ::::,.. ::::,.. 
MOMO 0 105 
!IV 
OMe 
OMe 
HO OH 
-9' 
::::,.. ::::,.. 
OH 0 106 
°xa OH -9' OMe H o 1 
::::,.. OH 
107 
!VI 
0X(X0H OMe v HO 
o 1 -
::::,.. OH OH 0 
OM. 
-9'1 \::X ::::,.. -9' OM. o 1 ::::,.. OH HO 
OH 0 
39 
Scheme 22 
Reagents: i) Coniferyl alcohol, Ag2C03, C6H6-acetone(5:1), 60°C, 7h; ii) MOMq 
THF, NaH, rt, 7h; iii) KOH, EtOH, 2,4,6-tris(methoxymethoxy)aceto-
phenone, 48h; iv) conc. HC!, MeOH, rt, 12h; v) NaOAc, MeOH, reflux 
3h; vi) DDQ, dry dioxane, reflux, 36h 
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R~ ~O~CH3 R~ ~O~CHO Xylene 
108 109 
Scheme 23 
1.2.3 Reactivity of chromone derivatives 
Chromones may react with nucleophiles, electrophiles or other reagents to give various 
derivatives. In this introduction, particular attention will be focussed on reactions of 
chromones with nitrogen nucleophiles to afford ring-opened and addition products. 
1.2.3.1 Ring-opening reactions 
Chromones readily undergo nucleophilic cleavage at the C-2 position of the heterocyclic 
ring,'8 and a variety of nitrogen nucleophiles have been used in the ring opening of 
chromones at this position. The pyran-4-one ring in chromone 1 is cleaved by oxygen 
nucleophiles and by primary and secondary amines to yield enarnines.79 Thus, Kostka et al. 80 
showed that chromone 1 reacts with primary and secondary amines 110 to produce p-
amino vinyl ketones 111 having either E- or Z-double-bond configurations (Scheme 24). 
Zagorevskii et al. 80,81 used IH NMR spectroscopy to study the detailed structure of the p-
aminovinylketone products 111 and proposed a reaction mechanism to account for their 
formation, based on deuterium labelling data. 
The chromone-2-carboxylate ester 112 reacts with amines or ammonia to give different 
products depending on the nature and quantity of the amine, and the reaction conditions used 
(Scheme 25). Secondary and tertiary carboxarnides 113 may be produced under very mild, 
anhydrous conditions, while use of an excess of amine or prolonged reaction affords coloured 
acrylamides 114.81 -85 The latter reaction is presumed to proceed via the carboxarnide with a 
second mole of amine cleaving the ring, since treatment of the preformed carboxarnide with 
benzylamine afforded the corresponding acrylarnide.86 The susceptibility of chromone 
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derivatives to ring-opening via nitrogen nucleophilic attack at C-2 prompted Kaye and co-
workers to explore the amine-mediated formation of (E)-2-(N,N-dimethylamino )-3-(2-
hydroxybenzoyl)acrylamides 117 from the 4-oxo-4H-chromone-2-carboxamides 116 
(Scheme 26),87,88 They also showed that the dimethylarnine-mediated ring-opening of 
chromone-2-carboxamides 116 follows a third-order kinetics and proposed the mechanistic 
sequence detailed in Scheme 26,87 
o 
cO 
1 
Scheme 24 
Reagents: i) R1R!NH (110), 80-85°C, 2h. 
Scheme 25 
Reagents: i) RNH2 (I molar eq,) 
ii) RNH2 (2 molar eq,) 
iii) RNH2 (1 molar eq,) 
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114 
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.. Ai o 
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Scheme 26 
o ro I,ii. 
R 0 eOOH 
115 
Reagents: i) SOCJz, DMF-ClCH2CH2Cl; ii) Me2NH2Cl, pyridine 
iii) Me2NH, EtOH 
1.2.3.2 Nucleophilic addition to chromone carbaldehydes 
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Despite the susceptibility of chromone derivatives to ring-opening of the pyran-4-one moiety 
by nucleophiles, chromone-3-carbaldehyde 27 generally undergoes nucleophilic addition}it 
the formyl carbon to afford condensation products. Chromone-3-carbaldehyde 27 has been 
shown to react with a monofunctional nucleophile, such as malonic acid in the presence of 
pyridine to afford the acrylic acid derivative 118 in ca. 74% yield (Scheme 27).89 However, 
synthesis ofbenzopyran compounds having unsaturation in the 3-alkyl side chain is generally 
difficult.90 Sabitha and co-workers, however, have recently reported the synthesis of the 
acetylenes 121 under mild conditions by condensing chromone-3-carbaldehydes 27 with 3-
methyl-5-isoxazolone 119 in ethanol at room temperature, and selectively reducing the 
resulting isoxazolone intermediate 120 with sodium borohydride in methanol to give the 
desired acetylene derivatives 121 in high yield (> 80%) (Scheme 28).90 
28 
o 0 
~H ~O) 
27 
Scheme 27 
o 
Scheme 28 
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o 
W' , 
C=C-CH3 
ii, jii 
• 
Reagents: i) Ethanol; ii) NaB14, methanol; iii) aq. NaN02, FeS04, AcOH. 
Chromone-3-carbaldehyde 27 also reacts readily with primary aromatic arnines91 .92 and 
secondary amines such as piperidine.93 Chromone-3-carbaldehydes 27 have been shown to 
condense with aromatic amines to give, firstly, the 3-ary!inJinomethylchromones 122 and 
then following the addition of a second molecule of amine to the imine intermediates, the 2-
arylarnino-3-arylaminomethylenechroman-4-ones 123 (Scheme 29).94 The 3-arylimino-
methyl group apparently stabilizes the chromone ring towards the usual ring-cleavage by 
-aromatic amines and also facilitates the addition of other external nucleophiles which would 
not otherwise react with the chromone ring.94 
29 
o 
roC HO_---, 
R 0 
27 
Scheme 29 
Reagents: i) Dry benzene, reflux 30min. 
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Chromone derivatives having heterocyclic substituents at C-2 and C-3 have been shown to 
exhibit coronary spasmolytic and bronchodilatory activities, and some are used in the 
treatment of asthma.31 Iagadeesh et al. 75 has successfully carried out the condensation of 
chromone-2-carbaldehydes 26 with two equivalents of ethyl arninocrotonate 124 via a 
modified Hantzsch synthesis to give the chromone derivatives 125 in good yield (Scheme 
30).75 
° ro 0 R a CHO 
26 C02E! 
'<::: 
CH3 
H3C H ~ NH 
H2ri=<C02E! Et02C 125 CH3 
124 
Scheme 30 
Reagents: i) AcOH, rt, 96h. 
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Cbromone-3-carbaldehyde 27 may react with a bifunctional nucleophile (Nul-Nu2) to form a 
new heterocycle. Thus, nucleophilic attack at the formyl carbon gives, initially, an interme-
diate 126 which, following intramolecular attack by Nu2 at the reactive C-2 position, results 
in the ring-forming! ring-opening sequence illustrated in Scheme 31.95 This approach has 
been used to prepare products such as 4-(2-hydroxybenzoyl)pyrazole 127.96 
o 
o 
27 
Scheme 31 
o 
RUrCHO 
"'" I I ---, 
o 
27 
H2N-GH2CH2-NH2 ----' 
128 
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o H 
R 
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Scheme 32 
Reagents: i) Dry benzene, reflux, 2h. 
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Condensation of chromone-3-carbaldehydes 27 with the binucleophile, 1,2-ethanediamine 
128 in dry benzene affords the bis-aldimines 131 in excellent yield (Scheme 32).97 The first 
step in the reaction involves the formation of aldimines, which may exist in two isomeric 
forms 129 and 130. The E-isomer 129 cannot undergo intramolecular cyclization because the 
terminal amino group is too far away to react with either of the two electrophilic centres viz., 
C-2 and the carbonyl carbon of the chromone moiety; it may, however, condense with a 
second molecule of the chromone 27 to give the corresponding bis-imine 131 (Scheme 32). 
The Z-isomer, on the other hand, may cyclize to afford a fused diazepine 132 as illustrated in 
Scheme 32.97 
1.2.3.3 Other reactions of chromone derivatives 
Chromones undergo many different types of reaction, some of which provide access to 
derivatives with interesting medicinal properties. Ellis et al.31,32 have shown that the 
antiallergic chromones are generally those which contain a carboxamide group at C-2, and 
there has been a continuing interest in the synthesis of analogues of such chromone 
derivatives. Recently, reaction of2-amino-5-methyl-l,3,4-thiadiazole 134 with chromone-2-
carbonyl chloride 133 was shown to give the carboxamide 135 (Scheme 33),98 while 
Davidson et al. 99 achieved the synthesis of N,N-dimethylchromone-2-carboxamides 137 in 
excellent yield by reacting the corresponding acid chlorides 136 with dimethylammonium 
chloride in dry pyridine (Scheme 34).99 
o 
~+ V--OJlCOCI 
133 134 
Scheme 33 
Reagents: i) Dry benzene, reflux, 3h. 
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Scheme 34 
Reagents: i) Me2NH2CI, dry pyridine, DoC. 
In an approach used for the synthesis of the pharmacologically active hormothamniones 
17,24,25,100 base-induced condensation of a 2-methy1chromones 138 with substituted 
benzaldehydes 139 afforded the 2-styry1chromones 140 (Scheme 35).101 
~R1 
R~O--lCH3 o 
138 
140 
139 
Scheme 35 
Reagents: i) NaOEt, EtOH, rt, 24h. 
The 3-chlorochromones 142 and 143 have been prepared in excelle~t yield by selectiv.e£~ 
monochlorination of 2-methylchromones 141 and chromone-2-carbaldehydes 26 using 
aqueous sodium hypochlorite and acetic acid (Scheme 36);102 these products are starting 
materials for the synthesis of chromone derivatives having heterocyclic substituents at C-2, as 
discussed in Section 1.2.3.2. p.30. 
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Reagents: i) NaOCl, AcOH; ii) Se02, xylene. 
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Chromones typically resist electrophilic attack, since electrophilic reagents are often strongly 
acidic and, hence, likely to protonate the pyran-4-one ring, thus inhibiting further attack by 
the electrophile.2 However, amino methylation of 8-methoxychromone 144 may be achieved 
under less acidic Mannich reaction conditions to afford 3-aminomethylchromone 145 
(Scheme 37).103 This reaction is, however, inhibited by a methyl substituent at C_2.103 3-
Hydroxychromone 146 may be brorninated, nitrated and aminated at C-2, a position which is 
usually electron-deficient but is presumably activated by the hydroxyl group to give the 
corresponding derivatives 147 as shown in Scheme 38.103 
Scheme 37 
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Reagents: i) HCHO, Me2NH, AcOH. 
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Electrophilic reagents may react with the side chains of certain chomone derivatives to give 
interesting products. Thus, 2,2-dibromomethyl-3-methylchromone 149, a key intermediate in 
the synthesis of 3-methylchromone-2-carbaldehyde 150, has been synthesized in high yield 
(ca. 79%) by treating 2,3-dimethylchromone 148 with slightly more than a two-fold excess of 
bromine in boiling benzene (Scheme 39),77 dibromination of the C-2 side chain occurring in 
preference to addition or substitution on the chromone nucleus. 
roo OH % I I o 
146 
R= Br, N02 or NHR 
Scheme 38 
I • citH' --"ii_ .. ~ 
o CHBr2 
o 
06cCH3 I I % 0 CHO 
148 149 150 
Scheme 39 
Reagents: i) Br2, dry benzene; ii) AgN03• 
Photoirradiation of a methanolic solution of the 2-thienyl derivative 151 with pyrex-filtered 
UV light has been reported to afford the cyclized product 152 (Scheme 40).71 
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Scheme 40 
Baeyer-Villiger oxidation of chromone-3-carbaldehyde 27 using m-chloroperbenzoic acid 
(MCPBA) in boiling dichloromethane has been reported to afford 3-hydroxychromone 154 in 
good yield, as compared to other methods (Scheme 41).104 3-Hydroxychromone 154 has also 
been prepared by simply oxidizing 2,3-unsubstituted chromones with m-chloroperbenzoic 
acid in dry benzene.104 
__ . cx:rOH o roCHO ~ I I • o 
27 153 154 
Scheme 41 
Reagents: i) MCPBA, CH2Ch. 
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1.2.4 HIV Protease inhibitors 
Since the human immunodeficiency virus (lilV) epidemic outbreak some 15 years ago, an 
estimated 47 million or more people world-wide have been infected with the virus, and more 
than 2.2 million deaths were attributed to the disease in 1998. IllV/AIDS is now considered 
to be the fourth leading cause of death, with its impact likely to increase if the problem does 
not receive urgent attention. lOS The alarming rate of spread of the acquired immuno-
deficiency syndrome (AIDS) has prompted widespread efforts to understand and find ways of 
combating this disease.106 The identification of the molecular events, which occur during the 
replication stage of the virus, has permitted the selection of several chemotherapeutic 
strategies. 106 The genome of the IllV-1 virus encodes a proteinase (IllV-l protease) which 
cleaves the gag-pol proteins; inhibition of this cleavage results in the production of immature 
virions which are non-infectious, thus, inhibiting multiplication of the virus. The chemical 
inhibition of this deadly viral enzyme has been recognized as a powerful strategy for the 
development of an effective therapy for the treatment of AIDS and other related diseases.l07 
Although, the role of viral replication at particular stages of the disease progression is still 
being debated, there is a general consensus that inhibition of IllV replication in infected 
patients will result in a reduction of mortality. 108 Hence, IllV -1 protease has been recognized 
as an attractive target for antiviral therapy, and the discovery of potent inhibitors has been the 
focus of many research programmes. 109 
1.2.4.1 1llV-1 protease inhibitor design 
Computer-aided drug design strategies have been applied in the development of a variety of 
highly potent inhibitors,110 and an increasing number of crystal structures of IllV -I protease 
inhibitors are. available in the Brookhaven Protein Data Bank (PDB).11l.1l2 Figure I shows 
the X-ray structure (coded as 1HXW) of IllV -1 protease complexed with ritonavir 156,113 a 
drug in clinical use. IllV -1 protease is an aspartic acid protease, which cleaves specific 
amide bonds (peptides) in a similar manner to renin and endothiopepsin. It is a dimer made 
up of two 99-amino acid monomers, each contributing an aspartic acid residue at the catalytic 
site.109 The enzyme functions as a "molecular pair of scissors", hydrolyzing the viral gag-pol 
precursor proteins to produce structural proteins needed by the human immunodeficiency 
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Virus. 109 The ideal HIV -1 protease inhibitor:- should be potent against various HIV clinical 
isolates; be specific for HIV -1 protease (compared with other mammalian aspartic acid 
proteases), so as to minimize possible adverse effects; have good oral bioavailability and 
duration in humans; and safe to use and well tolerated. 109.1 10.1 14 
There are currently four HIV protease inhibitors approved for marketing as drugs in the USA 
in the clinical treatment of AIDS. These are:- Inverase® (Saquinavir mesylate; Hoffman-La 
Roche) 155; Norvir® (Ritonavir; Abbott laboratories) 156; Crixivan® (lndinavir sulfate; 
Merck) 157; Viracept® (Nelfinavir mesylate; Agouron Pharmaceuticals) 158. Others, like 
Arnprenavir 159, are in late-stage clinical trials. 109.1 15 
, 
"'.,-"'""-_ HIV -1 protease 
, 
, 
Ritcnavir 
Figure 1. X-ray crystallographic structure (coded as lHXW) of HIV-l protease complexed with the drug, 
ritonavir 156 (see ref. 113). . 
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Many ofthe highly potent HIV-I and mV-2 protease inhibitors, which incorporate the non-
hydrolyzable hydroxyethylamine 160 and hydroxyethylene dipeptide 161 isosteres, are active 
lar . . 108 at nanomo concentratIOns. These inhibitors have a defined configuration at the 
hydroxyl-bearing asymmetric carbon, and these configurations are considered to be important 
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for inhibitory potency. mv protease inhibitors, which incorporates the hydroxyethylene 
isostere 161, have been shown to possess an S-configuration at this centre,116,117 while 
inhibitors incorporating the hydroxyethylarnine isostere 160 show a marked preference for an 
R_configuration. 116,118 Thus, the absolute configuration is very important for biological 
activity. The hydroxyl group in the isosteres has been shown to participate in hydrogen-
bonding interactions with the catalytic aspartic acid residues of the mv -protease, and the 
orientation of the hydroxyl group plays an important role with respect to the degree of 
binding. 
Ph H ?H (H (y~~~)l 
o 0 0 ptf 
161 
Hydroxyethylarnine isostere Hydroxyethylene dipeptide isostere 
1.2.4.2· Chromones and their phenyI-substitnted derivatives as HIV-1 protease 
inhibitors 
It has been foundl08,1 19,120 that chromones such as 162 - 164, which bear hydroxylated phenyl 
substituents at C-2 (flavones) and the 3-substituted derivatives 165, can inhibit H1V-I 
protease. Such compounds are known as non-peptidic H1V-I protease inhibitors, in which 
the hydroxyl substituents interact with the enzyme via hydrogen-bonding. 120,121 
Isolicoflavonol 164 and glycyrrhisoflavone 165, have been isolated from licorice and show 
antiviral properties, including anti-my activity, by inhibiting the cytopathic activity of the 
mv ViruS. l22,123 5,2',4'-Trihydroxy-6,7,5'-trimethoxytlavone 163, a ·chromone derivative 
isolated from Artemisia capillaris Thunb., exhibits significant activity against mv 
replication in H9 lymphocytic cells. 124,125 The plant, A. capillaris, is a famous traditional 
Chinese medicine used mainly as a choleretic, anti-inflammatory and diuretic agent in the 
treatment of epidemic hepatitis; in addition, the plant has found use in the traditional 
treatment of viral-induced liver inflammation andjaundice.124,125 
40 
Introduction 
0 OH 0 
;::?' OH MeO OH 
~ ;::?' OH ;::?' 0 MeO 0 I ~ ~ 
162 OH 
163 OMe 
OH 
HO 
"'" 
OH 
OH 0 
OH 4- OH 
164 
HO 
165 
1.3 Previous work done in the group and aims of the present investigation 
As a result of their varied biological activities, chromone derivatives have been the subject of 
considerable pharmaceutical and chemical interest, and the investigation of their chemistry, 
which forms the basis of this project, is part of an ongoing progarnrne within our research 
group. 
Over the past years, work in this area has been focussed on synthetic and physical organic 
studies of chromone derivatives. Infrared studies of substituted chromone-2-carboxylate 
esters revealed doubling of the IR carbonyl bands, which was shown to be solvent-, 
substituent- and temperature-dependent, and which was rationalized in terms of rotameric 
equilibria between syn-s-trans and anti-s-trans forms.126 An efficient synthesis of substituted 
chromone-2-carboxamides has been developed,99 and dynamic NMR studies of these 
compounds revealed a temperature-dependent splitting of the N-alkyl IH_ and I3C NMR 
signals, which was attributed to internal rotation of the amide groUp.127 
The susceptibility of chromone derivatives to ring-opening via nucleophilic attack at C-2 has 
been illustrated by the amine-mediated ring-opening of substituted chromone-2-carbox-
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amides,87 and a kinetic-mechanistic study demonstrated the influence of substituents on the 
ring-opening process. 88 Mass spectrometric analysis of the ring-opened, polyfunctional 
acrylamide derivatives has permitted elucidation of their major fragmentation patterns,128 
while dynamic NMR analysis of rotational isomerism in these systems permitted the 
calculation of internal rotational barriers. 129 
Dynamic IH NMR spectroscopic technique was used to explore the influence of substituents 
on the internal rotation of the amino group in 2-(N,N-dialky1amino)chromones;lJo nitrogen 
lone-pair delocalization was presumed to inhibit rotation about the N-C(O) bond - a property 
which has some influence on the basicity of these compounds, as will be discussed later. 
Research has also addressed the influence of various substituents on the electron density at C-
2 and, hence, on the acidity in a series of 2-carboxychromonesl3l and, an investigation of 
substituent effects on the basicity of 2-(N,N-dimethylamino)chromones was seen as a 
possible extension of these studies. 
Applications of the Morita-Baylis-Hillman reaction have also enjoyed considerable attention 
in our group. Morita-Baylis-Hillman products have provided convenient access to 2-
substituted indolizines,132 quinoline derivatives, III chromenes,134 thiochromenesl35 and 
coumarinS. 136 Chromone-3-carbaldehydes were identiiied as interesting substrates for the 
continuation of these studies. 
Consequently, the aims of this research have included the following. 
1. The synthesis and characterization of a series of substituted 2-(N,N-dimethy1amino)-
chromones. 
2. Potentiometric analysis of the substituted 2-(N,N-dimethylamino )chrornones to 
explore the effect of substituents on their basicity. 
3. Synthesis, characterization, and bioassay analysis of the natural product, granulosin 
[7,8-(methylenedioxy)-2-propylchromoneJ, and its C-2 side-chain analogues. 
4. Synthesis, characterization, and bioassay analysis of the natural product, 5-hydroxy-
7-methoxy-2-isopropylchromone, and its C-2 side-chain analogues. 
5. An investigation of the mass fragmentation patterns exhibited by the "granulosin" 
and 5-hydroxy-7-methoxy-2-alky1chromone series. 
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6. Synthesis and characterization of novel chromone-containing analogues of the HIV-
1 protease inhibitor, ritonavir. 
1. Computer-modelling studies of the chrornone-containing analogues of the HIV-l 
protease inhibitor, ritonavir, using an interactive docking programme to explore 
their binding to the enzyme active site. 
S:. Synthesis of substituted chromone-3-carbaldehydes and chromone-2-carbaldehydes, 
and an investigation of their reactions with acrylonitrile and methyl acrylate under 
Morita-Baylis-Hillman condition. 
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2. DISCUSSION 
2.1 Synthesis and pKa studies of 2-(N,N-dimethylamino)chromone 
derivatives 
2.1.1 Synthesis of2-{N,N-dimethylamino)chromones 
As indicated in the introduction, a number of 2-aminochromones have been shown to exhibit 
pharmacological activity3 and, in this study, a range of 2-(N,N-dimethylarnino )chromones 
were prepared in order to examine the effects of substituents on their basicity. The 
compounds were targeted to complete a study initiated in these laboratories by Sabbagh. 144 
The synthetic methodology used involved the formation of phosgeniminium salt 
intermediates from o-hydroxyacetophenone precursors. 
The substituted o-hydroxyacetophenones 174 and 175 (Scheme 42) were prepared via Fries 
rearrangemene of the corresponding substituted phenyl acetates 168 and 169 which, in turn, 
were obtained by acetylation of the appropriate phenols 166 and 167, as described by Bryan 
et al. m The acetates were heated in an oil bath at high temperature (ca. 190°C) which 
favours rearrangement to the o-hydroxyacetophenones rather than the p_analogues. 138 The 
Fries rearrangement of 4-fluorophenyl acetate 169 afforded 5'-fluoro-2'-hydroxyaceto-
phenone 175 in 70% yield, while 2-fluorophenyl acetate 168 give 3'-fluoro-2'-hydroxy-
acetophenone 174 in low yield (ca. 12%). 
2'-Hydroxy-6'-methoxyacetophenone 176 was prepared in excellent yield (ca. 80%) by 
methylation of 2',6'-dihydroxyacetophenone 170, using one equivalent of methyl iodide and 
one equivalent ofK2C03 in acetone, as described by Lau et al. l39 2'-Hydroxy-3'-methoxy-
acetophenone 177 was obtained in moderate yield (ca. 52%) via selective demethylation of 
2',3'-dimethoxyacetophenone 172 at high temperature in the presence of anhydrous AlCb, 
following the method described by Baker et al.;50 the precursor 172 was prepared, in turn, via 
a Grignard reaction of2,3-dimethoxybenzonitrile 171 with methyl magnesium bromide. 140 
2'-Hydroxy-3'-nitroacetophenone 178, which was required as a precursor for the synthesis of 
2-(N,N-dimethyarnino )-8-nitrochromone 184, is not commercially available and, 
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consequently, was synthesized in good yield (ca. 63%) as indicated in Scheme 42. This 
method involves nitration ofcbromone 1 using P.Da Re' s procedure,141 followed by alkaline 
hydrolysis of the resulting 8-nitrocbromone 173 to afford the required 2'-hydroxy-3'-
nitroacetophenone 178.141 
~y 1 . 
::::,.. OH 
0 
3 166R2=H, R3=F 
!i 
167R2 =F, R3=H 
ex) 
::::,.. 0 ~y 0 c:{N 1 ! vi 
. ::::,.. 3
1 ~::: = H, R3 = F ::::,.. OMe 0 Me 
!ii 
169R2=F,R3=H 171 yJ !w ::::,.. 0 ~ 0 N02 
R2 
173 v 7'"1 ~ 
OH 
::::,.. 
OH 0 
Y R3 Me ex: R1 R2 R3 172 ::::,.. OH 174 H H F 
170 175 H F H 
176 MeO H H 
177 H H MeO 
178 H H N02 
Scheme 42 
Reagents: i) aq. NaOH, AczO, O°C; ii) AlC!), heat; iii) Mel, K2C03, acetone; 
iv) MeMgBr, dry Et20; v) AlC!), dry Et20, reflux; vi) conc.H2S04, 
fuming HN03; vii) 5% KOH, reflux. 
0 
OMe 
The 1H NMR spectrum of compound 178 (Figure 2) reveals the presence of an acetyl methyl 
singlet at l5 2.74 ppm and a low-field singlet at l5 12.85 ppm corresponding to the strongly 
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deshielded, hydrogen-bonded phenolic proton. Confirmation of the structure of the product, 
2'-hydroxy-3'-nitroacetophenone 178, is provided by the DEPT-J3S and I3C NMR spectra 
(Figures 3 and 4, respectively). The DEPT-J3S spectrum shows 4 carbon signals 
corresponding to one methyl and three methine carbons, while the I3C NMR spectrum shows 
8 carbon signals with the acetyl methyl group resonating at 26.7 ppm and the carbonyl carbon 
at 203 ppm.' 
OH 
, 
D 
, 
" 
0 
~ 
N02 
178 
, 
u 
, 
to 
Figure 2. 400 MHz 1 H NMR spectrum of compound 178 in CDCh. 
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Figure 3. DEPT-J3S NMR spectrum of compound 178 in CDCh. 
I Compound 178 has been reported previously and was prepared following a literature procedure. l4I Careful 
examination of the spectroscopic data, however, has revealed certain anomalies, which would also apply to the 
derivatives 183, 189 and 195. These will be addressed in future studies. 
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Figure 4. 100 MHz l3C NMR spectrum of compound 178 in CDCh. 
The 2-CN,N-dimethylamino)chromones 191 - 195, most of which have not been reported 
previously, were prepared following the method reported by Morris et al.,68 which is 
summarized in Scheme 43. Treatment of the o-hydroxyacetophenones 174 -178 with boron 
trifluoride-etherate in dry diethyl ether gave the corresponding 2'-hydroxyacetophenone-
boron difluoride complexes 179 - 183. The boron difluoride complexes 179 - 183 were then 
heated with phosgeniminium chloride 184 at 80°C to afford the corresponding 3-chloro-3-
CN,N-dimethylammo)-I-C2-hydroxyphenyl)propenone-boron difluoride complexes 185 -189. 
The crude boron difluoride complexes were identified by IH NMR analysis and used without 
further purification. Subsequent methanolysis and cyclization at ca. 50°C finally afforded 
the required 2-CN,N-dimethylamino )chromones 191 - 195 in yields ranging from 60 to 87% 
CTable I); the products were recrystallized to obtain the analytically pure material necessary 
for the pI<. studies. The protection of the phenolic group with boron trifluoride-etherate is 
necessary in order to direct the reaction of the phosgeniminium salt to the methyl group 
instead of the hydroxyl group, as established by Morris et al. in their preliminary 
experiments.68 
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Table 1. Comparative yields (%) of the 2-(N,N-dimethylamino)chromones 191 -195, 
prepared as shown in Scheme 43. 
Compd. Rl Rz R3 Yield (%)* 
191 H H F 87 
192 H F H 60 
193 MeO H H 63 
194 H H MeO 72 
195 H H NOz 83 
* Isolated product 
The 2-(N,N-dimethylamino)chromones 191 - 195 were fully characterized by elemental 
(HRElMS) and spectroscopic (IR, IH_ and 13C NMR) analysis, and their purity is illustrated 
by the IH and 13C NMR spectra of the 8-nitro derivative 195 (Figures 5 and 6). The IH NMR 
spectrum clearly shows the dimethylamino singlet at I) 3.15 ppm, and the characteristic 3-
methine proton singlet at I) 5.46 ppm, while the 13C NMR spectrum reveals the presence of 10 
carbon signals, with the N,N-dimethyl nuclei resonating as a singlet at I) 37.8 ppm and the 
characteristic 3-methine carbon signal at I) 86.3 ppm. Signal assignments were facilitated by 
the use of DEPT-13S, COSY, HMQC and HMBC spectra, and it is evident that the 
substituent changes do not appear to influence the 1 H and 13 C chemical shifts significantly. 
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Figure 5_ 400 MHz IH NMR spectrum of 2-(N, N-dimethylamino )-8-nitrochromone 195 in CDC!,. 
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Figure 6. 100 MHz l3C NMR spectrum of2-(N,N-dimethylamino)-8-nitrochromone 195 in CDC!,. 
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2.1.2 pKa studies of 2-{N,N-dimethylamino)chromones 
The pI<. studies were carried out in order to demonstrate the influence of remote substituents 
on the basicity of the 2-(N,N-dimethylamino )chromones 190 - 195. The pI<. values were 
determined in ethanol-water (1:1) by potentiometric analysis, as described by Albert and 
Serjeant.142 Solutions of the 2-(N,N-dimethylamino )chromones were titrated with 
hydrochloric acid (0.1063 mol.dm-3) in 0.20 mL increments, the pH being measured after 
each addition and the temperature being held constant at 25°C. 
The pI<. values were calculated using the ionization constant I<.: 
thus 
I<. = rKlfBJ 
[BHl 
pI<. = pH + log [BHl-log [B] 
where [BHl represents the concentration of the protonated species (i. e. the conjugate acid) 
and [B] the concentration of the free base. 
The concentration on which the calculations are based is reached, in each case, at the mid-
point of the titration. 142 Tables 2 and 3 summarize the analytical data for 5-methoxy-2-(N,N-
dimethylamino)chromone 193; BIr is the number of moles of hydrogen ions in the volume 
of acid added, while B represents the difference between the number of moles of the 2-(N,N-
dimethylamino)chromone and BIr. From Table 2, the observed pH values lie outside the 
range pH 5-10, therefore, it is necessary to make corrections for the hydrogen ion activity.142 
These corrections were effected following Albert and SeIjeant's method,142 and are 
summarized in Table 3, in which lH1 (column ii) expresses the hydrogen ion concentration 
given by the negative antilogarithm of the measured pH. This value is then multiplied by the 
total volume (in litres) to give the number of moles of Ir (column iii). The pI<. values 
(column vi) reflect the sum of the measured pH and column v. The pI<. values in column vi 
cannot be averaged directly and a mean result is obtained as follows. The antilogarithms of 
the values in column vi are given in column vii; the average of these values is calculated, 
with the exclusion of the first and the last entries, (as recommended by Albert and 
Serjeant142) and converted back to pI<.. The variance about the mean value finaIly obtained 
for the pI<. (2.52) faIls within the limits of ± 0.06, considered acceptable by Albert and 
~~ 
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Serjeant. 142 All titrations were carried out in triplicate to ensure reproducibility and the 
results are tabulated in the experimental section. The pI<. values calculated for the series of2-
(N,N-dimethylarnino)chromones 190 -195 are summarized in Table 4. 
Table 2. Concentration of the protonated and non-protonated S-methoxy-2-(N,N-dimethyl-
arnino)chromone 193 as a function of pH. 
Cone. Vol. Mass Molar No. of pH BIr a Bb 
Hel Titrant (g) mass moles 
(mL) (glmo!) 
0.1063 0.00 0.0438 219 0.0002 S.OO 0.00 0.000200 
0.1063 0.20 0.0438 219 0.0002 3.60 2.13E-OS 0.000179 
0.1063 0.40 0.0438 219 0.0002 3.24 4.2SE-OS 0.000157 
0.1063 0.60 0.0438 219 0.0002 3.05 6.38E-05 0.000136 
0.1063 0.80 0.0438 219 0.0002 2.89 8.S0E-OS 0.000115 
0.1063 1.00 0.0438 219 0.0002 2.76 0.000106 9.37E-05 
0.1063 1.20 0.0438 219 0.0002 2.66 0.000128 7.24E-05 
0.1063 1.40 0.0438 219 0.0002 2.S8 0.000149 5.12E-OS 
0.1063 1.60 0.0438 219 0.0002 2.49 0.000170 2.99E-OS 
0.1063 1.80 0.0438 219 0.0002 2.42 0.000191 8.66E-06 
0.1063 2.00 0.0438 219 0.0002 2.34 0.000213 -1.26E-05c 
• Moles of conjugate acid 
b Moles of residual free 2-(N,N-dimethylamino)chromone. 
, The negative concentration reflects the excess concentration oftitrant. 
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Table 3. Calculation ofpK. values for 5-methoxy-2-(N,N-dirnethylamino)chromone 193, 
corrected for hydrogen-ion activity. 
(i) (ii) (iii) (iv) (v) (vi) (vii) 
Total vol. [Hi II' BII'-II' log(col.iv) pK. lO.pKa 
(roL) B+II' 
. 
-
. 
-0.000949 - -
. 
-
-
-19.00 0.000010 1.9000E-06 
19.20 0.000251 4.8228E-06 0.089545 -1.047957 2.552043 0.002805 
19.40 0.000575 1.1164E-05 0.185933 -0.730643 2.509357 0.003095 
19.60 0.000891 1.7469E-05 0.301333 -0.520953 2.529047 0.002958 
19.80 0.001288 2.5507E-05 0.423819 -0.372820 2.517180 0.003040 
20.00 0.001738 3.4756E-05 0.556953 -0.254181 2.505819 0.003120 
20.20 0.002188 4.4193E-05 0.714784 -0.145825 2.514175 0.003061 
20.40 0.002630 5.3657E-05 0.907715 -0.042051 2.537949 0.002898 
20.60 0.003236 6.6660E-05 1.070816 0.029715 2.519715 0.003022 
20.80 0.003802 7.9079E-05 1.279478 0.107033 2.527033 0.002971 
21.00 0.004571 9.5989E-05 1.398412 0.145635 2.485635 0.003269 
pK. = 2.52 ± 0.06 
The pK. value for chromone itself, obtained by this method, was 1.77; this value is, however, 
lbwerthan the value (2.00) obtained by the spectrophotometric analysis method reported by 
To1rnachev et al. 143 Protonation of chromone is favoured at the carbonyl oxygen, 
delocalization of the ether oxygen lone pair stabilizing the conjugate acid (Figure 7a). The 
increased basicity of the 2-(N,N-dirnethylamino )chromones (PK. 1.92-2.52) relative to 
chromone may be attributed to the additional delocalization of the nitrogen lone pair (Figure 
7b), provided protonation occurs at the chromone carbonyl oxygen rather than at the amine 
nitrogen. Preferential protonation of the carbonyl atygen is supported by the results of aBC 
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NMR study conducted in our laboratories by Sabbagh. 144 Moreover, AMI semi-empirical 
molecular orbital calculations by C. W. McCIeiandl44 showed that, in these systems, 
protonation of the oxygen atom is favoured over nitrogen by ca. 27 kcal mOrl . 
Ei) Ei) 
(OH R1 OH ~ Rz P'I -q Y:. Me ~ q ~ o W' I 
3 Me 
(a) (b) 
Figure 7. Lone-pair delocalization stabilizing the conjugate acids of:- (a) chromone; and 
(b) the 2-(N,N-dirnethylarnino )chromones 190 - 195. 
Table 4. pI<. data for the 2-(N,N-dirnethylarnino )chromones 190 - 195 
R1 0 
Rz 
NMez 
R3 
Compd. Rl R2 R3 pI<.b 
190 H H H 2.47 
191 H H F 1.98 
192 H F H 2.20 
193 MeO H H 2.52 
194 H H MeO 2.50 
195 H H N02 1.92 
i I 
bA125°C in H20-EtOH (1:1); estimated error ± 0.06. 
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From the results detailed in Table 4, it is apparent that the measured pI<. values lie within a 
relatively narrow range (1.92 - 2.52), thus, indicating that the remote substituents at positions 
C-5, C-6 and C-8 have relatively little effect on the basicity of the 2-(N,N-dimethyl-
amino )chromones studied. Their influence is, nevertheless, discernible. The trend observed 
for the pI<. values of the 8-substituted derivatives decreases in the order:- pI<.: 194 
(RJ=OMe) > 190 (R3=H) > 191 (R3=F) > 195 (R3=N02). This reflects the general 
expectation that basicity should be increased by electron-releasing substituents and decreased 
by electron-withdrawing substituents, although the pI<. value for the 8-fluoro analogue 191 is 
lower than might have been expected. In the case of the 8-nitro analogue 195, the low pI<. 
value (1.92) clearly reflects the electron-withdrawing character of the 8-nitro substituent, 
while the 8-methoxy derivative 194 shows an increase in basicity (PI<. 2.50), reflecting the 
electron-releasing character of the methoxy group. 
The 5-methoxy analogue 193 exhibits similar basicity (PI<. 2.52) to the 8-methoxy derivative 
194, but appears to have significantly more negative stabilization energy (-6.80 kcal morl ) 
[as calculated by C. W. McCleland]I44; this is attributed to two factors, viz: (i) relative 
destabilization of the free base 193, and (ii) intramolecular H-bonding stabilization of the 
conjugate acid. Hydrogen-bonding effects may also explain the low pI<. value (1.98) 
measured for the 8-fluoro analogue 191, in that the location of the fluorine and pyran oxygen 
atoms may permit chelation of a water molecule. Such intra-molecular hydrogen-bonding 
would not only inhibit lone-pair delocalization by both atoms into the chromone nucleus, but 
also expose the electron-withdrawing inductive effect of the fluorine substituent. The 
obtained pI<. values were supported by the optimized AMI semi-empirical calculations dom: 
by C.W. McCleland. 144 
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2.2 Granulosin and C-2 side chain analogues 
2.2.1 Synthesis ofgranulosin and C-2 side-chain analogues 
Lopez et ai. 47 in their investigation of Costa Rican medicinal plants, have recently reported 
the isolation of a chromone derivative, granulosin 40, from the bark of Galipea granulosa, a 
plant used by the Indians of Bolivia for the treatment of parasitic infections, particularly 
cutaneous leishmaniasis. The activity shown by an extract of this plant in the brine shrimp 
test and our interest in chromones prompted us to synthesize granulosin 40 and four structural 
analogues 209 - 212. From the retrosynthetic analysis (Scheme 44), it was envisaged that 
the 2',3',4'-trihydroxyacetophenone 196 could be used as the key starting material. 
o 
o 0 
\.----
40 
Scheme 44 
The first step of the synthesis involved formation of the dioxolane derivative 197 via 
regioselective acetalisation of 2',3',4 '-trihydroxyacetophenone 196 (Scheme 45) using 
bromochloromethane in the presence of cesium carbonate. 14S The strong intramolecular 
hydrogen-bonding between the 2'-hydroxyl and acetyl carbonyl groups in the 2'-
hydroxyacetophenone 196 was expected to inhibit reaction of the 2'-hydroxyl group and 
favour selective acetalisation of the 3'- and 4'- hydroxyl groups. 
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\.-0 
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OH 
R 
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204 CH3 
205 CHsCH2 
206 CH3CH2CH2 
207 (CH3l2CH 
208 PhCH2 
Reagents: i) BrCH2CI (1 eq.), CS2C03(1 eq.), DMF; ii) BrCH2Cl (1.5 eq.), CS2C03(1.5 eq.), 
DMF; iii) NaOEt, EtOH; iv) RC02Et; v) AcOH, H2S04. 
In an initial attempt to prepare the precursor 197, using 1.5 equivalents of bromochloro-
methane for each equivalent of 2',3',4'-trihydroxyacetophenone 196, the expected acetal 197 
together with the unexpected product 198 was obtained in a 12 : 88 mole ratio. The 
unexpected, major product 198 clearly arose from reaction of all three phenolic hydroxyl 
groups. The lH NMR spectrum of the "dimeric" system 198 (Figure 8) reveals a four proton 
singlet at 0 5.95 ppm, corresponding to the two dioxolane methylene protons, while the other 
methylenedioxy protons resonate as a two proton singlet at 0 6.09 ppm; the singlet at Ii 2.38 
ppm corresponds to the two acetyl methyl groups. The BC NMR spectrum of the compound · 
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198 (Figure 9) shows the presence of 10 distinct signals. A close inspection of the spectrum 
reveals the presence of an acetyl methyl carbon signal at /) 30.8 ppm, the methylenedioxy and 
dioxolane methylene signals at /) 94.3 and 102.0 ppm respectively (the difference in intensity 
consistent with the number of carbon nuclei present), and a carbonyl carbon signal at /) 197.3 
ppm. Assignment of the structure was supported by COSY, HMQC and HMBC correlations. 
Further confirmation is provided by the IR spectrum of the "dimeric" system 198, in which 
the carbonyl absorption band at 1665 cm-1 and the absence of a hydroxyl band are significant. 
High-resolution mass spectrometric analyses indicated the molecular formula to be, as 
expected, C19H160S. 
When the proportion of the bromo chloromethane was limited to one equivalent, the reaction 
proceeded smoothly to afford the required 2'-hydroxy-3',4'-(methylenedioxy)acetophenone 
197 in 80% yield. The IH NMR spectrum of the acetal 197 (Figure 10) reveals a singlet at /) 
12.27 ppm corresponding to an aromatic hydroxyl group. The down-field shift is indicative 
of hydrogen-bonding between the 2'-hydroxyl group and the carbonyl oxygen, hence, 
supporting the selective acetalisation of the 3'- and 4'- hydroxyl groups in 2',3',4'~ 
trihydroxyacetophenone 196. The IH NMR spectrum also reveals a singlet at /) 6.07 ppm 
corresponding to the methylenedioxy protons, while the acetyl methyl protons resonate as a 
singlet at /) 2.56 ppm The J3C NMR spectrum of compound 197 (Figure 11) shows 9 carbon 
signals with the methylene carbon of the methylenedioxy group resonating at /) 103.0 ppm. 
The COSY, HMQC and HMBC data were used to assigned all the signals. 
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Figure 9. 100 MHz 13C NMR spectrum of dimer 198 in CDCh. 
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Treatment of 2'-hydroxy-3',4'-(methylenedioxy)acetophenone 197 with two equivalents of 
sodium ethoxide in ethanol afforded the enolate which, on reaction with a series of ethyl 
carboxylate esters [R = CH3, CH3CH2, CH3CH2CH2, (CH3)zCH, PhCH2] gave mixtures, 
indicated by 1 H NMR spectroscopy to contain the corresponding acylated products (existing, 
in each case, as an enol tautomer) formulated as structures 199 - 203 and their cyclised 
derivatives 204 - 208. These reaction mixtures were then treated with a mixture of acetic 
and sulfuric acids to afford the corresponding chromone derivatives 40 and 209 - 212 in 
yields ranging from 58 to 85%. All ofthe products were purified by flash chromatography, 
and the structures were assigned on the basis of elemental (HREIMS) and spectroscopic (lR, 
IH and l3C NMR) analysis. The IH NMR spectrum of granulosin 40 (Figure 12) reveals a 
triplet at Ii 0.96 ppm corresponding to a methyl group, a multiplet and a triplet at Ii 1.68 and 
2.61 ppm, respectively, corresponding to the two methylene groups in the alkyl chain. The 
methylenedioxy nuclei (OCH20) resonate as a singlet at Ii 6.27 ppm, and the singlet at Ii 6.12 
ppm corresponds to the characteristic 3-methine proton of the chromone nucleus. The l3C 
NMR spectrum in CDCb (Figure 13) clearly reveals, as expected, the presence of 13 distinct 
carbon signals, while in DMSO-d6 (Figure 14), only 12 distinct carbon resonances, are 
evident due to the coincidence of the two signals at Ii 119.3 ppm. Inspection of the l3C NMR 
spectrum in DMSO-d6 (Figure 14) reveals the presence of one methyl signal at Ii 13.3 ppm 
and two methylene signals at Ii 19.7 and 35.1 ppm corresponding to the propyl side- chain. 
The characteristic methylene carbon of the methylenedioxy group is observed to resonate at Ii 
103.6 ppm, and the chromone carbonyl carbon at Ii 175.9 ppm. The signal at ca. Ii 169 ppm 
is characteristic of the C-2 carbon of most chromone nuclei. The DEPT-135 spectrum 
(Figure 15) confirms assignment of the methylene carbons of the propyl chain and the 
methylenedioxy group. The aromatic signals were differentiated using the COSY spectrum 
and the IH and l3C NMR chemical signal assignments were fucilitated using the HMQC and 
HMBC data. The IH and l3C NMR data obtained for the 2-propyl derivative 40 were shown 
to correspond closely to those reported47 for granulosin in DMSO-d6 (the IH chemical shifts 
lie within 0.03-0.19 ppm and the l3C shift within 0.1-1.1 ppm of the reported values). 
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Figure 12. 400 MHz IH NMR spectrum of granulosin 40 in CDCh. 
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Figure 15. DEPT-135 NMR spectrum ofgranulosin 40 in CDCh. 
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2.2.2 Assessment of the biological activity of granulosin 40 and C-2 side-
chain analogues 
In the light of the reported biological activity of granulosin 40,47 it was decided to evaluate 
the biological activity of compound 40 and selected structural analogues. Artemia salina 
larvicidal bioassays were performed as described by Solis et al. 146 Estimates of median lethal 
concentrations were obtained by probit analysis147 of A. salina mortality data from 12 
solutions across the concentration ranges:· 25.00 - 0.586 llg/mL for granulosin 40; and 400.0 
- 12.50 llg/mL for compounds 209 - 212. 
Table 5. Summary of Artemia salina biological assay data": 
a 
\-
Compd. 
209 
210 
40 
211 
212 
R 
R LCso b (J.U11ImL) 
CH3 131.8 
CH3CH2 22.3 
CH3CH2CH2 4.3 
(CH3)2CH 21.3 
PhCH2 108.6 
95% Confidence interval (IlmlmL) 
Lower limit Upper Limit 
112.6 156.3 
19.8 25.0 
3.5 5.2 
18.2 24.7 
93.4 126.7 
BAW" 
-
1001100 
-
-
1001100 
'Analyses conducted by C.A. Gray.b 
"'The estimated median lethal concentration values (LC,o) represent the concentration of compound required to 
halve the amount of substrate cleaved during the allotted reaction period, as obtained by probit analysis. l47 
'BAW: Beet army worm biological assay data (insect pests on crops). 
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All five of the chromone derivatives 40 and 209 - 212 showed significant cytotoxic effects 
against the brine shrimp Artemia salina. LCso values estimated by probit analysis147 (Table 
5) indicate an interesting range in activity with granulosin 40 being highly toxic (LCso : 4 
ppm), the analogues 210 and 211 displaying less toxicity (LCso : 22 and 21 ppm respectively) 
and 209 and 212 being significantly less active (LCso : 132 and 109 ppm respectively). Anti-
parasitic activity assays were carried out on compounds 40 and 209 - 212 and the results also 
summarized in Table 5. From the Beet army worm (BA W) data obtained, only compounds 
210 and 212 showed 100% BAW activity, while the other compounds 40, 209 and 211 
showed no activity. Thus, granulosin 40 despite being highly toxic to th, ~rjrul shrimp 
Artemia salina, showed absolutely no activity against the beet army worm. 
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2.2.3 Mass spectrometric analysis of granulosin 40 and C-2 side-chain 
analogues 
As indicated in the introduction (Section 1.1), when chromone 1 is subjected to electron-
impact mass spectrometry, it fragments via two main pathways involving, initially, loss of 
carbon monoxide or ring-cleavage by a retro-Diels-Alder (RDA) reaction (Scheme 1). An 
electron-impact (EI) mass spectrometric study of granulosin 40 and the four structural 
analogues 209 - 212 was undertaken to explore the effect of the various substituents on the 
fragmentation patterns. Examination of the high-resolution electron-impact (EI) and low-
resolution mass spectrometric data (Table 6), as well as the BIE link-scan data, has permitted 
elucidation of the significant peaks in the mass spectra of these compounds. 
Scheme 1 
o-r 
~ ~oJ 
1a 
mlz146 
-:It 
~o 
a c -co .. 
"" 0 
mlz 120 
\ + 
~. 
V-c! 
mlz 118 
mlz92 
l-co 
+ 
Cst0' 
mlz64 
The EI mass spectrum ofthe parent system, granulosin 40, is illustrated in Figure 16, and the 
proposed fragmentation pathways are outlined in Scheme 46. In the mass spectrum of the 
parent compound 40, the molecular ion I at m/z 232, which corresponds to the base peak, 
fragments via four major pathways (A, D, C, and D). 
66 
·§ 
., 
:l 
<> .~ 
Q 
§ 
tl 
l 
SCAN GRAPH. Flagging:Hlgh ROSoiutiOnMliFllter={lntO:S%. Exot. ReflEx ).Hlghlighti"ll=Sas"POOk. . 
100 __ Scan 16i<2:07 - 2112:45. SUb=8ID:52 -10#1:22. enbiOs=Sl. Base MIz=232.07413.1DD% Inl=6.89749. EI. POS: 
90 -
BO-
70-
OD 
'i' 
l £f 50-
• c 
~ 
40-
30-
20-
10- 53.~ 
o I" "III", " '" I 
4D OD 
78.'(0071 
l06·rS52 
i 
\ 94.1,!l524 
,IL 11,11 [' 
'I .... ' .... I 
80 ' 100 
I 
120 
164.01127 
. \ 
, 
134.00086 
, .. 
i 
L II 
' ( "" I"" ("" I 
140 160 
High Resolution MIz 
l~~;ga~ 
, 
'T 
'180 
.2D4.!l43S9 
.\ 
\ 
217/}5 
i 
I 
, I 
2DD 
, I ' , • , t ' 
220 
232.07413 
, ...... . 
, I 
240 
, I , I 
280 
-= 
"'" 
.S 
en 
.9 § 
.... 
bIl 
..... 
O 
i 
. .., 
Q.. 
en 
en 
~ 
til 
~ 
.Q 
:; 
-0 
en 
.., 
.... 
.a 
bIl 
53 
..c 
-f 
& 
~ 
t-
\C 
N
crO 
«~~H 
\-0 
[RDA+Ht 
- 0 
-
V rnk 165.01760 
CaHs04 (165.01878) 
o 
\-0 
o 
II rnk 217.05000 
C12H904 (217.05008) 
-CH+: 
I rnk232.07413 
M ~ C13H1204 (232.07356) 
RDA J.c 
Ncr~t 
O~O 
\-0 
VI rnk164.01127 
CS~04 (164.01096) 
-J-HCHO 
+ C7H20~ . 
VII rnk 134.00086 
C7H203 (134.00039) 
-J-CO 
+ CSH20~' -co 
VIII rnk 106.00552 
CsH202 (106.00548) 
.. 
Results and Discussion 
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Scheme 46. EI mass fragmentation pathways for granulosin 40. Accurate masses (mlz) are 
followed, in parentheses, by calculated formula masses; an asterisk indicates a 
pathway supported by the BIB link-scan data. 
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In path [A], the loss of a methyl radical from the molecular ion I, followed by rearrangement, 
gives the well-stabilized cation II (mlz 217, M'"-15). In path [B], loss of ethylene by a 
McLafferty-type rearrangement of the molecular ion I gives the radical-cation ill (mlz 204, 
M'-28), which subsequently loses CO and a hydrogen atom to give fragment IV (mlz 175). 
In path [C], loss ofpent-l-yne by a retro-Diels-Alder (RDA) pathway, which is characteristic 
of the chromone nucleus, affords fragment VI (mlz 164, M'"-68), which then loses HCHO to 
give fragment VII C7H20/' (mlz 134). Sequential decarbonylation of fragment VII then 
affords fragment VIII C6H20/' (mlz 106) and fragment IX CSH20+' (mlz 78). Formation of 
fragment V (mlz 165) from the molecular ion I is attributed to an RDA-type process 
accompanied by proton transfer, i.e, [RDA+Ht, which is also characteristic of the 2- and 3-
aJkyl chromones6 {Path [D]}; subsequent deprotonation also gives the ketene radical-cation 
VI. 
In the mass spectra of the analogues 209 and 210, additional fragments were observed and 
these are illustrated in Schemes 47 - 49. Thus, fragment X arises from loss of a hydrogen 
atom from the molecular ion, while decarbonylation of the molecular ion gives the ring-
contracted species XI (Scheme 47). The fragmentation patterns exhibited by the analogue 
211 are very similar to that of granulosin 40, a notable difference being the appearance of a 
peak at mlz 189, attributed to loss of CO and a methyl radical from the molecular ion, as 
illustrated in Scheme 48. 
0 0 I~ 
,,qr I' -H" -;7 -co .. • ~ I CH3 (tl • ~ • 
0 0 CH2 0 0 CH3 o 0 
\..- \..-0 \..-0 
X mlz 203.03526 Mt mlz 204,04290 XI mlz 176.04680 
C11 H704 (203.03443) C11 HS04 (204,04226) C10HS03 (176,04734) 
Scheme 47. Additional fragmentations of the molecular ion from compound 209 
Fragmentation of the 2-benzyl analogue 212 exhibits the additional fragments illustrated in 
Scheme 49. Fragment xm (mlz 252) arises from decarbonylation of the molecular ion, 
while subsequent loss of a hydrogen atom gives the fragment XIV (mlz 251). Formation of 
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the fragment XV (m/z 115) is attributed to heterolytic fission of the molecular ion via an 
RDA-type process; in this case, however, effective stabilization of the benzylic carbo cation 
presumably accounts for its formation as a cationic fragment. The fragmentation patterns of 
the structural analogues 209 - 212 are detailed in Table 6 and are supported by the BIE 1ink-
scan data. 
-co. 
o 
\-0 
Mt mlz 232.07364 
C'3H'204 (232.07356) 
• • 
o 
\-0 
XII mlz 189.05507 
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Scheme 48. Additional fragmentation of the molecular ion from compound 211 
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Scheme 49. Additional fragmentations in the mass spectrum of compound 212 
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Table 6. Selected peaks (m/z, followed, in parentheses, by % relative abundance) in the EI 
mass spectra of compounds 40 and 209 - 212, classified according to ion-types 1-
XV (Schemes 46 - 49). 
o 
o 0 R 
\...-
Ion-types 
Compd R I II III IV V VI VII VII 
209 CH3 204 175 164 134 106 
(100) (2) (57) (4) (12) 
210 CH3CH2 218 175 164 134 106 
(100) (4) (46) (3) (11) 
40 CH3CH2CH2 232 217 204 175 165 164 134 106 
(100) (3) (48) (10) (14) (55) (3) (12) 
211 (CH3)2CH 232 217 165 164 134 106 
(100) (3) (8) (26) (2) (2) 
212 PHCH2 280 165 164 106 
(100) (24) (31) (7) 
Ion-types 
Compd R IX X XI XII XIII XIV XV 
209 CH3 78 203 176 
(5) (29) (6) 
210 CH3CH2 78 217 190 
(4) (21) (2) 
40 CH3CH2CH2 78 
(5) 
211 (CH3)2CH 189 
(9) 
212 PHCH2 252 252 115 
(1) (2) (6) 
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2.3 5-Hydroxy-2-isopropyl-7-methoxychromone 35 and C-2 side-chain 
analogues 
2.3.1 Synthesis of 5-hydroxy-2-isopropyl-7-methoxychromone 35 and C-2 
side-chain analogues 
Recently, Tsui et al.,40 in their investigation of Hong-Kong medicinal plants, isolated a new 
chromone derivative, 5-hydroxy-2-isopropyl-7-methoxychromone 35, from the aerial parts of 
Baeckea frutescens L., a plant used in traditional Chinese medicine for treating rheumatism 
and snake-bite. In previous work, Nohara and co-workers89 have shown that the presence of 
hydroxyl groups on the benzene ring of the chromone system are important for biological 
activity. As part of the present study, we have developed an efficient synthesis and 
investigated the biological activity of 5-hydroxy-2-isopropyl-7-methoxychromone 35 and 
four structural analogues 231 - 234. From the retrosynthetic analysis Scheme 50, it was 
apparent that the synthesis should involve 2',6'-dihydroxy-4'-methoxyacetophenone 214 as a 
crucial synthon. 
OH 0 
35 
Scheme 50 
OH 0 
==>~ MeO~OH 
214 
JYl HO~OH 
213 
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In an initial attempt to prepare compound 214, using one equivalent of dimethylsulfoxide, 
one equivalent of the commercially available 2',4',6'-trihydroxyacetophenone 213 and one 
equivalent ofK2C03 as described by Haung et al., 148 a mixture of products, comprising 2',6'-
dihydroxy-4'-methoxyacetophenone 214, 2'-hydroxy-4',6'-dimethoxyacetophenone 215 and 
the starting materia~ 2',4',6'-trihydroxyacetophenone 213, was obtained. lH NMR. analysis of 
this mixture indicated that the desired product 214 had been formed in less than 40% yield. 
Because of the low yield, this approach was abandoned and the strategy outlined in Scheme 
51 was adopted. 
~ HO~OH 
213 
R 
216 CH3 
217 CH3CH2 
218 CH3CH2CH2 
219 (CH3)2CH MeO 
220 PhCH2 
OH 0 
& MeO::::'" 0 R 
R 
231 CH3 
232 CH3CH2 
233 CH3CH2CH2 
35 (CH3l2CH 
234 PhCH2 
Scheme 51 
OMe 
?'" 
I ::::,.. 
v 
.. 
ii, iii 
0 OH OMe 0 
?'" R 
+ 
OH MeO R 
R 
221 CH3 
222 CH3CH2 
223 CH3CH2CH2 
lw 
224 (CH3l2CH 
225 PhCH2 
OMe 0 
~ MeO~O~R 
R 
226 CH3 
227 CH3CH2 
228 CH3CH2CH2 
229 (CH3l2CH 
230 PhCH2 
Reagents: i) Me2S04 (2 eq.), K2C03 (2 eq.), acetone; ii) NaOEt, EtOH; iii) RC02Et; 
iv) AcOH, H2S04; v) AC20, HI, 115 DC, 30 min. 
73 
Results and Discussion 
The first step of the synthesis involved selective methylation of 2',4',6'-trihydroxyaceto-
phenone 213 with two equivalents of dimethylsulfoxide in the presence of two equivalents of 
anhydrous K2C03 in acetone under reflux for 5 h. The required 2'-hydroxy-4',6'-dimethoxy-
acetophenone 215149 was obtained in 90% yield. 
d~Meo S' <f? i " MeO .,~ 2' OH 
3' 
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Figure 17. 400 MHz 1H NMR spectrum of2'-hydroxy-4',6'-dimethoxyacetophenone 215 in CDCh. 
C~ 
, 
80 
2 KOCH, 
CH, 
, 
20 ppm 
Figure 18. 100 MHz J3C NMR spectrum of2'-hydroxy-4',6'-dimethoxyacetophenone 215 in CDCh. 
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The IH NMR spectrum of2'-hydroxy-4',6'-dimethoxyacetophenone 215 (Figure 17) reveals a 
singlet at 1) 13.92 ppm corresponding to the phenolic hydroxyl group, the low-field shift 
being attributed to strong intramolecular hydrogen-bonding between the acetyl carbonyl and 
the 2'-hydroxyl group (see also, Section 2.2.1, p. 60). The IH NMR spectrum also reveals a 
singlet at 1) 2.57 ppm corresponding to the acetyl methyl protons, two singlets at 1) 3.78 and 
3.82 ppm corresponding to the two methoxy groups and two doublets at 1) 5.88 and 6.01 ppm, 
with a meta-coupling constant of2.2 Hz, corresponding to the two aromatic protons, 5'-H and 
3'-H, respectively. The l3C NMR spectrum of 2'-hydroxy-4',6'-dimethoxyacetophenone 215 
(Figure 18) shows only 9 distinct carbon signals, instead of the expected 10; the signal at 1) 
55.4 ppm is very intense, suggesting coincidence of the two methoxy carbon signals - a 
conclusion supported by the COSY, HMQC and HMBC data. 
Treatment of 2'-hydroxy-4',6'-dimethoxyacetophenone 215 with two equivalents of sodium 
ethoxide in ethanol afforded the enolate which, on reaction with a series of ethyl carboxylate 
esters [R = CH3, CH3CH2, CH3CH2CH2, (CH3)2CH, PhCH2] gave mixtures, indicated by IH 
NMR spectroscopy, to contain the corresponding C-acylated products (existing, in each case, 
as an enol tautomer, formulated as structures 216 - 220) and their cyc1ized derivatives 221 -
225. Treatment of these mixtures with a mixture of acetic and sulfuric acids afforded the 
chromone derivatives 226 - 230 in yields ranging from 40 to 70%. The dimethoxychromone 
derivatives 226 - 230 were then selectively demethylated at the C-5 position by treating with 
boiling acetic anhydride and hydriodic acidl50 to afford the desired monomethoxychromone 
derivatives 35 and 231 - 234 in yields ranging from 55 to 80%. The product structures were 
confirmed by elemental (HREIMS) and spectroscopic (IR, IH and l3C NMR) analysis. 
The IH NMR spectrum of the 2-isopropyl-5,7-dimethoxychromone 229 (Figure 19) reveals a 
doublet at 1) 1.26 ppm, with a vicinal coupling constant of 6.9 Hz, corresponding to the two 
isopropyl methyl groups, a multiplet at 1) 2.74 ppm corresponding to the methine proton 
signal and two singlets at 1) 3.86 and 3.91 ppm corresponding to the two methoxy groups. 
The characteristic 3-H signal of the chromone nucleus appears at 1) 6.00 ppm, while the two 
doublets at 1) 6.32 and 6.42 ppm, with a meta-coupling constant of 2.2 Hz, correspond to the 
two aromatic protons, 6-H and 8-H, respectively. 
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Figure 19, 400 MHz IH NMR spectrum of2-isopropyl-5,7-dimethoxychromone 229 in CDCh. 
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Figure 20. 100 MHz!3c NMR spectrum of2-isopropyl-5,7-dimethoxychromone 229 in CDCh. 
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The I3C NMR spectrum (Figure 20) shows only 12 distinct carbon signals, instead of the 
expected 13 (with two signals overlapping at 108.92 and 108.93 ppm). The methyl and 
methine carbons resonating at .s 19.9 and 32.5 ppm, respectively, while the two methoxy 
carbons resonate at .s 55.6 and 56.3 ppm The aromatic carbon signals were differentiated 
using the COSY spectrum, and all of the carbon signals were assigned using HMQC and 
HMBC correlations. 
The ! H NMR spectrum of 5-hydroxy-2-isopropyl-7 -methoxychromone 35 (Figure 21) reveals 
a doublet at .s 1.29 ppm, with a vicinal coupling constant of 6.9 Hz due to the isopropyl 
methyl groups, a methine proton multiplet at .s 2.82 ppm, and a singlet at .s 3.85 ppm 
corresponding to the 7-methoxy group. The characteristic 3-H signal of the chromone 
nucleus appears at .s 6.03 ppm, while the two doublets at /:) 6.32 and 6.36 ppm exhibit a meta-
coupling constant of 2.2 Hz and correspond to the two aromatic protons, 6-H and 8-H, 
respectively. The low-field singlet at .s 12.70 ppm is attributed to the intramolecularly 
hydrogen-bonded phenolic group at C-5. The I3C NMR spectrum (Figure 22) shows the 
expected 12 signals with the methyl and methine carbons resonating at /:) 20.1 and 33.2 ppm, 
respectively, the methoxy group at.s 55.7 ppm and the carbonyl carbon at /:) 182.8 ppm The 
aromatic carbon signals were differentiated using the COSY spectrum and all of the carbon 
signals were assigned using HMQC and HMBC correlations. The IR spectrum shows a 
broad band at ca. 3000 cm-! (absent in the IR spectrum of the dimethoxy derivatives 226-
230), attributed to the presence of the hydrogen-bonded phenolic group. The high-resolution 
mass spectrum reveals a peak at mlz 234 corresponding to the molecular ion. The 
spectroscopic data obtained for the 5-hydroxy-2-isopropyl-7-methoxychromone 35 were 
shown to correspond to those reported for the natural product. 40 
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Figure 21. 400 MHz IH NMR spectrum of 5-hydroxy-2-isopropyl-7-methoxychromone 35 in 
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Figure 22. 100 MHz l3C NMR spectrum of5-hydroxy-2-isopropyl-7-methoxychromone 35 in 
CDCh. 
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2.3.2 Assessment of the biological activity of 5-hydroxy-2-isopropyl-7-
methoxychromone 35, its C-2 side-chain analogues and their dimethoxy 
derivatives 
In order to evaluate their biological activity, Artemia salina larvicidal bioassays were 
performed using the method of Solis et al.,146 as discussed in Section 2.2.2. Estimates of 
median lethal concentrations were obtained by probit analysisl47 (and use of the trimmed 
Spearman-Karber methodl51) of the A. salina mortality data from 12 solutions across 
concentration ranges of 200.0 - 10.00 J.!g/mL for compounds 35 and 231 - 233, 700.0 -
300.0 J.!g/mL for compound 234 and 400.0 - 50.00 J.!g/mL for compounds 226 - 230. 
Table 7. Sununary of Artemia salina biological assay data for compounds 226 - 230". 
Estimates of median lethal concentrations obtained by pro bit analysisl47 and the 
trimmed Spearman-Karber method. 151 
OMe 0 
JYr Meo~oJlR 
Compd. R LC50 (J.!lllImL) 95% Confidence interval (J.!mlmL) 
Lower limit Upper Limit 
226 CH) 315.1 223.9 443.3 
227 CH3CH2 200.1 182.3 219.7 
228 CH3CH2CH2 106.0 95.0 118.3 
229 (CH3)2CH 94.2 82.5 107.5 
230 PhCH2 247.3 217.1 281.8 
'Analyses conducted by C.A. Gray 
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Table 7 shows the LCso values of the dimethoxychromone derivatives 226 - 230, and it is 
apparent that these compounds are, in general, considerably less active than the 
monomethoxy compounds 35 and 231 - 234 (Table 8). These data indicate that the hydroxyl 
group at C-5 is important for biological activity. Four of the chromone derivatives 35 and 
231 - 233 showed significant cytotoxic effects against the brine shrimp Artemia salina. The 
2-benzyl derivative 234, however, appears to be even less active than the dimethoxy 
derivatives (Table 7). The LCso values (Table 8) indicate an interesting range in activity with 
5-hydroxy-2-isopropyl-7-methoxychromone 35 being highly toxic (LCso : 23 ppm), whilst 
the analogues 232 and 233 display less toxicity (LCso : 39 and 32 ppm respectively) and 
compounds 231 and 234 are significantly less active (LCso : 112 and 517 ppm respectively). 
Table 8. Summary of Artemia salina biological assay data for compounds 35 and 231 - 234". 
Estimates of median lethal concentrations obtained by probit analysisl47 and the 
trimmed Spearman-Karber method. lSI 
OH 0 
JYr Meo~oJlR 
Compd. R LCso (~m1mL) 95% Confidence interval (~m1mL) 
Lower limit Upper Limit 
231 CHJ 112.2 94.8 132.9 
232 CHJCH2 39.0 35.7 42.6 
233 CHJCH2CH2 31.5 27.4 36.4 
35 (CHJ)2CH 23.8 21.2 26.8 
234 PhCH2 516.6 445.4 599.2 
• Analyses conducted by C.A. Gray 
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2.3.3 Mass spectrometric analysis of 2-isopropyl-5, 7-dimethoxychromone 229 
and C-2 side-chain analogues 
A study of the electron impact (EI) mass fragmentation patterns of 2-isopropyl-5,7-
dimethoxychromone 229 and the C-2 side-chain analogues 226 - 230 was undertaken, using 
a combination of low-resolution, high-resolution and BIE link-scan data, and selected 
fragmentation data for these compounds are summarized in Table 9. The EI mass spectrum 
of the parent system, 2-isoprbpyl-5,7-dimethoxychromone 229 is illustrated in Figure 23, 
while the proposed fragmentation patterns are outlined in Scheme 52. 
In the mass spectrum of the parent compound 229, the base peak at m/z 248 corresponds to 
the molecular ion I, which fragment via two major pathways (A and B). In path [A], loss of a 
hydrogen atom from the molecular ion I gives fragment II (m/z 247) which, on loss of carbon 
monoxide, affords cation III (m/z 219). In path [B], loss ofHCHO from the molecular ion I 
gives rise to the radical cation IV (m/z 218), in a fragmentation which is common in aromatic 
methoxy derivatives.152 Fragment IV then undergoes three different fragmentation pathways 
(C, D and E). In path [C], loss of a hydrogen atom affords cation V (m/z 217), which then 
loses HCHO in a fragmentation associated with the second aromatic methyl ether group to 
give cation VI (m/z 187). In path [E], loss of 2-methyl-l-butyne by the retro-Diels-Alder 
(RDA) pathway, characteristic of the chromone nucleus, gives the ketene VIII (m/z 150), 
which then undergoes decarbonylation to give the ring-contracted fragment IX (m/z 122). 
Formation of the protonated ketene VII (m/z 151) from fragment IV is to attributed an 
[RDA+Ht process (path [D]), which is also characteristic of most chromone system; 
deprotonation then leads to the ketene radical cation VIII (m/z 150). 
The ion-types designated I - IX (Scheme 52), were generally observed in the mass spectra of 
the analogues 226 - 230 (as indicated in Table 9), while the 2-benzyl analogue 230 exhibits 
the specific, additional fragments illustrated in Scheme 53. The fragment X (m/z 116) is 
attributed to fission of the molecular ion via the [RDA+Ht-type process. Loss of a hydrogen 
atom from fragment X then affords the resonance-stabilized benzylic-propargylic carbo cation 
XI (mlz 115), which was also observed in the fragmentation of 2-benzyl-7,8-
(methylenedioxy)chromone 212 (see p. 70). The additional fragment XII (mlz 91) results 
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Scheme 52. EI mass-fragmentation patterns for compound 229. Accurate masses (mlz) are 
followed, in parentheses, by calculated formula masses; an asterisk indicates a 
pathway supported by the BIE link-scan data. 
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Table 9. Selected peaks (mlz; followed, in parentheses, by % relative abundance) in the EI 
mass spectra of compounds 226 - 230, classified according to ion-types I - XII 
(Schemes 52 and 53). 
OMe 0 
JYr MeoA)lo~R 
Ion-types 
Compd R I II III IV V VI 
226 CH3 220 219 191 190 189 159 
(100) (50) (33) (13) (10) (3) 
227 CH3CH2 234 233 216 204 203 173 
(100) (60) (2) (13) (12) (3) 
228 CH3CH2CH2 248 247 219 218 217 
(100) (67) (38) (4) (13) 
229 (CH3)2CH 248 247 219 218 217 187 
(100) (66) (37) (12) (13) (3) 
230 PhCH2 296 295 267 
(100) (49) (28) 
Ion-types 
Compd R VII VIII IX X XI XII 
226 CH3 150 122 
(10) (6) 
227 CH3CH2 151 150 122 
(4) (9) (6) 
228 CH3CH2CH2 151 150 122 
(5) (13) (4) 
229 (CH3)2CH 151 150 122 
(6) (7) (3) 
230 PhCH2 151 150 122 116 115 91 
(18) (4) (3) (3) (8) (6) 
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2.3.4 Mass spectrometric analysis of 5-hydroxy-2-isopropyl-7-methoxy-
chromone 35 and C-2 side-chain analogues 
The EI mass spectrum of the parent system, 5-hydroxy-2-isopropyl-7-methoxychromone 35, 
is illustrated in Figure 24, while the proposed fragmentation pathways are outlined in Scheme 
54. 
The base peak at m/z 234 corresponds to the molecular ion I, from which five major 
fragmentations pathways (A, B, C, D and E) are apparent. In path [A], loss of a hydrogen 
atom from the molecular ion I gives the tertiary carbocation II (m/z 233), which loses carbon 
monoxide to give the ring-contracted cation IV (m/z 205). In path [B], loss of a methyl 
radical from the molecular ion gives the resonance-stabilized carbocation fragment ill (m/z 
219), which subsequently undergoes decarbonylation to give the ring-contracted fragment VI 
(m/z 191). In path [C], the elimination of HCHO, characteristic of aromatic methyl ethers, IS2 
affords the radical-cation V (m/z 204), subsequent decarbonylation of the radical cation V 
affords fragment X (m/z 176). In path [D], the molecular ion I undergoes the expected retro-
Diels-Alder reaction (RDA), characteristic of the chromone nucleus, with the loss of 2-
methyl-l-butyne to give fragment vm (m/z 166). Fragment vm then loses carbon 
monoxide to give the ketene IX (m/z 138), which further loses carbon monoxide to afford the 
radical cation XI ((m/z 110). The formation of fragment VII (m/z 167) {path [E]} from the 
molecular ion is attributed to the [RDA+Ht process, which is also common in chromone 
derivatives; subsequent deprotonation provides an alternative route to fragment VID. 
While, most of the ion-types, designated I - XI, were consistently observed in the mass 
spectra of the analogues 231 - 234, additional fragments observed for the 2-benzyl derivative 
234 (Scheme 55) arise from the presence of the phenyl group. Thus, formation of fragment 
XII (m/z 115) is attributed to heterolytic fission of the molecular ion via an RDA-type 
process; as in the previous case involving 2-benzylchromones (see pp. 70 and 84), effective 
stabilization of the benzylic-propargylic carbocation presumably accounts for its formation. 
The tropylium cation xm (m/z 91) and the phenyl cation XIV (m/z 77) are typical of alkyl 
benzenes. The link-scan data supports these fragmentations. 
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Scheme 54. EI mass-fragmentation patterns for compound 35. Accurate masses (mlz) are 
followed, in parentheses, by calculated formula masses; an asterisk indicates a 
pathway supported by the BIE link-scan data. 
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Table 10. Selected peaks (m/z followed in parentheses, by % relative abundance) in the EI 
mass spectra of compounds 35 and 231 - 234, classified according to ion-types I -
XIV (Schemes 54 and 55). 
OH 0 
JYr MeoAJlo~R 
Ion-types 
Compd R I II III IV V VI VII 
231 CH3 206 205 191 177 176 163 167' 
(100) (15) (1) (48) (16) (9) 
232 CH3CH2 220 219 205 191 190 177 
(100) (15) (1) (37) (12) (9) 
233 CH3CH2CH2 234 233 219 205 204 191 167 
(100) (10) (1) (23) (6) (2) (3) 
35 (CH3)2CH 234 233 219 205 204 191 167 
(100) (12) (I) (23) (8) (12) (4) 
234 PhCH2 282 281 253 252 167 
(100) (8) (13) (4) (5) 
Ion-types 
Compd R VIII IX X XI XII XIII XIV 
231 CH3 166" 138 148 110 
(4) (10) (2) 
232 CH3CH2 166 138 162 110 
(I) (3) (5) (2) 
233 CH3CH2CH2 166 138 176 110 
(4) (3) (2) (1) 
35 (CH3)2CH 166 138 176 110 
(2) (2) (2) (1) 
234 PhCH2 166 138 224 110 115 91 77 
(2) (I) (2) (I) (7) (6) (2) 
'0/0 relative abundance under 1 
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2.4 Synthesis of potential HIV -1 protease inhibitors 
The rapid spread of the acquired immune deficiency syndrome (AIDS) and the identification 
of the human immunodeficiency virus (mV) as the main cause of the epidemic have 
prompted efforts to understand the viral replication process and, hence, to establish suitable 
targets for antiviral therapy. HIV is known to be a member of the Lentiviridae, a subfamily 
retroviruses.106,109 Like other retroviruses it contains 3 major genes, viz., gag, pol and 
env,109,153 with the gag and pol genes expressed as polyproteins. These proteins are 
catalytically cleaved by aspartic acid residues in the HIV -1 protease enzyme to produce 
structural protein needed by the virus for replication. 154-157 Thus, mv -1 protease acts as a 
"molecular pair of scissors" that cleaves the gag and pol precursor proteins to produce viral 
structural proteins. 109 Scheme 56 illustrates the proposed mechanism by which mV-l 
protease hydrolyzes and cleaves the protein substrate. \09 
HIV-1 protease 
Scheme 56 
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Catalytic hydration of the protein substrate by a water molecule affords the transition-state 
intermediate 235, which undergoes fission to afford fragments with carboxylic acid and 
amine termini. These fragments are used by the virus for replication, and the interruption of 
this catatylical process results in the production of immature virions which are non-
infectious.158 Consequently, the HIV -1 protease enzyme has emerged as an important target 
for AIDS chemotherapy, and a number of HIV protease inhibitors are currently being used 
for the treatment of AIDS.159 Recent clinical studies have shown that many HIV protease 
inhibitors reduce the viral load and increase the number of CD4+ lymphocytes (T-cells) in 
patients infected with HIV. The severe decrease in the number ofCD4+ lymphocytes in such 
patients often results in opportunistic infections and diseases.16o Many potent and selective 
HIV -1 protease inhibitors have been designed as transition~state 235 mirnetics, which 
incorporate a non-hydrolyzable hydroxyethylamine 160 or hydroxyethylene 161 dipeptide 
isostere at the PI-PI' catalytic site.114,117,161 As indicated in Section 1.2.4.2 (pp. 40-41), some 
chromone derivatives have been shown to inhibit HIV-l protease activity, and belong to the 
class of non-peptidic HIV protease inhibitors. AIl five ofthe clinically useful HIV -1 protease 
inhibitors (saquinavir 155, ritonavir 156, indinavir 157, nelfinavir 158 and amprenavir 159) 
and other synthetic inhibitors, currently on clinical trials, incorporate either hydroxy-
ethylarnine or hydroxyethylene dipeptide isosteres. 
HIV-1 protease amino acid residues 
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Figure 25. Hypothetical hydrogen-bonding interactions and ring-opening of the chromone 
ring in the HIV protease receptor cavity (X = 0, S, NH). 
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However, despite the host of publications to date, no attention appears to have been given to 
the synthesis of systems containing both chromone and dipeptide isostere moieties. We 
hypothesized that attachment of chromone nuclei on to the hydroxyethylene dipeptide 
isostere 161 might:- i) improve aqueous solubility and oral bioavailability; ii) permit 
hydrogen-bonding between the chromone carbonyl and ether oxygens, on one hand, and 
structural water molecules or amino acid residues in the enzyme receptor cavity, on the other; 
and iii) permit nucleophilic ring-cleavage of the chromone pyran ring by suitably located 
amino acid residues, resulting in covalent links between the enzyme and the inhibitor (Figure 
25). 
Of the five mv -I protease inhibitors in clinical use, ritonavir 156, is considered the single 
most potent but, recently, multidrug therapy has been reported to be very effective in 
combatting the disease. 1l5,162 In the present study, the synthesis of ritonavir analogues, 
containing chromone termini was investigated, and an interactive computer programme was 
used to model the docking of these analogues into the active site of the enzyme. The synthetic 
strategy which we adopted was to first synthesize the non-hydrolyzable hydroxyethylene 
dipeptide isostere 236, which could then be coupled to chromone carboxylic acids to afford 
the required ritonavir analogues as illustrated in the retrosynthetic analysis in Scheme 57. 
o 
H OH ,/Ph O 
~~ 
, N , [ 
0 ' H Ph./' 
o 
2x ~+ R~O~COOH 
SchemeS7 
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2.4.1 Synthesis o/the hydroxyethylene dipeptide isostere 
The hydroxyethylene dipeptide isostere 236 was synthesized following the approach reported 
by Stuk et aI.,163 as outlined in Scheme 58. The synthetic sequence, which begins with 
commercially available L-phenylalanine 237, involves seven steps and requires diastereo-
selective reduction of the enaminone intermediate 240. In order to ensure that this reduction 
affords the required alcohol, prior dibenzylation of the adjacent amino group was necessary 
to inhibit possible chelation-controlled hydride addition to the amino ketone intermediate 
241. 
Scheme 58163 
o 
H2N~ ~ OH 
Ph/'" 237 
v 
• 
I • 
viii 
• 
o 
Bn2N~ ~ OBn 
Ph/'" 238 
Iv 
o 
Ii. Bn2N~CN 
Ph/'" 239 
Reagents: i) BnCI, K2C03, H20; ii) CH3CN, NaNH2, dry THF; iii) BnMgCI, dry THF; iv) 
NaB~, MsOH; v) NaBH3(OTFA), vi) PdlC, HC02~; vii) HCl(aq), iPrOH; 
viii) NaHC03(aq). 
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L-phenylalanine 237 was treated with benzyl chloride under basic conditions to give the 
tribenzylated derivative 238. The cyanomethyl ketone 239 was obtained via acyl substitution 
by reacting the acetonitrile-derived anion with the ester 238 at -40 °c (the temperature and 
mode of addition being important in minimizing racernisation). The Grignard reagent, benzyl 
magnesium chloride, reacted efficiently with the nitrile 239 at 20°C, to afford the enaminone 
240 in 92% yield. The next crucial step was the generation of the C-3 and C-5 chiral centers. 
This involved treatment of the enaminone 240 with excess sodium borohydride in the 
presence of methanesulphonic acid, and stereose1ective reduction of the ketone intermediate 
241 using NaBH3(OTFA), generated in situ from trifluoroacetic acid and sodium 
borohydride, to afford a mixture of diastereomeric amino alcohols 242. The ratio of the 
diastereomers was not determined, but the IH and 13C NMR spectroscopic data were identical 
with those reported by Stuk et al.163 Debenzylation of the diastereomers 242 was achieved in 
ca. 68% yield using a 5% palladium-on-carbon catalyst in the presence of ammonium 
formate, while purification was achieved by precipitating the product from isopropyl alcohol 
and concentrated HCI to afford the dihydrochloride salt 243, which was readily converted to 
the free diamine 236 by treatment with saturated aqueous sodium hydrogen carbonate. 
One- and two-dimensional NMR spectroscopy was used to confirm the formation of 
compounds 236 - 243, the IH and 13C NMR data being consistent with those reported by 
Stuk et al. ,163 (only the m.p. of compound 239 was higher than the reported value). The IH 
NMR spectrum of the free diarnine 236 (Figure 26) reveals the 3-H signal at cS 3.72 ppm, the 
5-H proton signal at cS 3.11 ppm and the signals corresponding to the diastereotopic 4-
methylene protons as multiplets at cS 1.56 ppm and 1.70 ppm. The 13C NMR spectrum 
(Figure 27) reveals characteristic signals for the 3-methine carbon at cS 74.5 ppm, the 2-
methine carbon at cS 57.5 ppm and the 5-methine carbon at cS 54.0 ppm. The three methylene 
carbons, C-I, C-4, and C-6, resonate at cS 39.1, 41.3 and 47.3 ppm, respectively, their 
assignment being supported by the DEPT-135 spectrum (Figure 28). The COSY, HMQC and 
HMBC data, confirm attachment of the three pairs of diastereotopic methylene protons to the 
corresponding carbon nuclei, C-I, C-4 and C-6. 
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Figure 26. 400 MHz lH NMR spectrum of hydroxy ethylene dipeptide isostere 236 in CDCI). 
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Figure 27. 100 MHz \3C NMR spectrum of hydroxy ethylene dipeptide isostere 236 in CDCI). 
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Figure 28. DEPT-135 NMR spectrum of hydroxy ethylene dipeptide isostere 236 in CDC!). 
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2.4.2 Synthesis of chromone-2-carboxylic acid derivatives 
The chromone-2-carboxylic acid derivatives 258 - 262, required for coupling with the 
diarnine 236, were prepared as outlined in Schemes 59 and 60. Claisen acylation of the 
substituted o-hydroxyacetophenones 244 - 248 with diethyl oxalate in the presence of 
sodium ethoxide (as described by Fitton and Smalley164 and by Ellis et al. 165,166), followed by 
one-pot acid-catalyzed cyclization, dehydration and hydrolysis, afforded the corresponding 
chromone-2-carboxylic acids 258 - 261 directly. The 7-hydroxychromone-2-carboxylic acid 
262 was obtained by acid-catalyzed hydrolysis of the ester 257, isolated following the 
procedure reported by Ellis et al. 166 
244 H H 
245 H CI 
246 H MeO 
247 MeO H 
o OH 
"'mH o C02Et 
R1 R2 
249 H H 
250 H CI 
251 H MeO 
252 MeO H 
253 H H 
254 H CI 
255 H MeO 
256 MeO H 
258 H H 
259 H CI 
260 H MeO 
261 MeO H 
Scheme 59 
Reagents: i) NaOEt, EtOH, (C02Et)2; ii) HCI-AcOH (1:1), heat. 
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o o ~ 
HoAAoH 
i-iii ..... ~ 
HoAAoJlC02Et 
iv 
.. ~ 
HoAAoJlcOOH 
248 257 
Scheme 60 
Reagents: i) NaOEt, EtOH, (CO~t)2; ii) conc. HCI; iii) charcoal, H20; 
iv) HCI-AcOH (1:1), heat. 
262 
The reaction intermediates, viz, the diketones (existing as enol tautomers) 249 - 252 and the 
substituted 2-hydroxychromanones 253 - 256 were readily distinquished by IH NMR 
spectroscopy, and the crude mixtures were used in the next step without further purification. 
The IH and l3C NMR spectra of 6-methoxychromone-2-carboxylic acid 260 are illustrated in 
Figures 29 and 30. The IH NMR spectrum reveals a singlet at Ii 6.88 ppm, which is 
characteristic of the 3-H nucleus of the chromone ring, and a singlet at Ii 3.87 ppm 
corresponding to the methoxy protons. The carboxylic acid proton was not observed, 
preswnably, due to rapid exchange with water present in the DMSO-d6 used as the solvent; 
the IR spectrum, however, revealed a broad band in the region 3300 - 2200 cm-1 
corresponding to the carboxylic hydroxyl group. The l3C NMR spectrum clearly shows 11 
carbon signals, with the methoxy carbon resonating at Ii 55.7 ppm. The use of COSY, 
HMQC and HMBC experiments facilitated the interpretation of both the IH and l3C NMR 
spectra. 
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Figure 29. 400 MHz IH NMR spectrum of 6-methoxychromone-2-carboxylic acid 260 in 
DMSO-d6. 
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Figure 30. 100 MHz 13C NMR spectrum of6-methoxychromone-2-carboxylic acid 260 in 
DMSO-d6. 
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2.4.3 Synthesis of chromone-containing analogues of the HIV-J protease 
inhibitor, ritonavir 
Initial attempts to synthesize chromone-containing analogues of ritonavir, using two 
equivalents of N,N'-carbonyldiimidazole (Cm) as the coupling agent, in the presence of dry 
DMF as outlined in Scheme 61, afforded both the bis- and tris-chromone derivatives, with 
the yields of the tris-chromone derivatives 268 - 270 being higher than those of the desired 
bis-chromones 263 - 265. The formation of the tris-chromone compounds 268 - 270 was 
clearly due to the ability of cm to promote the coupling of arnines with acids as well as acids 
with alcohols.167.168 The tris-chromone derivatives 268 - 270 were characterized using IH 
and l3C NMR, IR and high-resolution mass spectrometric analysis. Thus, the IH NMR 
spectrum of compound 270 reveals three distinct singlets in the region /) 3.80 - 4.00 ppm 
corresponding to the three methoxy groups, and singlets at /) 7.00, 7.04 and 7.09 ppm 
corresponding to the characteristic 3'-H nuclei of the three chromone rings. 
....... Ph OH 0 
R, 0 R2 ; .. ·' ·'3' 
e' 1 I. 
R3 7' ~. e.' 0 
· ,. 
H:z~NH:z 
Ph"'" 236 
263 H H H 31 
264H CI H 27 
266 H MeO H 35 
Scheme 61 
+ R'm 
R, R, R" 
268 H H H 
1 1 
R" "" 0 COOH 259 H CI H 
260 H MeO H 
CDI.DMF 
268H H H54 
289 H CI H 49 
270 H MeO H 60 
The l3c NMR spectrum clearly reveals the presence of three methoxy carbons resonating at /) 
55.8, 55.9 and 56.0 ppm, while the high-resolution F AB spectrum exhibits a peak at mlz 891 
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corresponding to the molecular ion (M+H') (see experimental section for spectroscopic 
data). Because of our desire to improve the yield of the desired bis-chromone products, in 
which the crucial 3-hydroxyl group is available for binding with the enzyme, a search for 
suitable peptide coupling agents was undertaken. Use of N-ethyl-N'-(dimethylarninopropyl)-
carbodiimide hydrochloride (EDC) in the presence of I-hydroxybenzotriazole hydrate 
(HOBt) has been shown to effect such coupling,117 and the diamine 236, in dry DMF, was 
treated with two equivalents of each of the chromone-2-carboxylic acids 258 - 262 in the 
presence of two equivalents of EDC, two equivalents of HOBt and basified with drops of 
triethylamine. Work-up and purification of the reaction mixture by flash chromatography on 
silica gel afforded, in each case, the desired chromone-containing ritonavir analogues 263 -
267 as the sole products in yields ranging from 52 to 82% (Scheme 62). 
/Ph ~& R1 R2 ~ OH " H2N~ 258 I I H H H , NH2 + 
R3::::'" 0 COOH 259 H CI H 
Ph/ 236 260 H OMe H 261 OMe H H 
262 H H OH 
EDC, HOBt EI3N, DMF 
R1 0 
48' 4' 
3' 
I .. 
H OH 8("Ph 0 
I~' N 2 " 
_ 3 5 N 
, 4
1 /1 H Ph 
R 
0 
R1 R2 R3 Yields/% 
263 H H H 60 
264 H CI H 52 
265 H OMe H 56 
266 OMe H H 82 
267 H H OH 78 
Scheme 62 
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The ritonavir analogues 263 - 267 were fully characterized by elemental (HREIMS), one-
and two-dimensional NMR, and IR spectroscopic analysis. The IH NMR spectrum of the 
parent compound 263 (Figure 31) reveals a multiplet at 1i 1.83 ppm, corresponding to the 
diastereotopic 4-methylene protons, and a complex of multiplets at 1i 2.86-3.00 ppm 
corresponding to the benzylic 1- and 6-methylene protons. The broad singlet at 1i 3.89 ppm is 
characteristic of the 3-methine proton, while the 2- and 5-methine protons resonate as 
multiplets at ca. 1i 4.40 ppm. The IH NMR spectrum also reveals two singlets at 1i 6.96 and 
7.05 ppm which are typical of the 3'-H nuclei, and a broad singlet at 1i 4.24 ppm 
corresponding to the 3-hydroxyl group. The BC NMR spectrum (Figure 32) shows three 
methine carbons resonating at 69.4 ppm (C-3), 55.6 ppm (C-2) and 49.9 ppm (C-5), while the 
methylene carbons at C-1, C-4 and C-6 resonate at 38.2, 39.4 and 40.8 ppm respectively. The 
methylene and methine signal assignments were established from the DEPT-135 spectrum 
(Figure 33), while the COSY spectrum (Figure 34) shows the coupling between the 4-
methylene protons and the 5-methine and 3-methine protons, between the I-methylene 
protons and the 2-methine proton and between the 6-methylene protons and the 5-methine 
proton. The aromatic signals were assigned with the aid of the COSY, and the HMQC and 
HMBC spectra (Figures 35 and 36), while the high-resolution mass spectral data for the peak 
at m/z 628.22076 corresponds to the molecular formula of the parent system 263, C3sH32N207 
(628.22095). 
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Figure 31. 400 MHz IH NMR spectrum of the "parent" compound 263 in CDCh. 
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2.4.4 Computer modelling studies of the ritonavir analogues 
In recent years, the developments in molecular modelling and structure-based drug design 
have led to the production of several highly potent HIV -I protease inhibitors. Using a 
reported X-ray crystal structure1l3 of ritonavir 156 and an interactive docking procedure, we 
have investigated the docking of the chromone-containing ritonavir analogues 263 - 267 into 
the active site of the enzyme. Before attempting the docking experiments, preliminary 
computer alignment of the five clinically used drugs 155 -159 and our ritonavir analogues 
263 - 267 was carried out. The conformational energies of the ten compounds 155 - 159 and 
263 - 267 were minimized by molecular dynamics simulations to obtain their minimum 
energy conformations. 
(a) (b) 
Figure 37. Energy-minimized structures of (a) ritonavir 156 and (b) the chromone-
containing analogue 263. 
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Figures 37a and 37b show the energy-minimized structures of ritonavir 156 and the parent 
chromone-containing analogue 263, respectively. The energy-minimized structures, were 
aligned by first matching the corresponding atoms (i.e. the characteristic 3-hydroxy groups) 
manually. A preliminary overlay using this approach revealed the alignment of our 
compounds 263 - 267 and the five clinically used drugs (Figure 38) and the corresponding 
net receptor-binding surface (Figure 39). 
Figure 38. Alignment of the energy-minimized structures of compounds 155 -159 
and 263 - 267. 
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Figure 39. Receptor-binding surface containing the aligned, energy-minimized structures of 
compounds 155 - 159 and the chromone-containing analogues 263 - 267. 
However, it was apparent that the energy-minimized conformations bore little resemblance to 
the binding conformation adopted by ritonavir 156 in the enzyme active site. Consequently, 
it was decided to use the Cerius2 LIGAND FIT module to determine the most favourable 
bound conformations of each of the compounds 263 - 267 and investigate their interactions 
with the enzyme active site. 
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A number of high-resolution X-ray structures of complexes of linear inhibitors with the HIV-
1 protease dimer have been reported. 1l3,12I ,169,170,171 Two common features observed in these 
structures are illustrated in Figure 40YO,I69 The first is the presence of a structural water 
molecule linking the bound inhibitors to the flexible glycine-rich "flaps" of the enzyme. The 
structural water molecule accepts two hydrogen-bonds from the backbone amide hydrogens 
of the isoleucine residues, Ile SOA-NH and Ile SOB-NH, while donating two hydrogen-bonds 
to the carbonyl oxygens of the transition state mimetic of the inhibitor molecule. The second 
and probably most important, feature is the hydrogen-bonding between the hydroxyl group of 
the inhibitor molecule and the catalytic aspartic acid residues (Asp 25A-COO' and Asp 2SB-
COO") of the enzyme. Residues to the left of the HIV -1 protease inhibitor cleavage site 
(hydroxyl group) are referred to as the Ph P2, P3, etc positions, and those to the right as PI', 
P2', P3', etc, while their respective locations in the enzyme active site are designated the S], 
S2, S3, etc and SI', S2', S3', etc pockets. 
CatalytiC ASP25A-COO~, 'POC-ASP25B 
\ I 
\ H 0r~M~Y\ 
0.,."""""",,:1 H .•..••.•.•••••. '-o P2' 
</';P(\" • structural water 
Flap lie 50A-NI-( ~HN.lle 50B Flap 
Figure 40. Schematic representation of hydrogen-bonding interactions found for a typical 
peptidomimetic inhibitor binding at the HIV -1 protease active site via bridging 
structural water. llO,169 
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Figure 41. Active site of the dimeric HJV-I protease enzyme, as determined by 
Kempf et al. 113 
In order to study the nature of the interactions between the mv -1 protease enzyme and our 
compounds, the X-ray structure of the mV-I protease containing ritonavir, as determined by 
Kempf et aI., 113 was used as the starting point. Removal of the ligand, ritonavir, reveals the 
receptor cavity of the enzyme, (Figure 41). Three-dimensional computer models of 
compounds 263 - 267 were built and their energies minimized using a molecular mechanics 
routine. Using the interactive docking module "LIGAND FIT', the ligands 263 - 267 were 
each docked into the enzyme active site. 
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(b) 
Figure 42. The most favourable bound conformations of:- a) compound 263; and b) ritonavir 
156. 
The most favourable bound conformations of the ligands in the enzyme active site were 
determined, by scoring different conformations of each compound to obtain their van der 
Waals protein-ligand interaction energy. Figure 42 shows the most favourable bound 
conformer of the parent system 263 and that of ritonavir 156 in the active site of the HIV-I 
protease enzyme. The former has a van der Waals protein-ligand interaction energy of --60.8 
Kcal mor1 compared to -98.2 Kcal mor1 for the latter. Although, the value for the parent 
system 263 is somewhat higher than that for ritonavir 156, it is nevertheless a negative value, 
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indicating the relative stability of the enzyme-ligand 263 complex. Figures 43a and 43b 
illustrate the potential hydrogen-bonding interactions between ritonavir 156 and the receptor 
in the absence and presence of bridging structural water, respectively. Figures 44a illustrates 
the potential hydrogen-bonding interactions between the 3-hydroxyl group of the most 
favoured conformer of compound 263 with the side-chain catalytic aspartic acid residues, 
while Figure 44b illustrates the potential interactions between the 2-carbamoyl and the 
chromone ether oxygens, a bridging water molecule and the backbone (Ile 50A and Ile 50B) 
amide hydrogens. The potential interactions in the absence of structural water are detailed 
schematically in Figure 45a, in which it is apparent that the distances between the 3-hydroxyl 
group and the catalytic aspartic acid residues (Asp 25A-COO- and Asp 25B-COOj of the 
enzyme are 4.358 A and 3.259 A, compared to 2.327 A and 2.178 A for the corresponding 
distances for ritonavir 156 (Figure 43a). However, the 2-carbamoyl oxygen is only 3.155 A 
distant from the Ile 50A amide hydrogen compared to a distance of3.875 A for ritonavir 156. 
The potential hydrogen-bonding interactions between the ligand 263 and the enzyme receptor 
in the presence of structural water molecules are illustrated in Figure 45b. Thus, the 2-
carbamoyl and chromone (P2-P3) ether oxygens may accept two hydrogen bonds from a 
structural water molecule, while the Ile 50A and Ile 50B residues each donate an amide 
hydrogen to the structural water molecule, the respective inter-atomic distances of 2.804 A 
and 2.183 A indicating the possibility of strong hydrogen-bonding interactions. It is also 
apparent that a structural water molecule could accept a hydrogen-bond from the Asp 29A 
amide hydrogen (2.855A) and donate a hydrogen-bond to the chromone (P2'-P3) carbonyl 
oxygen (3 .953 A). Close examination of the docked structure reveals that the two chromone 
moieties fill the S2-S3 and S2'-S3' pockets of the enzyme receptor, while the two phenyl groups 
fIll the S\ and S\' pockets. The phenyl group in the S\ socket is involved in hydrophobic 
interactions with the Val82A and Ile 84A residues ofthe enzyme at distances of 3.091 A and 
2.865 A, respectively, while the phenyl group in the S\' socket interacts with the Arg 8B 
residue at 2.107 A. Other possible hydrophobic interactions between the bound ligand 263 
and the receptor include that ofthe benzene ring of the chromone P2-PJ moiety with the Asp 
29B residue (3.218 A) and the corresponding ring of the chromone P2'-PJ' moiety with the Pro 
8IB residue (2.410 A). Figure 46 shows the most favoured bound conformer of ligand 263 in 
the active site ofthe enzyme. 
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Figure 43a. Schematic representation of potential hydrogen-bonding interactions (with 
distances in A) between ritonavir 156 and the HIV -1 protease enzyme in the 
absence of bridging structural water molecules. 
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Figure 43b. Schematic representation of potential hydrogen-bonding interactions (with 
distances in A) between ritonavir 156 and the HIV -1 protease enzyme in the 
presence of bridging structural water molecules, 
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-
Figure 44a. Favoured bound conformer of compound 263 showing the potential hydrogen-
bonding interactions between the 3-hydroxyl group and the mv -1 protease 
aspartic acid residues. 
-. H./ . 
Figure 44b. Favoured bound conformer of compound 263 showing the potential hydrogen-
bonding interactions between the 2-carbamoyl group and chromone ether 
oxygen, a bridging water molecule and the backbone (lIe 50A and Ile SOB) 
amide hydrogens. 
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Figure 45a. Schematic representation of potential hydrogen-bonding interactions (with 
distances in A) between ligand 263 and the mv -1 protease enzyme in the 
absence of bridging structural water molecules. 
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Figure 45b. Schematic represention of potential hydrogen-bonding interactions (with 
distances in A) between ligand 263 and the mv -1 protease enzyme in the 
presence of bridging structural water molecules. 
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" parent" compound 263 
Figure 46. Illustration of the most favoured bound conformer of ligand 263 in the active site 
of the HlV-I protease enzyme. 
Docking experiments were also undertaken for the remaining synthetic ligands 264 - 267 and 
the resulting pertinent data are swnmarized in Table 11. In the case of ligands 265 and 267, 
the 6-methoxy and the 7-hydroxyl substituents on the P2-P3 chromone moiety exhibit 
potential hydrogen-bonding interactions with the Asp 29B amide hydrogen and the Asp 29B 
carboxylate group with inter-atomic distances of 2.190 A and 2.070 A, respectively. The 6-
chloro and 6-methoxy substituents on the P2-P3 chromone moiety (ligands 264 and 265) were 
also observed to lie close enough to the Val32B (3.199 A) and He 47B (2.414 A) residues to 
participate in hydrogen-bonding interactions. 
Figure 47 illustrates the complementary receptor-binding surface for the aligned ligand 263 
and ritonavir 156. Alignment of the favoured bound conformers of all the ligands 263 - 267 
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and ritonavir 156 was performed, and the complementary receptor-binding surface was 
generated in order access the structural similarities and steric demands of the various ligands 
(Figure 48). From Figures 47 and 48, it is seems that the ritonavir analogues 263 - 267, have 
the capacity to bind in the receptor cavity. 
Figure 47. Complementary receptor-binding surface for the aligned ligands 263 (blue) and 
ritonavir 156 (white). 
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Figure 48. Complementary receptor-binding surface for the aligned ligands 263 (blue), 264 
(light green), 265 (magenta), 266 (yellow), 267 (red) and ritonavir 156 (white). 
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Table 11. Data for the docking of ritonavir 156 and ligands 263 - 267 with the HIV-I 
protease receptor. 
Hydrogen-bonding interaction distances in A 
Compd. vdW enerel:' (KcaJ mor) Asp25A-COO·b Asp25B-COO·b I1e50A-NH' 
156 -98.19 2.327 2.178 1.731 -
263 -60.79 4.358 3.259 3.155 2.183d 
264 -46.10 5.649 3.769 2.316 2.162d 
265 -68.13 3.856 3.372 2.592 2.326d 
266 -56.51 6.362 3.751 3.592 3.818d 
267 -66.81 3.481 3.659 3.727 4.291d 
a van der Waals' energy of the protein-ligand interactions for the most stable arrangement. 
binteractions with the 3-hydroxyl group. 
'interaction with the chromone-2-carbamoyl oxygen 
dInteractions with P,-P, chromone ether oxygen. 
I1e50B-NH' 
1.679 
2.804 
2.471 
2.700 
3.436 
2.042 
The possibility of nucleophilic ring-cleavage of the chromone-pyran ring by a suitably 
located nucleophilic residue of the HIV -I enzyme was also investigated for the parent system 
263. It was observed that two structural water molecules located at an inter-atomic distances 
of3.298 A and 5.682 A from the electrophilic centres, C-2, ofthe P2-P3 and P2'-P3' chromone 
moieties respectively, as detailed in Figure 49, could possibly attack the chromone rings. 
Such attack could result in ring-opening and the formation of covalent links between the 
inhibitor and the structural water molecules. The presence of other structural water 
molecules capable of forming hydrogen-bonding interactions with the chromone-pyran 
carbonyl oxygens (2.664 and 4.338 A) could facilitate electron-delocalization and thus 
enhance electrophilicity at the C-2 position of the chromone rings making them more 
susceptible to nucleophilic ring-opening. Other nucleophilic centres located on the protein 
backbone with the potential for attacking one or other of the chromone C-2 centres are;- Asp 
29B-NH, Ala 28B-NH, Val 82B-NH and Gly 49B-NH with inter-atomic distances of 5.055 A 
5.723,5.419 and 6.054 A, respectively. 
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Figure 49. Schematic representation of potential interactions (distances in A) between the 
ligand 263 and suitably located structural water molecules. 
From the results obtained in the docking experiments, it is apparent that the favoured bound 
conformation adopted by each of the ligands in the enzyme active site is very different from 
the conformation corresponding to the respective global-minima obtained in the pre1iminary 
studies (Figures 37a and 37b). It is also expected, on the basis of the computer modelling 
data, that all of the synthetic ligands 263 - 267 should be capable of binding to the enzyme 
active site. The next phase in our programme will involve biological testing of these 
compounds. 
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2.5 Morita-Baylis-Hillman reactions of chromone-3-carbaldehydes 
The Morita-Baylis-Hillman reaction involves the coupling of activated alkenes with carbon 
electrophiles, particularly aldehydes, in the presence of a nucleophilic catalyst.172•17S The 
reaction results in the formation of a new carbon-carbon bond, a process which is 
fundamental to synthetic organic chemistry. These reactions typically require mild reaction 
conditions, and provide useful synthetic intermediates. A common drawback in Morita-
Baylis-Hillman reactions is that 1,4-diazabicyclo[2,2,2]octane (DABCO)-catalyzed reactions 
are often exceedingly slow. Several approaches have been proposed to address this problem; 
these include the use of other catalysts and different reaction conditions.174 The generally 
accepted mechanisml75 for the DAB CO-catalyzed reaction of acetaldehyde with methyl 
acrylate involves nucleophilic addition of the catalyst (i.e. DABCO) 272 to the activated 
alkene 271 to afford the Baylis-Hillman zwitterion 273, which then reacts with the 
electrophile to give the zwitterion 274 (illustrated in Scheme 63).175 Anti E2 elimination of 
the catalyst, followed by protonation, then leads to the Morita-Baylis-Hillman product 276 
and release of the catalyst. Alternatively, an internal proton transfer in the intermediate 274 
may occur to give the resonance-stabilized zwitterion 275, which proceeds to the product 276 
by an E 1 cB e1imination.175 
+ 
. 
272 
+ 
272 
Scheme 63 
~) MeCHO ~& .. 
273 OMe 
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Although the Morita-Baylis-Hillman reaction is enjoying attention by many research groups, 
no attention appears to have been given to its application to chromone-3-carbaldehydes.95 
Such reactions have been undertaken in our laboratories in the hope that novel and interesting 
transformations might occur. 
2.5.1 Synthesis of chronwne-3-carbaldehydes 
The substituted chromone-3-carbaldehydes, which were required to explore substituent 
effects on the subsequent Morita-Baylis-Hillman reactions, were synthesized via Vilsmeier-
Haack reaction of appropriately substituted o-hydroxyacetophenones and DMF, as reported 
by Nohara et al.56 The commercially available o-hydroxyacetophenones 43 and 277 - 281 
were treated with phosphorus oxychloride (POCh) in dry DMF at -20°C (in a dry ice-
acetone bath) to give the desired chromone-3-carbaldehydes 27 and 282 - 286 in yields 
ranging from 52 to 72% (Scheme 64). 
"'Ct R2 0 i) POCI3, DMF RWCHO .. ~ I I ~ OH ii) H2O 0 
R1 R2 R1 R2 
43 H H 27 H H 
277 Br H 282 Br H 
278 CI H 283 CI H 
279 F H 284 F H 
280 OMe H 285 OMe H 
281 H OMe 286 H OMe 
Scheme 64 
Recrystallization from acetone afforded the analytically pure products, which were fully 
characterized by elemental (HREIMS) and spectroscopic (IR, IH and !3C NMR) analysis. 
The lH NMR spectrum (Figure 50) of compound 283 reveals a singlet at Ii 8.52 ppm 
corresponding to the characteristic 2-methine proton, while the formyl proton resonates as a 
singlet at Ii 10.33 ppm. The \3C NMR spectrum (Figure 51) shows the expected 10 carbon 
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signals, with two signals overlapping at (5 120.2 and 120.3 ppm. The 2-methine carbon 
resonates at (5 160.6 ppm and the two carbonyl carbon signals appear at (5 174.8 and 188.0 
ppm. 
0 
Cl 4. 4 CRO P'" 
CHO , I 3 
2- 7 "'" 
2 
,. 0 
283 
, , , , , , , , , 
10 . 5 10.0 ,. S '. 0 • • S ' .0 7.S 7 . 0 6.S ppm 
I~I I~(~~( \~ I§I 
Figure 50. 400 MHz lH NMR spectrum of 6-chlorochromone-3-carbaldehyde 283 in CDCh. 
CHO C-2 
C=O 
J 
, , , , , , , , , , , , , , , 
2" 1 90 
'" 
170 160 l SO 140 130 120 110 100 
" 
eo 70 60 ppm 
Figure 51. 100 MHz l3C NMR spectrum of 6-chlorochromone-3-carbaldehyde 283 in CDCb. 
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2.5.2 Reactions of chromone-3-carbaldehydes with acrylonitrile 
Earlier work carried out in our laboratories by Sabbagh176 on the Morita-Baylis-Hillman 
reaction between chromone-3-carbaldehydes and the activated alkenes, methyl acrylate and 
acrylonitrile in the presence of DARCO afforded, in very low yields, the expected Morita-
Baylis-Hillman products (8 to 17%), together with unexpected chromone dimers (2 to 15%). 
Not only were the yields very low, but reaction times of several weeks and extensive 
purification procedures were also required. In the present study, we extended the preliminary 
optimization studies undertaken by Sabbagh176 (on an NMR tube scale) to obtain, principally, 
the Morita-Baylis-Hillman products. Attention was then given to the possibility of obtaining 
the chromone dimers in good yield. 
r N 
OH 
+ 3-HQ R 3 " CN 
R2 0 CHCI3 
l' 
R1W
CHO 
~ I I 
R, R2 0 
R, R2 287 H H 
288 Br H 
27 H H 289 CI H 
282 Br H 290 F H 
283 CI H 291 OMe H 
284 F H 292 H OMe 
285 OMe H 
286 H OMe 
Scheme 65 
After exploring varIOus protocols, a general procedure was developed which provided 
efficient access to the required Morita-Baylis-Hillman products on a preparative scale, Thus, 
a mixture of one equivalent of each of the chromone-3-carbaldehydes 27 and 282 - 286, 1.5 
equivalents of acrylonitrile and 5 equivalents of the catalyst, 3-hydroxyquinuclidine (3-HQ) 
in a minimum volume of chloroform was stirred at room temperature for 24 h (Scheme 65). 
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The crude reaction mixtures were purified by flash chromatography to afford the 
corresponding Morita-Baylis-Hillman products 287 - 292 in isolated yields ranging from 53 
to 67% (Table 12). The products were fully characterized by elemental (HREIMS) analysis 
and one- and two-dimensional NMR spectroscopy. The lH NMR spectrum (Figure 52) of the 
Morita-Baylis-Hillman product 289 reveals a doublet at {) 4.16 ppm corresponding to the 3'-
hydroxyl group, a doublet at {) 5.34 ppm corresponding to 3'-H nucleus and two distinct 
singlets at {) 6.13 and 6.32 ppm characteristic of the I'-methylene protons. The l3C NMR 
spectrum (Figure 53) clearly shows the expected 13 signals. The methine carbon C-3' 
resonates at {) 68.7 ppm and the carbonyl carbon at {) 176.3 ppm, while the DEPT-135 
spectrum (Figure 54) confirms assignment of the sole methylene signal (at {) 131.6 ppm) to 
C-l'. The signals were assigned with the aid of the COSY, HMQC and HMBC data. 
Table 12. Comparative yields of Morita-Baylis-Hi1lman products 287 - 292. 
R2 0 OH 
R, 5 4 2' eN 
6-:7 
4. 
3 3 
7 "'" 
12 
l ' 
6 
68 0 
Morita-Baylis-Hillman product 
Rl R2 
Compd. Yield" /% 
H H 287 64 
Br H 288 67 
CI H 289 59 
F H 290 53 
OMe H 291 54 
H OMe 292 60 
'Isolated yields 
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Figure 52. 400 MHz lH NMR spectrum of Morita-Baylis-Hillman product 289 in CDCb. 
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Figure 53. 100 MHz l3C NMR spectrum of Morita-Baylis-Hillman plOduct 289 in CDCb. 
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Figure 54, DEPT -135 NMR spectrum of Morita-Baylis-Hil1man product 289 in CDCh. 
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2.5.3 Reactions of chromone-3-carbaldehydes with methyl acrylate 
Encouraged by the ready accessibility of the Morita-Baylis-Hillman products 287 - 292 using 
the catalyst, 3-hydroxyquinuclidine (3-HQ), we extended the study to the reaction of 
chromone-3-carbaldehydes with methyl acrylate. As before, mixture of one equivalent of the 
chromone-3-carbaldehydes 27 and 282 - 286, 1.5 equivalents of the activated alkene, in this 
case, methyl acrylate and 5 equivalents of the catalyst, 3-hydroxyquinuclidine (3-HQ) in a 
minimum volume of chloroform was stirred at room temperature for 24 h. Efficient 
purification of the crude reaction mixtures by flash chromatography afforded the 
corresponding Morita-Baylis-Hillman products 293 - 298 (Scheme 66) in yields ranging 
R2 0 R, R2 
0 
R1WCHO 
(lOMe 
27 H H 
+ 
"'" I I 282 Sr H 283 CI H 0 284 F H 
285 OMe H 
3-HQ, CHCh 286 H OMe 
17 R, J 0 R2 
R2 0 OH 0 R2 0 13 C02Me 
R, R, 5 
4 15 16 
3' OMe ,;? 10a 10 "':: C02Me 
1
3 
e I 3 11 12 
e. 0 2 7"", 2 
e B BaO 9. 0 1 9 1 
R, R2 R, R2 
293 H H 299 H H 
294 Sr H 300 Sr H 
295 CI H 301 CI H 
296 F H 302 F H 
297 OMe H 303 OMe H 
298 H OMe 
Scheme 66 
131 
Results and Discussion 
from 50 to 79% (Table 13), together with the generally minor products identified as the 
"chromone dimers" 299 - 303 in yields ranging from 30 to 50%. The use of 3-
hydroxyquinuclidine (3-HQ) as the catalyst, suggested by Sabbagh's preliminary 
optimization studies,176 resulted in far better yields than those obtained using DABCO. In the 
case of the 5-methoxy system, however, the Morita-Baylis-Hillmanproduct 298 was the only 
product to be isolated. A mechanism which accounted for the formation of the chromone 
dimers has been proposed by Sabbagh (Scheme 69, p. 138). 
Table 13. Comparative yields of the Morita-Baylis-Hillman products and the corresponding 
dimers. 
o OH 0 
OMe 
, 
Morita-Baylis-Hillman product 
Rl R2 
Compd. Yield" /% 
H H 293 66 
Br H 294 63 
CI H 295 50 
F H 296 70 
OMe H 297 60 
H OMe 298 79 
'Isolated yield. 
o 13 C02Me 
" 15 16 
" C02Me 
...... 3 11 12 
Chromone dimer 
Compd. Yield" /% 
299 34 
300 37 
301 50 
302 30 
303 40 
- -
The products were characterized using elemental (HREIMS) and spectroscopic (IR and 
NMR) analysis. The IH NMR spectrum (Figure 55) of the Morita-Baylis-Hillman product 
298 reveals two distinct singlets at S 3.71 and 3.95 ppm corresponding to the ester methyl and 
5-methoxy protons, respectively, a poorly resolved doublets at S 4.78 and 5.51 ppm 
corresponding to the 3'-hydroxyl proton and the 3'-H nucleus, respectively, and two distinct 
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singlets at 0 6.19 and 6.43 ppm characteristic of the l'-methylene protons. The I3C NMR 
spectrum (Figure 56) shows 15 carbon signals with the ester methyl and 5-methoxy carbons 
resonating at 0 51.8 and 56.4 ppm, respectively and the C-3' nucleus at 0 68.0 ppm The 
DEPT-135 spectrum (Figure 57) confirms the presence of the C-1' methylene carbon 
resonating at 0127.0 ppm. The signal assigments were facilitated with the aid of the COSY, 
HMQC and HMBC data. 
The IH NMR spectrum (Figure 58) of the "parent" chromone dimer 299 reveals a pair of 
doublets at 0 3.13 and 3.37 ppm corresponding to the diastereotopic 13-methylene protons, 
two singlets at 0 3.61 and 3.66 ppm corresponding to the two methoxy groups, a pair of 
double doublets at ca. 04.50 ppm corresponding to the 2-methylene protons and a singlet at 0 
5.05 ppm corresponding to the 9a proton. The added multiplicity of the signals at 0 4.50 ppm 
is due to coupling of the diastereotopic 13-methylene protons and the 4-H nucleus. The l3C 
NMR spectrum (Figure 59) reveals 28 carbon signals, with the two methylene carbons (C-13 
and C-2) resonating at 0 28.4 and 65.8 ppm, respectively. Assignment ofthese two methylene 
carbon signals, and the 12 quarternary carbon signals was confirmed using the DEPT-135 
data (Figure 60). 
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Figure 55. 400 MHz IH NMR spectrum of Morita-Baylis-Hillman product 298 in CDCh 
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Figure 56. 100 MHz J3C NMR spectrum of Morita-Baylis-Hil1man product 298 in CDCI3, 
with an asterisk indicating signal due to impurity. 
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Figure 57. DEPT -135 NMR spectrum of Morita-Baylis-Hi11man product 298 in CDCh. 
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Figure 60, DEPT-I 35 NMR spectrum of chromone dimer 299 in CDCh. 
2.5.4 "Dimer" studies 
As discussed in Section 2.5.2 and 2.5.3, an earlier investigation176 of the reaction between the 
chromone-3-carbaldehydes and the two activated alkenes, acrylonitrile and methyl acrylate, 
in the presence of DAB CO afforded, in very low yields, the expected Morita-Baylis-Hillman 
products together with unprecedented bischromone adducts (in the case of acrylonitrile) or 
chromone dimers (in the case of methyl acrylate). Preliminary optimization studies 
undertaken by Sabbagh176 shown that the bischromone adducts could be obtained from a 
136 
Results and Discussion 
reaction between the Morita-Baylis-Hillman products and the corresponding chromone-3-
carbaldehydes in the presence of the catalyst, DABCO. However, several attempts to 
reproduce these earlier results by reacting one equivalent of the Morita-Baylis-Hillman 
product (287 - 292), one equivalent of the corresponding chromone-3-carbaldehyde (27 and 
283 - 286) and two equivalent of DABCO in a minimum volume of chloroform proved 
unsuccessful. However, when a mixture of one equivalent of the Morita-Baylis-Hillman 
product (293 - 298) and 3.0 equivalents of DAB CO were heated in an oil bath at 80°C for 3 
h, the reaction being monitored by TLC, IH NMR analysis of the crude reaction mixture, in 
each case, showed 100% conversion to the chromone dimer (299 - 304). Efficient 
purification of the crude reaction mixtures, using the Chrornatotron, afforded, principally, the 
desired chromone dimers 299 - 304 in yields ranging from 49 to 68% (Table 14). The 
mechanism proposed by Sabbagh176 to account for the formation of the chromone dimer 299 
and its substituted analogues is outlined in Scheme 67, p. 138. 
Table 14. Comparative yields of the chromone dimers 299 - 304. 
l' ~ 
z 0 'a' 
'<:::T 
,1 ~ 
17 46' b R1 J 4' 5' 0 2 
R2 0 13 C02Me 
4 
1S 16 
R1 10 C02Me 8 ~ 3 11 12 
2 
, 'a 0 96 0 
9 1 
Chromone dimer 
Rl R2 
Compd. Yield' /% 
H H 299 62 
Br H 300 59 
CI H 301 68 
F H 302 49 
OMe H 303 51 
H OMe 304 55 
,. Isolated YIelds 
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Scheme 67. Proposed mechanism for the formation of the chromone dimers. 176 
It is thus apparent that the use of 3-hydroxyquinuclidine (3-HQ) as a catalyst provides 
convenient access to chromone-3-carbaldehyde - derived Morita-Baylis-Hillman products on 
a preparative scale, and that the dimeric products 299 - 304 can be readily obtained from 
their respective precursors 293 - 298 using DABCO as the catalyst. Potential of these 
chromone dimers for elaboration to HIV -1 protease inhibitors will be explored further. 
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2.5.5 Synthesis of chromone-2-carbaldehydes 
As discussed in the introduction, cbromone-2-carbaldehydes are important intermediates, 
which are known to undergo a number of reactions involving the 2-formyl functionality to 
give a wide range of interesting products. Morita-Baylis-Hillman reactions of cbromone-2-
carbaldehydes had not hitherto been reported and, in view of our current interest in these 
reactions, we synthesized a range of cbromone-2-carbaldehydes with the intention of 
exploring their use in Morita-Baylis-Hillman reactions. 
The cbromone-2-carbaldehydes 26, 311 and 312 were synthesized via Se02. oxidation of the 
corresponding substituted 2-methylchromones 19, 309 and 310, as described by Jagadeesh et 
al.75•102 The 2-methylcbromones 19, 309 and 310 were obtained following a method reported 
by Wittig et al., 48 involving base-catalyzed acylation of the substituted o-hydroxyaceto-
phenones 43, 175 and 305 with ethyl acetate. The resulting intermediates 306 - 308 were 
then treated (without prior purification) with mixtures of acetic and sulfuric acids, to effect 
acid-catalyzed cyclization to the required compounds 19, 309 and 310 (Scheme 68). 
R 
43 H 
175 F 
305 MeO 
Scheme 68 
R~ 
~OH 
R 
26 H 
311 F 
312 MeO 
I, ii 
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• 
o OH 
OH 
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19 H 
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310 MeO 
R 
306 H 
307 F 
308 MeO 
Reagents: i) NaOEt, EtOH; ii) dry CHl C02Et; iii) AcOH, cone. H2S04; iv) Se02, xylene, 
heat. 
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Recrystallization of the crude 2-methylchromones 19, 309 and 310 from hexane afforded the 
products in analytical quality in yields ranging from 71 to 88%. The IH NMR spectrum of 
compound 19 (Figure 61) reveals a singlet at 1) 2.36 ppm corresponding to the methyl 
protons; the characteristic 3-H signal of the chromone nucleus appears at 1) 6.15 ppm and the 
aromatic region of the spectrum indicates the presence of four aromatic protons. The l3C 
NMR spectrum (Figure 62) shows the expected 10 carbon signals, with the methyl carbon 
resonating at 1) 20.5 ppm. 
The pure chromone-2-carbaldehydes 26, 311 and 312 were obtained by flash chromatography 
on silica gel in yields ranging from 35 to 40%. The IH NMR spectrum of compound 26 
(Figure 63) reveals a singlet at 1) 6.90 ppm, corresponding to the characteristic 3-H nucleus of 
the chromone ring, and a downfield singlet at 1) 9.79 ppm, corresponding to the 2-formyl 
proton. The l3C NMR spectrum (Figure 64) shows the expected 10 carbon signals, with the 
2-formyl carbon resonating at 1) 185.4 ppm. Unfortunately, time constraints did not permit 
investigation of the Morita-Baylis-Hillman reactions of these chromone-2-carbaldehydes. 
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2.6 Conclusions 
Many chromone derivatives are known to exhibit medicinal properties, and the present study 
has focussed, largely, on the synthesis of chromones with pharmacological potential. 
A series of substituted 2-(N, N-dimethylamino )chromones has been successfully synthesized 
via the corresponding boron difluoride complex intermediates for use as substrates in a pI<. 
study. The pI<. values, which were determined by potentiometric analysis and which lie 
within a relatively narrow range (1.92 - 2.52), provide insight into the effect of the various 
substituents on the basicity of the chromone carbonyl oxygen and confirm the general 
expectation that basicity should be increased by electron-releasing substituents and decreased 
by electron-withdrawing substituents. These results, which have been shown to be consistent 
with molecular orbital calculations at the semi empirical and ab initio levels, have already 
been published. 144 
The synthesis of the naturally-occurring chromone derivative, "granulosin" [7,8-
(methylenedioxy)-2-propylchromone], and a number of its C-2 side-chain analogues has been 
successfully achieved by base-catalyzed condensation of 2'-hydroxy-3',4'-(methylenedioxy)-
acetophenone with a range of ethyl carboxylate esters. The 2-propyl derivative (granulosin) 
and its 2-ethyl and 2-isopropyl analogues have been shown to exhibit significant cytotoxic 
activity against the brine shrimp, Artemia salina, while the 2-ethyl and 2-benzyl derivatives 
were found to possess 100% anti-pesticidic activity on Beet army worms (BA W). This 
synthetic methodology was extended to the synthesis of another, naturally-occurring and 
pharmacologically active chromone, 5-hydroxy-2-isopropyl-7-methoxychromone, and to 
several of its C-2 side chain analogues. This involved the preparation of the dimethoxy 
precursors, followed by selective C-5 demethylation. The 2-ethyl, 2-propyl and 2-isopropyl 
derivatives showed significant cytotoxic activity, and it was observed that demethylation to 
expose the 5-hydroxyl group is crucial for such activity. The electron-impact mass 
fragmentation patterns of both sets of chromone derivatives have been investigated using 
low-resolution, high-resolution and BIE link-scan MS data, permitting the identification of 
certain common fragmentation pathways. 
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A series of novel chromone-containing analogues of the HIV -1 protease inhibitor, ritonavir, 
have been synthesized by treating a specially prepared, hydroxyethylene dipeptide isosterel 63 
with a series of chromone-2-carboxylic acid derivatives using the coupling agent, N-ethyl-N'-
(dimethylarninopropyl)carbodiimide hydrochloride (EDC), in the presence I-hydroxybenzo-
triazole hydrate (HOBt). Use of the coupling agent, 1,I'-carbonyldiimidazole (CDI), gave, in 
addition to the desired bis-chromone derivatives, unexpected novel Iris-chromone 
derivatives. An interactive docking procedure was used to explore the docking of the 
established IllV -I protease inhibitor, ritonavir, and the novel chromone-containing analogues 
into the active site of the enzyme. The modelling results clearly demonstrate the ability of 
the novel, chromone-containing ritonavir analogues to form a number of significant 
hydrogen-bonding interactions with the IllV-I enzyme binding site. 
In a continuation of earlier work,176 a series of substituted chromone-3-carbaldehydes were 
successfully synthesized using Vilsmeier-Haack methodology. The application of these 
compounds in Morita-Baylis-Hillman reactions has been investigated using 3-
hydroxyquinuclidine (3-HQ) as catalyst and acrylonitrile and methyl acrylate as the activated 
alkenes, the intention being to optimize the reaction condition to establish a preparative scale 
synthesis of the Morita-Baylis-Hillman products and their "dimeric" derivatives. With 
acrylonitrile, the expected Morita-Baylis-Hillman products were finally obtained in yields 
ranging from 53 to 67%, and with methyl acrylate, the expected Morita-Baylis-Hillman 
products were obtained in yields ranging from 50 to 79%. It was also shown that, when the 
Morita-Baylis-Hillman products resulting from reaction with methyl acrylate were heated at 
80°C for 3 h, the corresponding chromone dimers were produced in yields ranging from 49 
to 68%. 
While all of the objectives ofthis investigation have been addressed, opportunities for further 
development have become apparent, and future research is expected to focus on the following 
areas. 
i) Biological evaluation of the IllV -1 protease inhibitory and antiviral 
activities of the novel chromone-containing ritonavir analogues. 
ii) Investigation of the reactions of substituted chromone-2-carbaldehydes 
under Morita-Baylis-Hillman conditions. 
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iii) Optimization of the reaction conditions for the synthesis of the his-
chromone-acrylonitrile products. 
iv) Functional elaboration and investigation of the pharmacological potential 
of the chromone "dimers". 
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3. EXPERIMENTAL 
3.1 General 
All melting points were determined using a Kofler hot-stage apparatus, and are uncorrected. 
The IH and BC NMR spectra were recorded on Bruker AMX400 or A VANCE 400 MHz 
spectrometers at 303, and were calibrated using the solvent signals. The coupling constants, 
where specified, are given in hertz (Hz). Where convenient, the atom numbering used in 
quoting NMR data follows the systematic nomenclature. IR spectra were recorded on a 
Perkin Elmer Spectrum 2000 FT-IR spectrometer. Low-resolution mass spectra were 
obtained on a Finnegan-Mat GCQ mass spectrometer, and high-resolution mass spectra were 
recorded on a VG70-SEQ double-focusing magnetic sector mass spectrometer (Cape 
Technikon Mass Spectrometry Unit). 
Flash chromatography was carried out using Merck silica gel 60 [particle size 0.040 - 0.063 
mm (230 - 400 mesh)] and preparative layer chromatography was achieved using Merck 
silica gel 60 PF254. Chromatotron plates, when necessary, were prepared using silica gel 60 
PF254 containing CaS04. Routine thin layer chromatography (TLC) was carried out on pre-
coated Merck silica gel F254 plates, visualization being achieved by exposure to iodine or 
inspection under UV light (254 run). 
All dry solvents were prepared using the procedures prescribed by Perrin and Armarego. 177 
Diethyl ether and THF were pre-dried over Cafh and then distilled from Na wire in the 
presence ofbenzophenone under nitrogen. Ethanol and methanol were dried by reaction with 
Mg turnings and iodine and then distilled from the resulting magnesium alkoxide under 
nitrogen. Chloroform and 1,2-dichloroethane were distilled from CaCh under nitrogen, while 
N,N-dimethylformamide (DMF) was distilled from 3 A molecular sieves under reduced 
pressure. 
Molecular modelling was performed on a Silicon Graphics 0 2 work station using the MSI 
CERIUS2 version 4.5 modelling platform at 300K using the Drieding force field. The Ligand 
Fit module supplied by Accelrys Inc. was used to explore receptor docking interactions. 
146 
Experimental 
3.2 . Synthesis and pK. analysis of 2-(N,N-dimethylamino )chromones 
3.2.1 Synthesis of substituted 2-hydroxyacetophenones 
2-Fluorophenyl acetate 168137.138.178 
AC20 (15 m1, 16.0 g, 0.16 mol) was added dropwise to a stirred solution of 2-fluorophenol 
166 (9.0 m1, 1l.0 g, 0.10 mol) and NaOH (6.4 g, 0.16 mol) in HzO (ca. 100 ml) maintained at 
ca. 0 °c in an ice-salt bath. After stirring for 2 h at DoC, the resuhing mixture was extracted 
with EtOAc (3 x 50 ml); the combined extracts were washed sequentially with 5% aq. 
NaHC03 (2 x 50 ml) and saturated aq. NaCI (50 ml), and then dried over anhydrous MgS04. 
The solvent was evaporated in vacuo to afford a yellow oil, which was distilled to give 2-
fluorophenyl acetate 168 as a colourless oil(12.5 g, 91%), b.p. 66-68 °C/lO mmHg (lit. , 178 
76.5-77 °CIlI mmHg); Vrnax (liquid film)/cm-1 1760 (CO); OH (400 MHz; CDCh) 2.32 (3H, s, 
CH3) and 7.11-7.20 (4H, m, Ar-H). 
4-Fluorophenyl acetate 169137,179 
The experimental procedure employed for the synthesis of 2-fluorophenyl acetate 168 was 
followed, using AczO (7.0 m1, 7.4 g, 72 mmol), 4-fluorophenol 167 (5.0 g, 45 mmol) and 
NaOH (3.0 g, 72 mmol) in HzO (ca. 46 ml), Work-up afforded an oil, which was distilled to 
give 4-fluorophenyl acetate 169 as a colourless oil (4.9 g, 71%), b.p. 55-58 °C/ l.O mmHg 
(lit.,179 85-87 °C/16 mmHg); Vrnax (liquid film)/cm-1 1755 (CO); OH (400 MHz; CDCh) 2.25 
(3H, s, CH3) and 7.04-7.48 (4H, m, Ar-H). 
2',3'-Dimethoxyacetophenone 172140 
To a stirred solution of2,3-dimethoxybenzonitrile 171 (5.0 g, 31 mmol) in dry EtzO (25 ml) 
was added methylmagnesiurn bromide (3.0M solution in diethyl ether; 10.3 ml, 31 mmol), 
and the mixture was stirred at room temperature for 12 h under Nz. The resulting mixture 
was boiled under reflux for 1 h and then quenched with 10% acetic acid_ The ethereal layer 
was washed with saturated aq. NaZC03 solution (50 ml), dried over anhydrous MgS04 and 
the solvent evaporated in vacuo to afford 2',3'-dimethoxyacetophenone 172 as a brick-red oil 
(4.8 g, 80%), (Found: M+, 180.07973. ClOH 1Z0 3 requires M, 180.07864); Vrnax (liquid 
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filin)/cm-1 1640 (CO); liH (400 MHz; CDCh) 2.78 (3H, s, CH3), 4.04 and 4.05 (6H,2 x s, 2 x 
OCH3) and 7.20 -7.45 (3H, m, AI-H); mlz 180 (M+, 62%) and 151 (100). 
8-Nitrochromone 173141 
Chromone 1 (5.0 g, 34 mmol) was dissolved in conc. H2S04 (30 ml), and the resulting 
reddish-orange solution cooled in ice-water. A solution of fuming RN03 (1.4 ml) in conc. 
H2S04 (5.0 ml) was added dropwise to the stirred solution over a period of 10 min. The 
resulting mixture was poured into ice-water (50 ml) and allowed to warm to room 
temperature. The precipitated solid was collected by filtration and washed well with water to 
give the crude product (4.2 g). Repeated recrystallization from benzene afforded 8-
nitrochromone 173 as a yellow crystalline solid (2.44 g, 38%), m.p. 172-174 °C (from 
benzene) (lit.,141 173-175 °C), (Found: M +, 191.02243. C9HSN04 requires M, 191.02186); 
vmax (KBr)/cm-1 1640 (CO); liH (400 MHz; CDCh) 6.42 (1H, eI, J= 6.1 Hz, 3-H), 7.62 (lH, d, 
J= 9.2 Hz, 7-H), 7.91 (1H, eI, J= 6.1 Hz, 2-H), 8.50 (lH, del, J= 2.8 and 9.4 Hz, 6-H) and 
9 .05 (lH, eI, J= 2.8 Hz, 5-H); mlz 191 (M+, 100%). 
3'-Fluoro-2'-hydroxyacetophenone 174137•178 
A stirred mixture of2-fluorophenyl acetate 168 (4.6 g, 30 mmol) and anhydrous AlCh (16 g, 
0.12 mol) under N2 was heated in an oil bath at ca. 190°C for 3 h. The reaction mixture was 
cooled, the complex was decomposed with 2M-HCl (80 ml) and the resulting mixture steam 
distilled until the distillate was no longer milky. The distillate was extracted with diethyl 
ether (3 x 50 ml), and the ethereal solution was then extracted with 0.5M-KOH (3 x 50 ml). 
The aqueous extract was washed with diethyl ether (3 x 50 ml), acidified with 2.5M-H2S04 
and then re-extracted into ether (3 x 50 ml). The combined organic extracts were dried over 
anhydrous MgS04, and the solvent was evaporated in vacuo to afford a yellow oil, which 
crystallized to give 3'-fluoro-2'-hydroxyacetophenone 174 as a colourless crystalline solid 
(0.50 g, 12%), m.p. 71-73 °C (from hexane) (lit.,l78 72-73 0c), (Found: M+, 154.04429. 
C8H7F02 requires M, 154.04301); Vrnax (KBr)/cm-1 3000-2800 (br, OH) and 1646 (CO); liH 
(400 MHz; CDCh) 2.64 (3H, s, CH3), 6.85, 726 and 7.52 (3H, 3 x m, AI-H) and 12.26 (lH, s, 
OH); mlz 154 (M+, 44%) and 139 (100). 
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5'-F1uoro-2'-hydroxyacetophenone 175137.178.180 
The experimental procedure employed for the synthesis of 3'-fluoro-2'-hydroxyacetophenone 
174 was followed, using 4-fluorophenyl acetate 169 (4.5 g, 30 mmol) and anhydrous AICh 
(16 g, 0.12 mol). Work-up afforded a yellow oil, which crystallized to give 5'-fluoro-2'-
hydroxyacetophenone 175 as a colourless crystalline solid (3.0 g, 70%), m.p. 46-48 °C (from 
hexane) (lit.,180 56°C), (Found: M'", 154.04389. C8H7F02 requires M, 154.04301); Vmax 
(KBr)/cm·1 3200-3000 (hr, OH) and 1648 (CO); OH (400 MHz; CDCh) 2.60 (3H, s, CH3), 
6.95, 7.22 and 7.40 (3H, 3 x ill, Ar-H) and 11.90 (lH, s, OH); m/z 154 (M'", 49%) and 139 
(100). 
2'-Hydroxy-6'-methoxyacetophenone 176138 
A mixture of 2',6'-dihydroxyacetophenone 170 (4.6 g, 30 mmol), K2C03 (4.2 g, 30 mmol) 
and methyl iodide 4.3 g (2.0 ml, 30 mmol) in acetone (75 ml) was boiled under reflux for 22 
h. The resulting mixture was filtered and the filtrate concentrated in vacuo to give a residue 
which crystallized to afford 2'-hydroxy-6'-methoxyacetophenone 176 as a yellow crystalline 
solid (4.0 g, 80%), m.p. 56-57°C (from hexane) (lit.,l39 57-58°C), (Found: M+, 166.06266. 
~HlO03 requires M, 166.06299); Vrnax (KBr)/cm-1 3500-2800 (hr, OH) and 1620 (CO); OH 
(400 MHz; CDCh) 2.65 (3H, s, CH3), 3.87 (3H, s, OCH3), 6.36 (lH, d, J= 8.3 Hz, 3-H), 6.54 
(lH, d, J= 8.4 Hz, 5-H), 7.32 (lH, t, J= 8.4 Hz, 4-H) and 13.20 (lH, s, OH); m/z 166 (1f", 
45%) and 151 (100). 
2'-Hydroxy-3 '-methoxyacetophenone 17750 
To a stirred suspension of anhydrous AICh (27 g, 0.20 mol) in dry Et20 (90 ml) under N2 was 
added 2',3'-dimethoxyacetophenone 172 (4.0 g, 22 mmol), and the resulting mixture was 
boiled under reflux for 12 h. The cooled reaction mixture was treated with ice-cold 2M-HCI 
(100 ml), and the resulting mixture steam distilled until the distillate was no longer milky. 
The distillate was extracted with Et20 (3 x 50 ml), and the combined ethereal extracts were 
dried over anhydrous MgS04• The solvent was evaporated in vacuo to afford an oil, which 
crystallized to give 2'-hydroxy-3'-methoxyacetophenone 177 as a pale yellow solid (1.8 g, 
52%), m.p. 50-52°C (from hexane) (lit.,50 54°C), (Found: M+, 166.06330. C9HlO03 requires 
M, 166.06299); vmax (KBr)/cm-1 3100-2800 (hr, OH) and 1640 (CO); OH (400 MHz; CDCh) 
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2.65 (3H, s, CH3), 3.92 (3H, s, OCH3), 6.83 (lH, t, J= 7.8 Hz, 5-H), 7.04 (lH, d, J= 7.2 Hz, 
4-H), 7.32 (lH, d, J= 7.5 Hz, 6-H) and 12.55 (lH, s, OH); m/z 166 (M+, 62%) and 151 (100). 
2 '-Hydroxy-3 '-nitroacetophenone 178141.1SI 
A mixture of 8-nitrochromone 173 (2.0 g, 10 mmol) and 10% aq. KOH (20 ml) was boiled 
under reflux for I h. The resulting green-yellow solution was cooled to room temperature 
and then acidified with 2.5M-H2S04. The resulting mixture was then extracted with EtOAc 
(3 x 75 ml), the combined extracts were dried over anhydrous MgS04 and the solvent was 
evaporate.d in vacuo to afford 2'-hydroxy-3'-nitroacetophenone 178 as a yellow solid (1.2 g, 
63%), m.p. 96-98 °C (from hexane) (lit.,141 103-104 °C), (Found: M+, 181.03666. C8H7N04 
requires M, 181.03751); vmax(KBr)/cm-1 3500-3200 (hr, OH), 1648 (CO) and 1523 (Ar-N02); 
OH (400 MHz; CDCh) 2.74 (3H, s, CH3), 7.07 (lH, d, J= 9.3 Hz, 4-H), 8.70 (lH, d, J= 2.7 
Hz, 6-H), 8.34 (lH, dd, J= 2.8 and 9,2 Hz, 5-H) and 12.85 (lH, s, OH); m/z 181 (~, 65%) 
and 166 (100). 
B.2.2 Synthesis of I:~,N-dimethylamino)chromones via phosgeniminium 
salt intermediates t·~ 
3'-Fluoro-2'-hydroxyacetophenone boron difluoride complex 17968 
BF3.0Et2 (0.83 ml,-6.5 mmol) was added to a solution of 3'-fluoro-2'-hydroxyacetophenone 
~ (LO .g, 6.5 mmo1). in dry Et20 (6.5 ml) under dry N2, and the mixture was stirred at'"room 
temperatur~l\}t.6 h. • resulting mixture was filtered and the solid material washed well 
with Et20 to 'give 3'-fluoro-2'-hydroxyacetophenone boron difluoride complex 179 as a 
greenish-yellow solid (0.70 g, 54%), [(Found: ~, 202.04193. C8~lIBF302 requires M, 
. 202~n9j; Vmax (KBr)/cm-1 1627 (CO); OH (400 MHz; CDCh) 2.70 (3H, s, CH3), 6.91, 7.48 
and 7.70 (31-1, 3 x m, Ar-H); m/z 202 ~, 36%) and 187 (100)], which was used without 
further purification. 
5'-Fluoro-2'-hydroxyacetophenone boron difluoride complex 180 
The experimental procedure employed for the synthesis of 3'-fluoro-2'-hydroxyacetophenone 
boron difluoride complex 179 was followed, using 5'-fluoro-2'-hydroxyacetophenone 175 
(1.0 g, 6.5 mmol), dry EhO (6.5 ml) and BF3.OEt2 (0.83 m1, 6.5 mmol). Work-up afforded 
5'-fluoro-2'-hydroxyacetophenone boron difluoride complex 180 as an orange solid (0.80 g, 
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61%), [(Found: M+, 202.04142. CSH61IBF302 requires M, 202.04129); Vmax (KBr)!cnil 1622 
(CO); OH (400 MHz; CDCb) 2.88 (3H, s, CH3), 7.16, 7.44 and 7.63 (3H, 3 x m, Ar-H); m/z 
202 (~, 41%) and 187 (100)], which was used without further purification. 
2'-Hydroxy-6'-methoxyacetophenone boron difluoride complex 181 
The experimental procedure employed for the synthesis of 3'-fluoro-2'-hydroxyacetophenone 
boron difluoride complex 179 was followed, using 2'-hydroxy-6'-methoxyacetophenone 176 
(1.0 g, 6.0 mmol), dry Et20 (6.0 ml) and Bf].OEt2 (0.80 ml, 6.0 mmol). Work-up afforded 
2'-hydroxy-6'-methoxyacetophenone boron difluoride complex 181 as a yellow solid (0.97 g, 
76%), [(Found: M+, 214.06144. C9H9 11BF203 requires M, 214.06128); Vmax (KBr)!cm-1 1617 
(CO); OH (400 MHz; CDCb) 2.89 (3H, s, CH3), 3.98 (3H, s, OCH3), 6.40 (lH, d, J= 8.3 Hz, 
3-H), 6.70 (lH, d, J= 8.5 Hz, 5-H) and 7.65 (lH, t, J= 8.4 Hz, 4-H); m/z 214 (~, 48%)], 
which was used without further purification. 
2'-Hydroxy-3'-methoxyacetophenone boron difluoride complex 182 
The experimental procedure employed for the synthesis of 3'-fluoro-2'-hydroxyacetophenone 
boron difluoride complex 179 was followed, using 2'-hydroxy-3'-methoxyacetophenone 177 
(1.0 g, 6.0 mmol), dry Et20 (6.0 ml) and Bf].OEt2 (0.80 ml, 6.0 mmol). Work-up afforded 
2'-hydroxy-3'-methoxyacetophenone boron difluoride complex 182 as a yellow solid (0.98 g, 
77%), [(Found: ~, 214.06175. C9H911BF203 requires M, 214.06128); Vmax (KBr)!Cnil 1616 
(CO); OH (400 MHz; CDCb) 2.87 (3H, s, CH3), 3.95 (3H, s, OCH3), 6.96 (lH, t, J= 8.2 Hz, 
5-H), 7.23 (lH, d, J= 8.3 Hz, 4-H) and 7.35 (lH, d, J= 8.4 Hz, 6-H); m/z 214 (M+, 63%)], 
which was used without further purification. 
2'-Hydroxy-3'-nitroar,:etophenone boron difluoride complex 183 
The experimental procedure employed for the synthesis of 3'-fluoro-2'-hydroxyacetophenone 
boron difluoride complex 179 was followed, using 2'-hydroxy-3'-nitroacetophenone 178 
(0.50 g, 2.8 mmol), dry EhO (6.0 ml) and Bf].OEh (0.82 ml, 5.6 mmol). Work-up afforded 
2'-hydroxy-3'-nitroacetophenone boron difluoride complex 183 as a brownish-yellow solid 
(0.24 g, 38%), [vmax (KBr)!cm-1 1648 (CO) and 1523 (Ar-N02); OH (400 MHz; CDCh) 2.75 
(3H, s, CH3), 7.30, 8.62 and 8.84 (3R, 3 x m, Ar-H)] , which was used without further 
purification. 
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3-Chloro-3-(N,N-dimethylamino)-1-(3jluoro-2-hydroxyphenyl)propenone, boron difluoride 
complex 18568 
A suspension of3'-fluoro-2'-hydroxyacetophenone boron difluoride complex 179 (0.40 g, 2.0 
mmol) and phosgeniminium chloride 184 (0.35 g, 2.0 mmol) in dry 1,2-dichloroethane (7.5 
ml) was heated at 80 ·C under N2 for 2 h. The mixture was cooled at 0 ·C, and the resulting 
solid was filtered off and washed with cold 1,2-dichloroethane (5.0 ml) and Et20 (5.0 ml) to 
afford the crude 3-chloro-3-(N,N-dimethylamino)-1-(3-jluoro-2-hydroxyphenyl)propenone, 
boron difluoride complex 185 as a yellow solid (0.55 g, 95%), [(Found: W, 291.04456. 
CllHIO llBC1F3N02 requires M, 291.04452); Vrnax (KBr)/cm-1 1624 (CO); OH (400 MHz; 
DMSO-d6) 3.54 (6H, s, NM~), 6.32 (1H, s, 2-H), 6.95, 7.52 and 7.87 (3H, 3 x In, Ar-H); mlz 
291 (M", 19%) and 256 (100)], which was used without further purification. 
3-Chloro-3-(N,N-dimethylamino)-1-(5jluoro-2-hydroxyphenyl)propenone, boron difluoride 
complex 186 
The experimental procedure employed for the synthesis of 3-chloro-3-(N,N-dimethylamino)-
1-(3-fluoro-2-hydroxyphenyl)propenone, boron difluoride complex 185 was followed, using 
5'-fluoro-2'-hydroxyacetophenone boron difluoride complex 180 (0.50 g, 2.4 mmol), 
phosgeniminium chloride 184 (0.41 g, 2.4 mmol) and dry 1,2-dichloroethane (9.5 ml). 
Work-up afforded the crude 3-chloro-3-(N,N-dimethylamino)-1-(5jluoro-2-hydroxyphenyl)-
propenone, boron difluoride complex 186 as a yellow solid (0.63 g, 90%), [(Found: M+, 
291.04398. CllHIOllBC1F3N02 requires M, 291.04452); Vmax (KBr)/cm-1 1566 (CO); OH (400 
MHz; OMSO-d6) 3.01 (6H, s, NMe2), 6.47 (lB, s, 2-H), 7.01, 7.38 and 7.57 (3H, 3 x In, Ar-
H); mlz 291 ~, 12%) and 256 (100)], which was used without further purification. 
3-Chloro-3-(N ,N-dimethylamino)-1-(2-hydroxy-6-methoxyphenyl)propenone, boron 
difluoride complex 187 
The experimental procedure employed for the synthesis of 3-chloro-3-(N,N-dirnethylamino)-
1-(3-fluoro-2-hydroxyphenyl)propenone, boron difluoride complex 185 was followed, using 
2'-hydroxy-6'-methoxyacetophenone boron difluoride complex 181 ( 0.50 g, 2.3 mmol), 
phosgeniminium chloride 184 (0.40 g, 2.3 mmol) and dry 1,2-dichloroethane (7.5 ml). Work-
up afforded the crude 3-chl(Jro-3-(N,N-dimethylamino)-1-(2-hydroxy-6-methoxyphenyl)-
propenone, boron difluoride complex 187 as a yellow solid (0.69 g, 98%), [(Found: W, 
303.06419. C12HI311BCIF2N03 requires M, 303.06451); Vmax (KBr)/cm-1 1604 (CO); OH (400 
MHz; COCh) 3.45 (6H, s, NMe2), 3.90 (3H, s, OCH3), 6.39 (lB, d, J= 8.4Hz, 3'-H), 6.67 
152 
Experimental 
(lH, d, J= 8.5 Hz, 5'-H), 6.76 (lH, s, 2-H) and 7.37 (lH, t, J= 8.4 Hz, 4'-H); m/z 303 (M+, 
16%) and 268 (100)], which was used without further purification. 
3-Chloro-3-(N,N-dimethylamino)-1-(2-hydroxy-3-methoxyphenyl)propenone, boron 
difluoride complex 188 
The experimental procedure employed for the synthesis of 3-chloro-3-(N,N-dimethylamino)-
1-(3-fluoro-2-hydroxyphenyl)propenone, boron difluoride complex 185 was followed, using 
2'-hydroxy-3'-methoxyacetophenone boron difluoride complex 182 (0.60 g, 2.8 mmol), 
phosgeniminium chloride 184 (0.50 g, 2.8 mmol) and dry 1,2-dichloroethane (10 ml). Work-
up afforded the crude 3-chloro-3-(N,N-dimethylamino)-1-(2-hydroxy-3-methoxyphenyl)-
propenone, boron difluoride complex 188 as a yellow solid (0.82 g, 97%), [(Found: M+, 
303.06499. C12H\311BCIF1N03 requires M, 303.06451); Vmax (KBr)/cm-1 1609 (CO); OH (400 
MHz; DMSO-d6) 3.51 (6H, s, NMel), 3.78 (3H, s, OCH3), 6.22 (lH, s, 2-H), 6.86 (lH, t, J= 
8.2 Hz, 5'-H), 7.16 (lH, d, J= 7.6 Hz, 4'-H) and 7.55 (lH, d, J= 8.2 Hz, 6'-H); m/z 303 (M+, 
15%) and 268 (100)], which was used without further purification. 
3-Chloro-3-(N,N-dimethylamino)-1-(2-hydroxy-3-nitrophenyl)propenone, boron diflluoride 
complex 189 
The experimental procedure employed for the synthesis of 3-chloro-3-(N,N-dimethylamino)-
1-(3-fluoro-2-hydroxyphenyl)propenone, boron difluoride complex 185 was followed, using 
2'-hydroxy-3'-nitroacetophenone boron difluoride complex 183 ( 0.30 g, 1.3 mmol), 
phosgeniminium chloride 184 (0.50 g, 2.6 mmol) and dry 1,2-dichloroethane (5.0 ml). Work-
up afforded the crude 3-chloro-3-(N,N-dimethylamino)-1-(2-hydroxy-3-nitrophenyl)-propen-
one, boron difluoride complex 189 as a yellow solid (0.35 g, 85%), [(Found: M+, 318.03957. 
CllHlOllBClFzNz04 requires M, 319.03902); Vmax (KBr)/cm-1 1650 (CO); OH (400 MHz; 
DMSO-~) 3.02 (6H, s, NMez), 6.50 (Ill, s, 2-H) and 7.18-8.60 (3H, 3 x m, Ar-H); m/z 318 
(M+, 13%) and 283 (100)], which was used without further purification. 
2-(N,N-Dimethylamino)-8-fluorochromone 19168 
A solution of 3-chloro-3-(N,N-dimethylamino )-1-(3-fluoro-2-hydroxyphenyl)propenone, 
boron difluoride complex 185 (0.34 g, 1.0 mmol) in MeOH (20 ml) was stirred at 50°C for 
30 min. The solvent was evaporated in vacuo, and the residue dissolved in saturated aqueous 
NaHC03. The resulting mixture was extracted with CHzCh (3 x 75 ml), and the combined 
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extracts were washed with brine (1 x 75 ml) and dried over anhydrous MgS04• The solvent 
was evaporated in vacuo to give 2-(N,N-dimethylamino)-8-fluorochromone 191 as a white 
solid (0.18 g, 87%), m.p. 162-163 °c (from EtOAc), (Found: M+, 207.06972. CuHlOFN02 
requires M, 207.06956); Vrnax (KBr)/cm" 1622 (CO); BH (400 MHz; CDCh) 3.11 (6H, s, 
NMe2), 5.40 (1R, s, 3-H), 7.15-7.30 (2H, ill, 6-H and 7-H) and 7.86 (lH, d, J= 7.8 Hz, 5-H); 
Be (100 MHz; CDCh) 37.5 (NMe2), 86.3 (C-3), 118.0 and 124.1 (C-6 and C-7), 120.5 (C-5), 
126.0 (C-4a), 149.1 (C-8), 151.7 (C-8a), 162.5 (C-2) and 175.5 (C=O); mlz207 (W, 100%). 
2-(N,N-Dimethylamino)-6-fluorochromone 192 
The experimental procedure employed for the synthesis of 2-(N;N-dimethylamino)-8-
fluorochromone 191 was followed, using 3-chloro-3-(N,N-dimethylamino )-I-(5-fluoro-2-
hydroxyphenyl)propenone, boron difluoride complex 186 (0.50 g, 1.7 mmol) and MeOH (34 
rnl). Work-up afforded 2-(N,N-dimethylamino)-6-fluorochromone 192 as a white solid (0.21 
g, 60%), m.p. 176-178 °c [from hexane-EtOAc (1:1)], (Found: M+, 207.07103. CllHlOFN02 
requires M, 207.06956); Vrnax (KBr)/cm'" 1622 (CO); BH (400 MHz; CDCh) 3.12 (6H, s, 
NMe2), 5.41 (lH, s, 3-H), 7.18-7.28 and 7.78 (3H, 3 x ill, Ar-H); Be (100 MHz; CDCh) 37.5 
(NMe2), 85.9 (C-3), 111.0 (C-5), 117.9 and 119.5 (C-7 and C-8), 124.6 (C-4a), 149.7 (C-6), 
158.1 (C-8a), 163.2 (C-2) and 175.5 (C=O); mlz 207 (W, 100%). 
2-(N,N-Dimethylamino)-5-methoxychromone 193 
The experimental procedure employed for the synthesis of 2-(N;N-dimethylamino)-8-
fluorochromone 191 was followed, using 3-chloro-3-(N;N-dimethylamino )-I-(2-hydroxy-6-
methoxyphenyl)propenone, boron difluoride complex 187 (0.50 g, 1.6 mmol) and MeOH (32 
rnl). Work-up afforded 2-(N,N-dimethylamino)-5-methoxychromone 193 as a white solid 
(0.22 g, 63%), m.p. 166-168 °C (from EtOAc), (Found: M+, 219.08927. C12B 13N03 requires 
M, 219.08954); vrnax(KBr)/cm-' 1620 (CO); BH (400 MHz; CDCh) 3.01 (6H;s, NMe2), 3.92 
(3H, s, OCH3), 5.28 (1R, s, 3-H), 6.73 (lH, d, J= 8.3 Hz, 8-H), 6.86 (lH, d, J= 8.3 H~. (l-H) 
\' '. 
and 7.37 (lH, t, J= 8.3 Hz, 7-H); Be (100 MHz; CDCh) 37.2 (NMe2), 56.4 (OCH3), 87.4 (C-
3), 106.7 (C-8), 108.9 (C-6), 113.0 (C-4a), 131.8 (C-7), 155.9 (C-5), 159.5 (C-8a), 161.6 (C-
2) and 177.2 (C=O); mlz 219 (W, 100%). 
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2-(N,N-Dimethylamino)-8-methoxychromone 194 
The experimental procedure employed for the synthesis of 2-(N,N-dimethylamino)-8-
fluorochromone 191 was followed, using 3-chloro-3-(N,N-dimethylamino )-I-(2-hydroxy-3-
methoxyphenyl)propenone, boron difluoride complex 188 (0.60 g, 2.0 mmol) and MeOH (40 
ml). Work-up afforded 2-(N,N-dimethylamino)-8-methoxychromone 194 as a white solid 
(0.32 g, 72%), m.p. 147-148 °C (from EtOAc) (lit.,I78 147-148 °C), (Found: W , 219.09041. 
CI2Hi3N03 requires M, 219.08954); Vmax (KBr)/cm-1 1625 (CO); liH (400 MHz; CDCh) 3.10 
(6H, s, NMe2), 3.93 (3H, s, OCH3), 5.40 (lH, s, 3-H), 7.05 (lH, d, J= 6.8 Hz, 7-H), 7.20 (lH, 
t, J= 8.0 Hz, 6-H) and 7.71 (lH, d, J= 8.0 Hz, 5-H); lie (100 MHz; CDCh) 37.3 (NMe2), 56.3 
(OCH), 86.1 (C-3), 113.5 (C-7), 116.7 (C-5), 123.9 (C-6), 124.1 (C-4a), 143.8 (C-8), 147.8 
(C-8a), 162.8 (C-2) and 176.6 (C=O); mlz 219 (M" 100%). 
2 -(N ,N-Dimethylamino)-8-nitrochromone 195 
The experimental procedure employed for the synthesis of 2-(N,N-dimethylamino)-8-
fluorochromone 191 was followed, using 3-chloro-3-(N,N-dimethylamino )-I-(2-hydroxy-3-
nitrophenyl)propenone, boron difluoride complex 189 (0.30 g, 0.94 mmol) and MeOH (20 
ml). Work-up afforded 2-(N,N-dimethylamino)-8-nitrochromone 195 as a yellow solid (0.183 
g, 83%); m.p. 220-222 °C (from EtOAc), (Found: W, 234.06462. CllHlON204 requires 
234.06406); vmax(KBr)/cm-11639 (CO) and 1547 (Ar-N02); liH (400 MHz; CDCI3) 3.15 (6H, 
s, NMe2), 5.46 (lH, s, 3-H), 7.43 (lH, d, J= 9.1 Hz, 7-H), 8.37 (1H, dd, J= 2.8 and 9.1 Hz, 6-
H) and 9.00 (lH, d, J= 2.8 Hz, 5-H); lie (100 MHz; CDCh) 37.8 (NM~), 86.3 (C-3), 117.7 
(C-7), 122.2 (C-5), 123.5 (C-4a), 126.6 (C-6), 144.7 (C-8), 156.6 (C-8a), 162.9 (C-2) and 
174.2 (C=P); mlz 234 (M'", 100%). 
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3.2.3 Procedure for the determination of pKa values for the 2-(N,N-
dimethylamino)chromones 190 - 195142 
Aqueous-ethanolic solutions ofchromone 1 and the 2-(N,N-dimethylamino)chromones 190-
195 were prepared by dissolution of the appropriate quantity in distilled absolute EtOH (10 
ml) and dilution of the resulting solution with H20 (boiled prior to use; 9 ml) to afford, at 
half-neutralisation point, aliquots (20 ml) having a concentration of 0.Ql mol.dm·3 • The 
stirred 2-(N,N-dimethylamino )chromone solutions were titrated against hydrochloric acid 
(0.1063 mol.dm-3) at 25 ± 0.1 °C (stirring was stopped when taking pH readings). The titrant 
was added in 0.20 ml portions and was standardized against freshly recrystallized sodium 
tetraborate decahydrate. The pH was measured after each addition using Mettler Toledo 
MP225 pH meters fitted with a Beckman Type 39849 epoxy body calomel electrode. The pH 
meter was calibrated at pH 4.008 (using a potassium hydrogen phthalate buffer) and at pH 
1.679 (using a potassium tetroxalate buffer). All titratious were done in a water bath to 
maintain a coustant temperature and were replicated to ensure reproducibility. The pI<. values 
were determined following the method described by Albert and Serjeant.142 Tables 15 - 26 
summarize the data used to calculate the pI<. value and calculated errors for each compound; 
a detailed example of the method is described in Section 2.1.2 (pp. 51-54). 
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Table 15: Concentration of the protonated and non-protonated chromone 1 as a function of 
pH. 
Cone. Vol. Mass Molar No. of pH BW' Bb 
Hel Titrant (g) mass moles 
(mL) (wmoll 
0.1063 0.00 0.0292 146 0.0002 4.65 0.00 0.000200 
0.1063 0.20 0.0292 146 0.0002 3.16 2. 13E-05 0.000179 
0.1063 0.40 0.0292 146 0.0002 2.85 4.25E-05 0.000157 
0.1063 0.60 0.0292 146 0.0002 2.67 6.38E-05 0.000136 
0.1063 0.80 0.0292 146 0.0002 2.55 8.50E-05 0.000115 
0.1063 1.00 0.0292 146 0.0002 2.45 0.000106 9.37E-05 
0.1063 1.20 0.0292 146 0.0002 2.37 0.000128 7.24E-05 
0.1063 1.40 0.0292 146 0.0002 2.30 0.000149 5. 12E-05 
0.1063 1.60 0.0292 146 0.0002 2.24 0.000170 2.99E-05 
0.1063 1.80 0.0292 146 0.0002 2.18 0.000191 8.66E-06 
0.1063 2.00 0.0292 146 0.0002 2.15 0.000213 -1.26E-05' 
, Moles of conjugate acid; " Moles of residual free chromone; , The negative concentration reflects the excess 
concentration of titrant. 
Table 16: Calculation ofpK. values for chromone 1, corrected for hydrogen-ion activity. 
(i) (ii) (iii) (iv) (v) (vi) (vii) 
Total vol. [HJ W BW-W log( col.iv) pK, 10"'Ko 
(mL) B+W 
19.00 2.24E-05 4.2500E-07 -0.002122 
19.20 0.000692 1.3300E-05 0.041541 -1.381522 1.778478 0.016654 
19.40 0.001413 2.7400E-05 0.081764 -1.087438 1.762562 0.016159 
19.60 0.002138 4.1900E-05 0.122813 -0.910756 1.759244 0.016214 
19.80 0.002818 5.5800E-05 0.171207 -0.766478 1.783522 0.015303 
20.00 0.003548 7.1000E-05 0.214604 -0.668362 1.781638 0.015299 
20.20 0.004266 8.6200E-05 0.260962 -0.583423 1.786577 0.016346 
20.40 0.005012 1.0200E-04 0.303592 -0.517709 1.782291 0.016509 
20.60 0.005754 1.1900E-04 0.347159 -0.459472 1.780528 0.020200 
20.80 0.006607 1.3700E-04 0.369073 -0.432888 1.747112 0.019901 
21.00 0.007079 1.4900E-04 0.469847 -0.328044 1.821956 0.015068 
pK. = 1.77 ± 0.06 
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Table 17: Concentration of the protonated and non-protonated 2-(N,N-dimethylamino)-8-
fluorochromone 191 as a function of pH. 
Cone. Vol. Mass Molar No. of pH BH" Bb 
Hel Titrant (g) mass moles 
(mL) (Wmol) 
0.1063 0.00 0.0413 207 0.0002 4.55 0.00 0.000200 
0.1063 0.20 0.0413 207 0.0002 3.24 2.13E-05 0.000178 
0.1063 0.40 0.0413 207 0.0002 2.93 4.25&05 0.000157 
0.1063 0.60 0.0413 207 0.0002 2.75 6.38B-05 0.000136 
0.1063 0.80 0.0413 207 0.0002 2.62 8.50E-05 0.000114 
0.1063 1.00 0.0413 207 0.0002 2.52 0.000106 9.32E-05 
0.1063 1.20 0.0413 207 0.0002 2.43 0.000128 7.20E-05 
0.1063 1.40 0.0413 207 0.0002 2.36 0.000149 5.07E-05 
0.1063 1.60 0.0413 207 0.0002 2.29 0.0001 70 2.94E-05 
0.1063 1.80 0.0413 207 0.0002 2.24 0.000191 8. I 8E-06 
0.1063 2.00 0.0413 207 0.0002 2.20 0.000213 -1.3IE-05' 
• Moles of conjugate acid; 0 Moles of residual free amllochromone; , The negative concentration reflects the 
excess concentration of titrant 
Table 18: Calculation of pI<" values for 2-(N,N-dimethylamino)-8-fluorochromone 191, 
corrected for hydrogen-ion activity. 
(i) (ii) (iii) (iv) (v) (vi) (vii) 
Total vol. [H") II' BII'-II' log(coLiv) pK., lO'pKA 
(mL) B+II' 
19.00 2.82E-05 5.3500E-07 -0.002677 
19.20 0.000575 LlOOOE-05 0.053942 -1.268071 1.971929 0.010668 
19.40 0.001175 2.2800E-05 0.109722 -0.959705 1.970295 0.010708 
19.60 0.001778 3.4900E-05 0.169562 -0.770672 1.979328 0.010488 
19.80 0.002399 4.7500E-05 0.231785 -0.634915 1.985085 0.010349 
20.00 0.003020 6.0400E-05 0.298803 -0.524614 1.995386 0.010107 
20.20 0.003715 7.5100E-05 0.357193 -0.447097 1.982903 0.010402 
20.40 0.004365 8.9000E-05 0.427710 -0.368851 1.991149 0.010206 
20.60 0.005129 1.0600E-04 0.476958 -0.321520 1.968480 0.010753 
20.80 0.005754 1.2000E-04 0.560330 -0.251556 1.988444 0.010270 
21.00 0.0063\0 1.3300E-04 0.670745 -0.173443 2.026557 0.009407 
pI<" = 1.98 ± 0.06 
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Table 19: Concentration of the protonated and non-protonated 2-(N,N-dimethylamino )-6-
fluorochromone 192 as a function of pH 
Cone. VA!. Mass Molar No. of pH SW' S' 
Hel Titrant (g) mass moles 
(mL) (glmol) 
0.1063 0.00 0.0412 207 1.99E-04 5.75 0.00 0.000199 
0.1063 0.20 0.0412 207 1.99E-04 3.35 2. 13E-05 0.000178 
0.1063 0.40 0.0412 207 1.99B-04 3.05 4.25E-05 0.000157 
0.1063 0.60 0.0412 207 1.99E-04 2.86 6.38&05 0.000135 
0.1063 0.80 0.0412 207 1.99E-04 2.72 8.50B-05 0.000114 
0.1063 1.00 0.0412 207 1.99E-04 2.61 0.000106 9.27B-05 
0.1063 1.20 0.0412 207 1.99E-04 2.51 0.000128 7.15E-05 
0.1063 1.40 0.0412 207 1.99B-04 2.44 0.000149 5.02E-05 
0.1063 1.60 0.0412 207 1.99E-04 2.36 0.000170 2.90E-05 
0.1063 1.80 0.0412 207 1.99E-04 2.30 0.000191 7.69E-06 
0.1063 2.00 0.0412 207 1.99E-04 2.25 0.000213 -1.36E-05' 
• Moles of conjugate acid; , Moles of residual free aminochromone; , 'The negative concentration reflects the 
excess concentration of titrant. 
Table 20: Calculation of pI<. values for 2-(N,N-dimethylamino )-6-fluorochromone 192, 
corrected for hydrogen-ion activity. 
(i) (ii) (iii) (iv) (v) (vi) (vii) 
Total vol. [H'] H" BH"-H" log( coLiv) pK, lO-p'" 
(mL) B + H" 
19.00 1.78E-06 3.3800E-08 -0.000170 
19.20 0.000447 8.5800E-06 0.068064 -1.167085 2.182915 0.006563 
19.40 0.000891 1.7300E-05 0.145162 -0.838147 2.211853 0.006140 
19.60 0.001380 2.7100E-05 0.226262 -0.645388 2.214612 0.006101 
19.80 0.001905 3.7700E-05 0.311833 -0.506078 2.213922 0.006111 
20.00 0.002455 4.9100E-05 0.403346 -0.394322 2.215678 0.006086 
20.20 0.003090 6.2400E-05 0.486461 -0.312952 2.197048 0.006353 
20.40 0.003631 7.4100E-05 0.601473 -0.220784 2.219216 0.006036 
20.60 0.004365 8.9900E-05 0.674297 -0.171149 2.188851 0.006474 
20.80 0.005012 1.0400E-04 0.778028 -0.109005 2.190995 0.006442 
21.00 0.005623 1.1800E-04 0.904165 -0.043752 2.206248 0.006219 
pI<. = 2.20 ± 0.06 
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Table 21: Concentration of the protonated and non-protonated 2-(N,N-dimethylamino)-5-
methoxychromone 193 as a function of pH. 
Cone. Vol. Mass Molar No. of pH BH" Bb 
Hel Titrant (g) mass moles 
(mL) (gimol) 
0.1063 0.00 0.0438 219 0.0002 S.OO 0.00 0.000200 
0.1063 0.20 0.0438 219 0.0002 3.60 2. 13E-OS 0.000179 
0.1063 0.40 0.0438 219 0.0002 3.24 4.2SE-OS 0.0001S7 
0.1063 0.60 0.0438 219 0.0002 3.0S 6.38E-OS 0.000136 
0.1063 0.80 0.0438 219 0.0002 2.89 8.S0E-OS O.OooIIS 
0.1063 1.00 0.0438 219 0.0002 2.76 0.000106 9.37E-OS 
0.1063 1.20 0.0438 219 0.0002 2.66 0.000128 7.24E-OS 
0.1063 1.40 0.0438 219 0.0002 2.S8 0.000149 S.12E-OS 
0.1063 1.60 0.0438 219 0.0002 2.49 0.000170 2.99E-OS 
0.1063 1.80 0.0438 219 0.0002 2.42 0.000191 8.66E-06 
0.1063 2.00 0.0438 219 0.0002 2.34 0.000213 -1.26E-OS' 
• Moles of conjugate acid; , Moles of residual free aminochromone; , The negative concentration reflects the 
excess concentration of titrant. 
Table 22: Calculation ofpKa values for 2-(N,N-dimethylamino)-5-methoxychromone 193, 
corrected for hydrogen-ion activity. 
(i) (ii) (iii) (iv) (v) (vi) (vii) 
Total vol. [II'] II' BII'-II' log( coLiv) pK. lO-pKa 
(mL) B+II' 
19.00 0.000010 1.9000E-06 -0.000949 
19.20 0.000251 4.8228E-06 0.089545 -1.047957 2.552043 0.002805 
19.40 0.000575 1.l164E-05 0.185933 -0.730643 2.509357 0.003095 
19.60 0.000891 1.7469E-05 0.301333 -0.520953 2.529047 0.002958 
19.80 0.001288 2.5507E-05 0.423819 -0.372820 2.517180 0.003040 
20.00 0.001738 3.4756E-05 0.556953 -0.254181 2.505819 0.003120 
20.20 0.002188 4.4193E-05 0.714784 -0.145825 2.514175 0:003061 
20.40 0.002630 5.3657E-05 0.907715 -0.042051 2.537949 0.002898 
20.60 0.003236 6.6660E-05 1.070816 0.029715 2.519715 0.003022 
20.80 0.003802 7.9079E-05 1.279478 0.107033 2.527033 0.002971 
21.00 0.004571 9.5989E-05 1.398412 0.145635 2.485635 0.003269 
I pKa = 2.52 ± 0.06 1 
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Table 23: Concentration of the protonated and non-protonated 2-(N,N-dimethylamino)-8-
methoxychromone 194 as a function of pH. 
Conc. Vol. Mass Molar No. of pH BIr' Bb 
HCI Titrant (g) mass moles 
(mL) (glmol) 
0.1063 0.00 0.0437 219 0.0002 5.40 0.00 0.000200 
0.1063 0.20 0.0437 219 0.0002 3.60 2. 13E-05 0.000178 
0.1063 0.40 0.0437 219 0.0002 3.23 4.25E-05 0.000157 
0.1063 0.60 0.0437 219 0.0002 3.03 6.38E-05 0.000136 
0.1063 0.80 0.0437 219 0.0002 2.88 8.50E-05 0.000115 
0.1063 1.00 0.0437 219 0.0002 2.76 0.000106 9.32E-05 
0.1063 1.20 0.0437 219 0.0002 2.65 0.000128 7.20E-05 
0.1063 1.40 0.0437 219 0.0002 2.57 0.000149 5.07E-05 
0.1063 1.60 0.0437 219 0.0002 2.48 0.000170 2.95E-05 
0.1063 1.80 0.0437 219 0.0002 2.41 0.000191 8.20E-06 
0.1063 2.00 0.0437 219 0.0002 2.36 0.000213 -1.31E-05' 
, Moles of conjugate acid; " Moles of residual free aminochromone; , The negative concentration reflects the 
excess concentration oftitrant. 
Table 24: Calculation of pI<. values for 2-(N,N-dimethylamino)-8-methoxychromone 194, 
corrected for hydrogen-ion activity. 
(i) (ii) (iii) (iv) (v) (vi) (vii) 
Total vol. [H'] Ir BIr-Ir log( col.iv) pK, 10""" 
(mL) B+Ir 
19.00 3.98E-06 7.5600E-08 -0.000379 
19.20 0.000251 4.8200E-06 0.089769 -1.046880 2.553124 0.002798 
19.40 0.000589 1.1400E-05 0.184607 -0.733753 2.496247 0.003190 
19.60 0.000933 1.8300E-05 0.295272 -0.529777 2.500223 0.003161 
19.80 0.001318 2.6100E-05 0.419178 -0.377601 2.502399 0.003145 
20.00 0.001738 3.4800E-05 0.558940 -0.252635 2.507365 0.003109 
20.20 0.002239 4.5200E-05 0.702508 -0.153349 2.496651 0.003187 
20.40 0.002692 5.4900E-05 0.889066 -0.051066 2.518934 0.003027 
20.60 0.003311 6.8200E-05 1.042903 0.018244 2.498244 0.003175 
20.80 0.003890 8.0900E-05 1.238922 0.093044 2.503044 0.003140 
21.00 0.004365 9.1700E-05 1.538342 0.187053 2.547053 0.002838 
1 pI<. = 2.50 ± 0.06 1 
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Table 25: Concentration of the protonated and non-protonated 2-(N,N-dimethylarnino )-8-
nitrochromone 195 as a function of pH. 
Cone. Vol. Mass Molar No. of pH Bft' Bb 
HCI Titrant (g) mass moles 
(mL) (gImol) 
0.1063 0.00 0.0468 234 0.0002 5.00 0.00 0.000200 
0.1063 0.20 0.0468 234 0.0002 3.22 2. 13E-05 0.000179 
0.1063 0.40 0.0468 234 0.0002 2.90 4.25E-05 0.000157 
0.1063 0.60 0.0468 234 0.0002 2.72 6.38E-05 0.000136 
0.1 063 0.80 0.0468 234 0.0002 2.59 8.50E-05 0.000115 
0.1063 1.00 0.0468 234 0.0002 2.50 0.000106 9.37E-05 
0.1063 1.20 0.0468 234 0.0002 2.41 0.000128 7.24E-05 
0.1063 1.40 0.0468 234 0.0002 2.34 0.000149 5. 12E-05 
0.1063 1.60 0.0468 234 0.0002 2.28 0.000170 2.99E-05 
0.1063 1.80 0.0468 234 0.0002 2.22 0.000191 8.66E-06 
0.1063 2.00 0.0468 234 0.0002 2.18 0.000213 -1.26E-05' 
, Moles of conjugate acid; , Moles of residual free aminochromone; , The negative concentration reflects the 
excess concentration of titrant 
Table 26: Calculation ofpK., values for 2-(N,N-dimethylarnino)-8-nitrochromone 195, 
corrected for hydrogen-ion activity. 
(i) (ii) (iii) (iv) (v) (vi) (vii) 
Total vol. [HJ ft Bft-ft log(col.iv) pK, lO.pKa 
(mL) B+H" 
19.00 0.000010 1.9000E-07 -0.000949 
19.20 0.000603 1.1600E-05 0.050922 -1.293098 1.926902 0.011833 
19.40 0.001259 2.4400E-05 0.099486 -1.002237 1.897763 0.012654 
19.60 0.001905 3.7300E-05 0.152293 -0.817321 1.902679 0.012512 
19.80 0.002570 5.0900E-05 0.205881 -0.686384 1.903616 0.012485 
20.00 0.003162 6.3200E-05 0.274327 -0.561731 1.938269 0.011527 
20.20 0:003890 7.8600E-05 0.324265 -0.489099 1.920901 0.011998 
20.40 0.004571 9.3200E-05 0.384792 -0.414774 1.925226 0.011879 
20.60 0.005248 1.0800E-04 0.448957 -0.347795 1.932205 0.011689 
20.80 0.006026 1.2500E-04 0.492622 -0.307486 1.912514 0.012232 
21.00 0.006607 1.3900E-04 0.585469 -0 .232496 1.947504 0.011285 
pKa = 1.92 ± 0.06 
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Computational details 
Computations were conducted for the author by Professor C.W. McCleland (University of 
Port Elizabeth) using HyperChem (release 4.5)183 and MOPAC (version 6.0)184 packages on 
Pentium 90 MHz/16 MB RAM and 133 MHz/32 MB RAM personal computers. Structures, 
drawn in HyperChem and partially refmed using its MM+ molecular mechanics option, were 
exported to MOP AC. Geometries were then optimized without constraint through 
implementation of the AMI Hamiltonian, using the eigenvector-following routine (keyword 
EF). Use of the keyword PRECISE ensured that all geometry optimizations achieved energy 
gradient norms of at least 0.01 kcal.mor l A-I. Single-point HF/3-21G ab initio calculations 
on selected structures were carried out in HyperChem to an SCF convergence limit of 1 x 10-1 
kcal.mor l . Convergences were accelerated through application of the DIIS procedure. 
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3.3 Synthesis of "granulosin" [7,8-(methylenedioxy)-2-propylchromone 
and C-2 side-chain analogues 
2'-Hydroxy·3',4'-(methylenedioxy)acetophenone 197 
To a stirred suspension of 2',3',4'-trihydroxyacetophenone 196 (0.50 g, 3.0 mmol) and 
CS2C03 (0.97 g, 3.0 mmol) in dry DMF (7.5 mL) was added BrCH2CI (0.20 mL, 3.0 mmol), 
and the resulting mixture was boiled under reflux. After 3 h, the mixture was allowed to cool 
to room temperature and then filtered through a pad of Celite 545, washing with EtOAc. The 
fIltrate and the washings were concentrated in vacuo almost to dryness, and the residue 
diluted with H20 (20 mL) and extracted with EtOAc (3 x 50 mL). The combined extracts 
were washed with water (25 mL) and then with brine (25 mL), and dried over anhydrous 
MgS04. Evaporation of the solvent in vacuo gave a dark-tan solid, which was recrystallized 
from petroleum ether (b.p. 80-100 0c) to afford 2'-hydroxy-3 ~ 4'-(methylenedioxy)­
acetophenone 197 as a pale yellow solid (0.42 g, 80%), m.p. 96-98 °C (Found: M., 
180.04259. C9Hg04 requires M, 180.04226); Vrnax (KBr)/cm-1 1663 (CO); OH (400 MHz; 
CDCh) 2.56 (3H, s, CH3), 6.07 (2H, s, CH2), 6.46 (lH, d, J=8.4 Hz, 5'-H), 7.37 (lH, d, J=8.5 
Hz, 6'-H) and 12.27 (lH, s, OH); Oc (100 MHz; CDCh) 27.0 (CH3), 101.2 (C-5'), 103.0 
(CH2), 117.4 (C-l'), 127.0 (C-6'), 134.9 (C-3'), 147.4 (C-2'), 154.4 (C-4') and 203.8 (C=O); 
mlz 180 (M'", 54%) and 165 (100). 
Bis[6-acetyl-2,3-(methylenedioxy)phenoxyJmethane 198 
The experimental procedure employed for the synthesis of 2'-hydroxy-3',4'-(methylene-
dioxy)acetophenone 197 was followed, using of 2',3 ',4'-trihydroxyacetophenone 196 (1.0 g, 
6.0 mmol), CS2C03 (2.93 g, 9.0 mmol), dry DMF (15 mL) and BrCH2Cl (0.60 mL, 9.0 
mmol). After heating for 2 h, the reaction mixture was worked up to afford a yellow-brown 
solid. Flash chromatography on silica gel [elution with hexane-EtOAc (1 :1)] gave, as a white 
crystalline solid, bis[6-acetyl-2,3-(methylenedioxy)phenoxyJmethane 198 (1.96 g, 88%), m.p. 
133-135 °C (Found: W, 372.08495. Cl9Hl60g requires M, 372.08452); Vrnax (KBr)/cm-1 1665 
(CO); eSH (400 MHz; CDCh) 2.38 (6H, s, CH3), 5.95 (4H, s, 2xCH2), 6.09 (2H, s, CH2), 6.60 
(2H, d, J=8.3 Hz, 4-H) and 7.32 (2H, d, J=8.3 Hz, 5-H); eSc (100 MHz; CDCh) 30.8 (CH3), 
94.3 and 102.0 (2 x CH2), 104.0 (C-4), 125.5 (C-5), 126.5 (C-6), 137.2 (C-2), 139.2 (C-l), 
152.4 (C-3) and 197.3 (C=O); mlz 372 (M'", 2%) and 193 (100). 
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7,8-(Methylenedioxy)-2-propylchromone (Granulosin) 40 
A mixture of 2'-hydroxy-3',4'-(methylenedioxy)acetophenone 197 (0.50 g, 2.8 mmol) and 
CH3CH2CH2C02Et (1.6 mL, 12 mmol) was added dropwise to a stirred dispersion ofNaOEt 
[generated in situ by adding Na metal (0.27g, 12 mmol) to dry EtOH (2.0 mL)]. The resulting 
dark-green mixture was boiled gently under reflux for 8 h, during which time, a thick yellow 
slurry was formed. After cooling, the reaction mixture was poured into Et20 (15 mL) and, 
after standing for 2 h, the sodium salt was filtered off, washed with EhO and dissolved in ice-
cold water (15mL). The resulting solution was acidified with acetic acid, and then extracted 
with EhO (3 x 25 mL); the combined ethereal extracts were dried over anhydrous MgS04 
and evaporation in vacuo afforded a brick-red residue indicated, by lH NMR spectroscopy, to 
contain a mixture of 1-[2-hydroxy-3,4-(methylenedioxy)phenyl]-1,3-hexanedione (as an enol 
tautomer, formulated as 201) and 2-hydroxy-7,8-(methylenedioxy)-2-propy1chromanone 206, 
which was used without further purification. The crude mixture, together with glacial acetic 
acid (4.0 mL) and conc. H2S04 (0.1 mL), was boiled under reflux for 4 h. The hot solution 
was poured into ice-cold water (20 mL), the mixture was basified with 10% aq. NaHC03 (20 
mL) and the resulting dark-purple precipitate filtered and washed with cold water. Flash 
chromatography of the precipitate [on silica gel; elution with hexane-EtOAc (1 :1)] afforded a 
colourless solid, which was recrystallized from [petroleum ether (b.p. 80-100°C)-methanol 
(1:1)] to afford 7,8-(methylenedioxy)-2-propylchromone 40 as colourless crystals (0.48 g, 
76%), m.p. 101-103 °c (lit.,47 102-103 0c) (Found: M+, 232.07413. C13H1204 requires M, 
232.07356); Vmax (KBr)/cm-1 1658 (CO); liH (400 MHz; DMSO-d6) 0.96 (3H, t, J=7.4 Hz, 
CH3), 1.68 (2H, m, CH3CH2), 2.61 (2H, t, J=7.4 Hz, CH3CH2CH2), 6.12 (lH, s, 3-H), 6.27 
(2H, s, OCH20), 7.09 (lH, d, J=8.4 Hz, 6-H) and 7.56 (lH, d, J=8.4 Hz, 5-H); lie (100 MHz; 
CDCh) 13.3 (CH3), 19.7 (CH3CH2), 35.1 (CH3CH2CH2), 103.6 (OCH20), 107.1 (C-6), 109.0 
(C-3), 119.3 (C-4a and C-5; 119.3 and 120.1 in CDCh), 134.4 (C-8), 140.8 (C-8a), 152.1 (C-
7), 168.8 (C-2) and 175.9 (C=O); m/z 232 ~, 100%). 
2-Methyl-7,8-(methylenedioxy)chromone 209 
The experimental procedure employed for the synthesis of 7,8-(methylenedioxy)-2-propyl-
chromone (granulosin) 40 was followed, using the crude mixture of 1-[2-hydroxy-3,4-
(methylenedioxy)phenyl]-1,3-butanedione 199 and 2-hydroxy-2-methyl-7,8-(methylene-
dioxy)chromanone 204 {initially prepared using 2'-hydroxy-3',4'-(methylenedioxy)aceto-
phenone 197 (0.50 g, 2.8 mmol), dry CH3COzEt (1.20 mL, 12 mmol) and NaOEt [generated 
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in situ by adding Na metal (0.27g, 12 mmol) to dry EtOH (3.0 mL)]), glacial acetic acid (4.0 
mL) and conc. H2S04 (0.1 mL). Work-up afforded 2-methyl-7,8-(methylenedioxy)chromone 
209 as a white crystalline solid (0.32 g, 58%), m.p. 161-163 °C [from petroleum ether (b.p. 
80-100 DC)] (Found: ~, 204.04226. CUHS04 requires M, 204.04226); Vmax (KBr)/cm-1 1657 
(CO); OH (400 MHz; CDCb) 2.36 (3H, s, CH3), 6.06 (IH, s, 3-H), 6.15 (2H, S, OCH20), 6.90 
(lH, d, J=8.4 Hz, 6-H) and 7.74 (lH, d, J=8.4 Hz, 5-H); oe (100 MHz; CDCb) 20.3 (CH3), 
103.1 (OCH20), 106.9 (C-6), 110.1 (C-3), 119.7 (C-4a), 120.2 (C-5), 134.3 (C-8), 141.4 (C-
8a), 152.1 (C-7), 165.3 (C-2) and 177.1 (C=O); m/z 204 (11'", 100%). 
2-Ethyl-7, 8-(methylenedioxy)chromone 210 
The experimental procedure employed for the synthesis of 7,8-(methylenedioxy)-2-propyl-
chromone (granulosin) 40 was followed, using the crude mixture of 1-[2-hydroxy-3,4-
(methylenedioxy)phenyl]-1,3-pentanedione 200 and 2-ethyl-2-hydroxy-7,8-(methylene-
dioxy)chromanone 205 {initially prepared using 2'-hydroxy-3',4'-(methylenedioxy)aceto-
phenone 197 (0.50 g, 2.8 mmol), CH3CH2C02Et (1.40 mL, 12 mmol) and NaOEt [generated 
in situ by adding Na metal (0.27g, 12 mmol) to dry EtOH (3.0 mL)]), glacial acetic acid (4.0 
mL) and conc. H2S04 (0.1 mL). Work-up afforded 2-ethyl-7,8-(methylenedioxy)chromone 
210 as a white crystalline solid (0.49 g, 82%), m.p. 106-107 °C [from petroleum ether (b.p. 
80-100 DC)] (Found: ~,218.05884. C12HlO04 requires M, 218.05791); Vrnax (KBr)/cm-1 1653 
(CO); OH (400 MHz; CDCb) 1.29 (3H, t, J=7.5 Hz, CH3), 2.63 (2H, q, J=7.4 Hz, CH3CH2), 
6.06 (1H, s, 3-H), 6.15 (2H, s, OCH20), 6.89 (lH, d, J=8.5 Hz, 6-H) and 7.73 (lH, d, J=8.5 
Hz, 5-H); oe (100 MHz; CDCb) 10.9 (CH3), 27.2 (CH3CH2), 103.1 (OCH20), 106.8 (C-6), 
108.4 (C-3), 119.8 (C-4a), 120.1 (C-5), 134.4 (C-8), 141.4 (C-8a), 152.1 (C-7), 169.9 (C-2) 
and 177.3 (C=O); m/z 218 (M., 100%). 
2-Isopropyl-7,8-(methylenedioxy)chromone 211 
The experimental procedure employed for the synthesis of 7,8-(methylenedioxy)-2-propyl-
chromone (granulosin) 40 was followed, using the crude mixture of 1-[2-hydroxy-3,4-
(methylenedioxy)phenyl]-4-methyl-l,3-pentanedione 202 and 2-hydroxy-2-isopropyl-7,8-
(methylenedioxy)chromanone 207 {initially prepared using 2'-hydroxy-3',4'-(methylene-
dioxy)acetophenone 197 (0.50 g, 2.8 mmol), (CH3)2CHC02Et (1.60 mL, 12 mmol) and 
NaOEt [generated in situ by adding Na metal (0.27g, 12 mmol) to dry EtOH (3.0 mL)]), 
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glacial acetic acid (4.0 mL) and conc. H2S04 (0.1 mL). Work-up afforded 2-isopropyl-7,8-
(methylenedioxy)chromone 211 as a brown crystalline solid (0.40 g, 63%), m.p. 119-121 °c 
[from petroleum ether (b.p. 80-100 0C)] (Found: W, 232.07364. C13H1204 requires M, 
232.07356); Vrnax (KBr)/cm·1 1634 (CO); 8H (400 MHz; CDCh) 1.31 (6H, d, J=6.7 Hz, 2 x 
CH3), 2.S5 (lH, q, J=6.7 Hz, CH), 6.09 (lH, s, 3-H), 6.16 (2H, s, OCH20), 6.90 (lH, d, 
J=8.3 Hz, 6-H) and 7.74 (IH, d, J=8.3 Hz, 5-H); 8e (100 MHz; CDCh) 20.1 (CH3), 33.1 
[(CH3)2CH], 103.1 (OCH20), 106.8 (C-6), 107.0 (C-3), 119.8 (C-4a), 120.1 (C-5), 134.4 (C-
8), 141.4 (C-Sa), 152.1 (C-7), 173.4 (C-2) and 177.6 (C=O); m/z 232 cW, 100%). 
2-Benzyl-7,8-(methylenedioxy)chromone 212 
The experimental procedure employed for the synthesis of 7,8-(methylenedioxy)-2-propyl-
chromone (granulosin) 40 was followed, using the crude mixture of 1-[2-hydroxy-3,4-
(methylenedioxy)phenyl]-4-phenyl- l,3-butanedione 203 and 2-benzyl-2-hydroxy-7,S-
(methylenedioxy )chromanone 208 {initially prepared using 2'-hydroxy-3',4'-( methy lene-
dioxy)acetophenone 197 (0.50 g, 2.8 mmol), PhCH2C02Et (1.90 mL, 12 mmol) and NaOEt 
[generated in situ by adding Na metal (0.27g, 12 mmol) to dry EtOH (3.0 mL)]), glacial 
acetic acid (4.0 mL) and conc. H2S04 (0.1 mL). Work-up afforded 2-benzyl-7,8-
(methylenedioxy)chromone 212 as a white crystalline solid (0.66 g, 85%), m.p. 172-174°C 
[from petroleum ether (b.p. 80-100 °C)] (Found: W, 280.07415. C17HI204 M, 280.07356); 
Vmax (KBr)/cm-1 1657 (CO); 8H (400 MHz; CDCh) 3.90 (2H, s, CH2Ph), 6.00 (lH, s, 3-H), 
6.14 (2H, s, OCH20), 6.88 (1H, d, J=S.5 Hz, 6-H), 7.25-7.34 (SH, In, Ar-H) and 7.72 (lH, d, 
J=S.4 Hz, 5-H); 8e (100 MHz; CDCh) 40.4 (CH2Ph), 103.1 (OCH20), 106.9 (C-6), 110.2 (C-
3), 119.7 (C-4a), 120.2 (C-S), 127.S, 12S.9, 129.3 and 134.S (Ar-C), 134.6 (C-8), 141.4 (C-
Sa), 152.1 (C-7), 167.3 (C-2) and 177.2 (C=O); m/z 280 (M'", 100%). 
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3.4 Synthesis of 5-hydroxy-2-isopropyl-7-methoxychromone and C-2 
side-chain analogues 
2'-Hydroxy-4; 6'-dimethoxyacetophenone 215149 
A stirred solution of2',4',6'-trihydroxyacetophenone 213 (5.0 g, 30 mmol), Me2S04 (5.3 mL, 
56 mmol) and anhydrous K2C03 (8.2 g, 56 mmol) in acetone (90 mL) was boiled under 
reflux for 5 h. The reaction mixture was filtered and evaporated in vacuo to give a so lid. 
Recrystallization from petroleum-ether (b.p. 80-100 0c) - hexane (1:9) afforded 2'-hydroxy-
4',6'-dimethoxyacetophenone 215 as a pale yellow solid (5.2 g, 90%), m.p. 75-77 °C (lit.,182 
77-79°C) (Found: W, 196.07405. ClOH120 4 requires M, 196.07356); Vmax (KBr)/cm-1 3100 
(hr, OH) and 1620 (CO); OH (400 MHz; CDCh) 2.57 (3H, s, CH3), 3.78 and 3.82 (6H, 2 x s, 2 
X OCH3), 5.88 (lH, d, J=2.2 Hz, 5'-H), 6.01 (lH, d, J=2.2 Hz, 2'-H) and 13.92 (lH, s, OH); 
oe (100 MHz; CDCh) 32.7 (CH3), 55.43 and 55.44 (2 x OCH3), 90.6 (C-5'), 93.5 (C-3'), 
106.0 (C-1'), 162.9 (C-2'), 166.1 (C-6'), 167.5 (C-4'), and 203.1 (C=O); m/z 196 (M', 4%) 
and 181 (100). 
3.4.1 Synthesis of the C-2 substituted 5,7-dimethoxychromone derivatives 
2-Isopropyl-5, 7-dimethoxychromone 229 
A mixture of 2'-hydroxy-4',6'-dimethoxyacetophenone 215 (1.0 g, 5.1 mmol) and ethyl iso-
butyrate (3.0 mL, 22 mmol) was added dropwise to a stirred dispersion ofNaOEt [generated 
in situ by adding Na metal (0.51g, 22 mmol) to dry EtOH (4.0 mL)]. The resulting mixture 
was boiled gently under reflux for 8 h, during which time, a thick yellow slurry was formed. 
After cooling, the reaction mixture was poured into Et20 (30 mL) and, after standing for 2 h, 
the sodium salt was filtered off, washed with Et20 and dissolved in ice-cold water (15mL). 
The resulting solution was acidified with acetic acid, and then extracted with Et20 (3 x 30 
mL); the combined ethereal extracts were dried over anhydrous MgS04 and evaporated in 
vacuo to afford a brick-red residue indicated, by lH NMR spectroscopy, to contain a mixture 
of 1-(2-hydroxy-4,6-dimethoxyphenyl)-4-methyl-1,3-pentanedione (as an enol tautomer, 
formulated as 219) and 2-hydroxy-2-isopropyl-5,7-dimethoxychromanone 224, which was 
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used without further purification. The crude mixture, together with glacial acetic acid (5.0 
mL) and conc. H2S04 (0.1 mL), was boiled under reflux for 4 h. The hot solution was poured 
into ice-cold water (20 mL), and the resulting mixture was basified with 10% aq. NaHC03 
(20 mL) [monitored with pH indicator paper] and extracted with Et20 (3 x 50 mL). The 
combined ethereal extracts were dried over anhydrous MgS04 and evaporated in vacuo to 
give a tan-solid. Flash chromatography on silica gel (elution with EtOAc) afforded 2-
isopropyl-5, 7-dimethoxychromone 229 as a white solid (0.50 g, 40%), m.p. 54-56°C (Found: 
~,248.10486. C14H1604 requires M, 248.10486); vIlUIX(KBr)!cm"1 1656 (CO); OH (400 MHz; 
CDCh) 1.26 (6H, d, J=6.9 Hz, 2 x CH3), 2.74 (lH, q, J=6.8 Hz, CH), 3.86 and 3.91 (6H, 2 x 
s, 2 x OCHl), 6.00 (IH, s, 3-H), 6.32 (lH, d, J=2.2 Hz, 6-H) and 6.42 (lH, d, J=2.2 Hz, 8-
H); oe (100 MHz; CDCh) 19.9 (2 x CHl), 32.5 (CH), 55.6 and 56.3 (2 x OCHl), 92.6 (C-8), 
95.9 (C-6), 108.9 (C-3), 109.0 (C-4a), 160.2 (C-8a), 160.9 (C-5), 163.8 (C-7), 171.0 (C-2) 
and 177.9 (C=O); mlz248 (M'", 100%). 
5, 7-Dimethoxy-2-methylchromone 226 
The experimental procedure employed for the synthesis of 2-isopropyl-5,7-dimethoxy-
chromone 229 was followed, using the crude mixture of 1-[2-hydroxy-4,6-dimethoxyphenyl]-
1,3-butanedione 216 and 2-hydroxy-5,7-dimethoxy-2-methylchromanone 221 {initially 
prepared using 2'-hydroxy-4',6'-dimethoxyacetophenone 215 (1.0 g, 5.1 mmol), dry 
CH3C02Et (4.3 mL, 44 mmol) and NaOEt [generated in situ by adding Na metal (0.51g, 22 
mmol) to dry EtOH (5.0 mL)]), glacial acetic acid (5.0 mL) and conc. H2S04 (0.1 mL). 
Work-up afforded a crude residue, which was chromatographed [flash chromatography on 
silica gel; elution with CHCh - MeOH (9:1)] to afford 5,7-dimethoxy-2-methylchromone 
226 as a yellow crystalline solid (0.78 g, 70%), m.p. 121-123 °C [from hexane - EtOAc 
(7:3)] (lit./sO 124-125 0c) (Found: M+, 220.07366. C12H120 4 requires M, 220.07356); VIlUIX 
(KBr)!cm"11657 (CO); OH (400 MHz; CDCb) 2.24 (3H, s, CH3), 3.84 and 3.90 (6H, 2 x s, 2 x 
OCH3), 5.98 (lH, s, 3-H), 6.31 (lH, d, J=2.2 Hz, 6-H) and 6.39 (lH, d, J=2.2 Hz, 8-H); oe 
(100 MHz; CDCb) 19.7 (CH3), 55.6 and 56.3 (2 x OCH3), 92.6 (C-8), 95.9 (C-6), 108.9 (C-
4a), 111.9 (C-3), 160.1 (C-8a), 160.9 (C-5), 162.9 (C-7), 163 .7 (C-2) and 177.4 (C=O); mlz 
220 (M'", 100%). 
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2-Ethyl-5, 7-dimethoxychromone 227 
The experimental procedure employed for the synthesis of 2-isopropyl-S,7-dimethoxy-
chromone 229 was followed, using the crude mixture of 1-[2-hydroxy-4,6-dimethoxyphenyl]-
1,3-pentanedione 217 and 2-ethyl-2-hydroxy-S,7-dimethoxychrornanone 222 {initially 
prepared using 2'-hydroxy-4',6'-dimethoxyacetophenone 215 (1.0 g, 5.1 rnmol), 
CH3CH2C02Et (2.54 mL, 22 rnmol) and NaOEt [generated in situ by adding Na metal (O.Slg, 
22 rnrnol) to dry EtOH (5.0 mL)]), glacial acetic acid (5.0 mL) and cone. H2S04 (0.1 mL). 
Work-up afforded a crude residue, which was chromatographed (flash chromatography on 
silica gel; elution with CHCh) to afford 2-ethyl-S,7-dimethoxychromone 227 as a white 
crystalline solid (0.77 g, 65%), mp. 134-136 °C (lit./86 133-134 °C) (Found: M",234.08939. 
C!3H1404 requires M, 234.08921); Vrnax (KBr)/cm'l 1661 (CO); OH (400 MHz; CDCh) 1.28 
(3H, t, J=7.4 Hz, CH3), 2.59 (2H, q, J=7.S Hz, CH3CH2), 3.86 and 3.92 (6H, 2 x s, 2 x 
OCH3), 6.01 (lH, s, 3-H), 6.32 (lH, d, J=2.0 Hz, 6-H) and 6.41 (lH, d, J=2.0 Hz, 8-H); DC 
(100 MHz; CDCh) 10.7 (CH3), 26.7 (CH3CH2), 55.6 and 56.3 (2 x OCH3), 92.6 (C-8), 95.9 
(C-6), 109.1 (C-4a), 110.3 (C-3), 160.1 (C-8a), 160.9 (C-S), 163.7 (C-7), 167.5 (C-2) and 
177.6 (C=O); m/z 234 (M'", 100%). 
5,7-Dimethoxy-2-propylchromone 228 
The experimental procedure employed for the synthesis of 2-isopropyl-S,7-dimethoxy-
chromone 229 was followed, using the crude mixture of 1-[2-hydroxy-4,6-dimethoxyphenyl]-
1,3-hexanedione 218 and 2-hydroxy-S,7-dimethoxy-2-propylchrornanone 223 {initially 
prepared using 2'-hydroxy-4',6'-dimethoxyacetophenone 215 (1.0 g, 5.1 rnmol), 
CH3CH2CH2C02Et (3.0 mL, 22 rnmol) and NaOEt [generated in situ by adding Na metal 
(0.5Ig, 22 rnmol) to dry EtOH (5.0 mL)]), glacial acetic acid (5.0 mL) and conc. H2S04 (0.1 
mL). Work-up afforded a crude residue, which was chromatographed [flash chromatography 
on silica gel; elution with CHCh] to affurd S,7-dimethoxy-2-propylchromone 228 as white 
prisms (0.84 g, 67%), m.p. 129-131 °C (lit.,187 131-132 0c) (Found: M", 248.10515. 
Cl4Hl604 requires M, 248.10456); Vrnax (KBr)/cm,1 1660 (CO); DH (400 MHz; CDCb) 0.98 
(3H, t, J=7.4 Hz, CH3), 1.70 (2H, In, CH3CH2), 2.46 (2H, t, J=7.5 Hz, CH3CH2CH2), 3.84 
and 3.90 (6H, 2 x s, 2 x OCH3), 5.98 (lH, s, 3-H), 6.30 (IH, d, J=2.2 Hz, 6-H) and 6.39 (lH, 
d, J=2.2 Hz, 8-H); DC (100 MHz; CDC!) 13.5 (CH3), 19.9 (CH3CH2), 35.4 (CH3CH2CH2), 
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55.6 and 56.3 (2 x OCH3), 92.6 (C-8), 95.8 (C-6), 109.0 (C-4a), 111.2 (C-3), 160.1 (C-8a), 
160.8 (C-5), 163.7 (C-7), 166.2 (C-2) and 177.5 (C=O); m/z 248 (M", 100%). 
2-Benzyl-5, 7-dimethoxychromone 230 
The experimental procedure employed for the synthesis of 2-isopropyl-5,7-dimethoxy-
chromone 229 was followed, using the crude mixture of 1-[2-hydroxy-4,6-dimethoxyphenyl]-
4-phenyl-l ,3-butanedione 220 and 2-benzyl-2-hydroxy-5,7-dimethoxychrornanone 225 
{initially prepared using 2'-hydroxy-4',6'-dimethoxyacetophenone 215 (1.0 g, 5.1 romol), 
PhCH2C02Et (3.5 mL, 22 romol) and NaOEt [generated in situ by adding Na metal (0.51g, 
22 romol) to dry EtOH (5.0 mL)]), glacial acetic acid (5.0 mL) and conc. H2S04 (0.1 mL). 
Work-up afforded a crude residue, which was chromatographed [flash chromatography on 
silica gel; elution with EtOAc] to afford 2-benzyl-5,7-dimethoxychromone 230 as a brown 
crystalline solid (0.90 g, 60%), m.p. 170-171 °C (Found: M+, 296.10496. C18H1604 requires 
M, 296.10486); vrnax (KBr)/cm·11664 (CO); IiH (400 MHz; CDCh) 3.80 (2H, s, CH2Ph), 3.83 
and 3.89 (6H, 2 x s, 2 x OCH3), 5.96 (IH, s, 3-H), 6.30 (IH, d, J=2.0 Hz, 6-H), 6.37 (lH, d, 
J=2.1 Hz, 8-H) and 7.25-7.34 (5H, m, Ar-H); lie (100 MHz; CDCh) 39.9 (CH2Ph); 55.6 and 
56.3 (2 x OCH3), 92.7 (C-8), 96.0 (C-6), 109.0 (C-4a), 112.1 (C-3), 127.3, 128.8, 129.1 and 
135.0 (Ar-C), 160.1 (C-8a), 160.9 (C-5), 163.8 (C-7), 164.8 (C-2) and 177.4 (C=O); m/z 296 
(M+, 100%). 
3.4.2 Synthesis of the C-2 substituted 5-hydroxy-7-methoxychromone 
derivatives 
5-Hydroxy-2-isopropyl-7-methoxychromone 35 
A solution of2-isopropyl-5,7-dimethoxychromone 229 (50 mg, 0.20,romol), acetic anhydride 
(1.01 mL, 10.7 romol) and hydriodic acid (d. 1.7; 1.52 mL, 20.2 romol) was heated in an oil 
bath at 115°C for 30 min. The reaction mixture was cooled, and then diluted with aqueous 
sodium bisulphite. The resulting solution was neutralized with sO(,lium bicarbonate, and the 
precipitated solid filtered off and washed with water. Flash chromatography on silica gel 
[elution with hexane-EtOAc (5:1)] afforded 5-hydroxy-2-isoprop-yl-7-methoxychromone 35 
as a pale yellow solid (26 mg, 55%), m.p. 44-46 °C (lit.,40 40-43 0c) (Found: W, 234.08936. 
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C IJH l404 requires M, 234.08921); Vrnax (KBr)/cm-1 2966 (br, OH) and 1675 (CO); liH (400 
MHz; CDCh) 1.29 (6H, d, J=6.9 Hz, 2 x CH3), 2.82 (lH, m, CH), 3.85 (3H, s, OCH3), 6.03 
(lH, s, 3-H), 6.32 (lH, d, J=2.2 Hz, 6-H), 6.36 (lH, d, J=2.2 Hz, 8-H) and 12.70 (lH, s, 
OH); lie (l00 MHz; CDCh) 20.1 (2 x CH3), 33.2 (CH), 55.7 (OCH3), 92.4 (C-8), 97.9 (C-6), 
105.5 (C-4a), 105.9 (C-3), 158.1 (C-8a), 162.2 (C-5), 165.4 (C-7), 174.9 (C-2) and 182.8 
(C=O); m/z 234 (M'", 100%). 
5-Hydroxy-7-methoxy-2-methylchromone 231 
The experimental procedure employed for the synthesis of 5-hydroxy-2-isopropyl-7-
methoxychromone 35 was followed, using 5,7-dimethoxy-2-methylchromone 226 (200 mg, 
0.909 mmol), acetic anhydride (4.57 mL, 48.5 mmol) and hydriodic acid (6.86 mL, 91.0 
mmol). Work-up afforded a crude yellow solid, which was flash chromatographed on silica 
gel (elution with EtOAc) to afford 5-hydroxy-7-methoxy-2-methylchromone 231 as a pale 
yellow solid (108 mg, 58%), m.p. 114-115 DC [from hexane- EtOAc (85:15)] (lit./sO 118-119 
DC) (Found: W, 206.05842. CUHlO04 requires M, 206.05791); Vrnax (KBr)/cm-1 2980 (br, 
OH) and 1672 (CO); liH (400 MHz; CDCh) 2.33 (3H, s, CH3), 3.83 (3H, s, OCH3), 6.01 (lH, 
s, 3-H), 6.32 (IH, d, J=2.2 Hz, 6-H), 6.34 (lH, d, J=2.1 Hz, 8-H) and 12.68 (lH, s, OH); lie 
(100 MHz; CDCh) 20.4 (CH3), 55.7 (OCH3), 92.4 (C-8), 97.9 (C-6), 105.2 (C-4a), 108.7 (C-
3), 158.1 (C-8a), 162.2 (C-5), 165.3 (C-7), 166.8 (C-2) and 182.4 (C=O); m/z 206 (M'", 
100%). 
2-Ethyl-5-hydroxy-7-methoxychromone 232 
The experimental procedure employed for the synthesis of 5-hydroxy-2-isopropyl-7-
methoxychromone 35 was followed, using 2-ethyl-5,7-dimethoxychromone 227 (200 mg, 
0.855 mmol), acetic anhydride (4.30 mL, 45.3 mmol) and hydriodic acid (6.43 mL, 85.5 
mmol). Work-up afforded a crude yellow solid, which was flash chromatographed on silica 
gel [elution with hexane-EtOAc (8:2)] to afford 2-ethyl-5-hydroxy-7-methoxychromone 232 
as a brown solid (150 mg, 80%), m.p. 101-103 DC, [from hexane-EtOAc (8:2)] (Found: W, 
220.07272. C12H1204 requires M, 220.07356); Vmax (KBr)/cm·1 2975 (hr, OH) and 1660 (CO); 
8H (400 MHz; CDCh) 1.27 (3H, t, J=7.2 Hz, CH3), 2.61 (2H, q, J=7.4 Hz, CH3CH2), 3.87 
(3H, s, OCH3), 6.02 (1H, s, 3-H), 6.32 (lH, d, J=2.2 Hz, 6-H), 6.35 (If!, d, J=2.1 Hz, 8-H) 
and 12.67 (lH, s, OH); lie (l00 MHz; CDC h) 10.9 (CH3), 27.4 (CH3CH2), 55.7 (Q!:H3), 92.4 
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(C-8), 97.9 (C-6), 105.4 (C-4a), 107.2 (C-3), 158.1 (C-8a), 162.2 (C-5), 165.4 (C-7), 171.5 
(C-2) and 182.7 (C=O); mlz 220 (~, 100%). 
5-Hydroxy-7 -methoxy-2-propylchromone 233 
The experimental procedure employed for the synthesis of 5-hydroxy-2-isopropyl-7-
methoxychromone 35 was followed, using 5,7-dirnethoxy-2-propylchromone 228 (200 mg, 
0.806 rnrnol), acetic anhydride (4.03 rnL, 42.7 rnrnol) and hydriodic acid (6.06 rnL, 80.6 
rnrnol). Work-up afforded a crude yellow solid, which was flash chrornatographed on silica 
gel [elution with hexane-EtOAc (6:4)] to afford 5-hydroxy-7-methoxy-2-propylchromone 233 
as a pale yellow crystalline solid (125 mg, 66%), !D.p. 89-91 °c (Found: M+, 234.08937. 
C 13H!404 requires M, 234.08921); Vmax (KBr)!cm'! 2967 (hr, OH) and 1654 (CO); IlH (400 
MHz; CDCh) 1.01 (3H, t, )=7.4 Hz, CH3), 1.75 (2H, In, CH3CH2), 2.55 (2H, t, J=7.5 Hz, 
CH3CH2CH2), 3.84 (3H, s, OCH3), 6.02 (lH, s, 3-H), 6.32 (lH, d, ) =2.1 Hz, 6-H), 6.35 (IH, 
d, J =2.1 Hz, 8-H) and 12.69 (lH, s, OH); Ilc (100 MHz; CDCh) 13.5 (CH3), 20.2 (CH3CH2), 
36.1 (CH3CH3CH2), 55.7 (OCH3), 92.5 (C-8), 97.9 (C-6), 105.5 (C-4a), 108.1 (C-3), 158.2 
(C-8a), 162.2 (C-5), 165.4 (C-7), 170.3 (C-2) and 182.6 (C=O); mlz 234~, 100%). 
2-Benzyl-5-hydroxy-7-methoxychromone 234 
The experimental procedure employed for the synthesis of 5-hydroxy-2-isopropyl-7-
methoxychromone 35 was followed, using 2-benzyl-5,7-dimethoxychromone 230 (200 mg, 
0.676 mmol), acetic anhydride (3.38 rnL, 35.8 rnrnol) and hydriodic acid (5 .08 rnL, 67.6 
rnrnol). Work-up afforded a crude yellow solid, which was flash chrornatographed on silica 
gel [elution with hexane-EtOAc (8 :2)] to afford 2-benzyl-5-hydroxy-7-methoxychromone 234 
as a white crystalline solid (115 mg, 61%), !D.p. 152-153 °c, (from ethanol) (Found: ~, 
282.08880. C17H!404 requires M, 282.08921); vmax (KBr)!cm'!3000 (hr, OH) and 1677 (CO); 
IlH (400 MHz; CDCh) 3.83 (3H, s, OCH3), 3.87 (2H, s, CH2Ph), 5.96 (lH, s, 3-H), 6.32 (lH, 
d, J=2.1 Hz, 6-H), 6.34 (lH, d, ) =2.1 Hz, 8-H), 7.26-7.37 (5H, In, Ar-H) and 12.64 (lH, s, 
OH); Ilc (100 MHz; CDCh) 40.5 (CH2Ph), 55.7 (OCH3), 92.5 (C-8), 98.0 (-C-6), 105.3 (C-
4a), 108.9 (C-3), 127.5, 128.9, 129.2 and 134.5 (Ar-C), 158.1 (C-8a), 162.1 (C-5), 165.4 (C-
7), 168.8 (C-2) and 182.5 (C----O); mlz 282 (~, 100%). 
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3.4.3 Assessment of biological activity of compounds 35, 40, 209 - 212 and 
226 -234 
Artemia salina larvicidal bioassays were performed for the author by Mr C.A. Gray, 
following the method described by Solis et al. 146 Estimates of median lethal concentrations 
were obtained by pro bit analysis147 and the trimmed Spearman-Karber method151 of A. salina 
mortality data from 12 solutions across concentration ranges of:- 25.00 - 0.586 J.1g/mL for 
compound 40; 400.0 - 12.50 J.1g/mL for compounds 209 - 212; 200.0 - 10.00 J.1g/mL for 
compounds 35 and 231 - 233; 700.0 - 300.0 J.1g/mL for compound 234 and 400.0 - 50.00 
J.1g/mL for compounds 226 - 230. 
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3.5 Synthesis of potential HIV-l protease inhibitors 
3.5.1 Synthesis of the hydroxyethy/ene dipeptide isostere 
(L)-N,N-Dibenzylphenylalanine benzyl ester 238163 
To a homogeneous solution ofL-phenylalanine 237 (lOg, 60 mmol), K2C03 (27 g, 0.20 mol) 
and water (40 mL) was added benzyl chloride (22.7 mL, 194 mmol). The solution was boiled 
under reflux for 18 h (prolonged reflux is necessary to destroy excess BnCI). The reaction 
mixture was cooled and hexane (30 mL) and water (20 mL) were added. The organic phase 
was separated and washed with water-methanol (2:1 ; 2 x 20 mL), dried over anhydrous 
Na2S04 and concentrated in vacuo to afford (L)-N,N-dibenzylphenylalanine benzyl ester 238 
as a pale yellow oil (24.38 g, 94%), (Found: M+-Bn, 344.16540. C30H29N02 requires M-Bn, 
344.16505); Vmax (nujol mull/em-I) 1732 (CO); BH (400 MHz; CDCh) 3.21 and 3.33 (2H, 2 x 
dd, J=8.1 and 13.9 Hz, CH2), 3.63 (2H, d, J=14.0 Hz, CH2), 3.80 (IH, t, J=7.7 Hz, CR), 4.00 
(2H, d, J=14.0 Hz, CH2), 5.19 and 5.29 (2H, 2 x d, J=12.3 Hz, CH2), 7.05-7.45 (20H, In, Ar-
R); Be (100 MHz; CDCh) 35.7 (CH2), 54.4 (2 x CH2), 62.4 (CR), 66.0 (CH2), 126.2, 126.9, 
128.1, 128.2, 128.3, 128.4, 128.5, 128.7, 129.3, 136.0, 138.0 and 139.2 (Ar-C) and 172.1 
(C=O). 
(4S)-4-(Dibenzylamino)-3-oxo-5-phenylpentanenitrile 239163 
A solution ofthe crude benzyl ester 238 (10 g, 23 mmol) in dry THF ( 30 mL) was cooled to 
-45 °C under N2. A separate flask was charged with sodium amide (95%; 2.2 g, 55 mmol) 
under N2 followed by THF (25 mL). The slurry was cooled below -45 °C and CH3CN (3.1 
mL, 59 mmol) was added over a period of 15 min; the resulting solution was then added to 
the ester solution over 15 min. After stirring the mixture at -45 °C for 2 h, the reaction was 
quenched with 25% aqueous citric acid (60 mL). The organic layer was separated, washed 
with 20% brine (60 mL), filtered, dried over anhydrous Na2S04 and concentrated in vacuo to 
give a yellow viscous oil. Crystallization from ethanol (denatured with toluene) afforded 
(4S)-4-(dibenzylarnino)-3-oxo-5-phenylpentanenitrile 239 as white crystals (5.4 g, 64%), 
m.p. 132-134 °C (lit./63 84-85 0c) (Found: M+, 368.18897. C2sH24N20 requires M, 
368.18886); Vmax (nujol mull/cm-I) 2265 (CN) and 1739 (CO); BH (400 MHz; CDCh) 2.98 
(lH, dd, J=3.4 and 13.4 Hz, CH), 3.00 (lH, d, J=19.5 Hz, CR), 3.22 (lH, dd, J=9.6 and 13.5 
Hz, CR), 3.53 (lH, dd, .1=3 .5 and 9.5 Hz, CH), 3.57 (2H, d, .1=13.5 Hz, CH2), 3.80 (2H, d, 
175 
\ 
Experimental 
J=13.4 Hz, CH2), 3.85 (lH, d, .1=19.5 Hz, CH), and 7.14-7.38 (ISH, m, Ar-H); oe (100 MHz; 
CDCh) 28.5 (CH2), 30.0 (CH2), 54.8 (2 x CH2), 68.6 (CH), 113.8, 126.5, 127.8, 128.6, 128.8, 
129.0, 129.5, and 138.1 (Ar-C), 138.4 (CN) and 196.8 (C=O); mlz 368 (M+, 1%) and 91 
(100). 
(5S)-2-Amino-5-(dibenzylamino)-4-oxo-l, 6-diphenylhex-2-ene 240 163 
To a stirred solution of the nitrile 239 (5.0 g, 14 mmol) in dry THF (15 mL) at 10 DC was 
added, dropwise, a solution of benzylmagnesium chloride in dry THF (2.0M; 20 mL, 0.14 
mol), maintaining the temperature of the mixture below 5 DC. The solution was allowed to 
warm to 25 DC and stirring was continued for 24 h. The mixture was then cooled to 5 DC and 
the reaction quenched by the slow addition of 10% aqueous citric acid (70 mL). The organic 
layer was separated and washed with saturated brine (50 mL), dried over anhydrous Na2S04 
and concentrated in vacuo to give a yellow viscous oil. The crude oil was crystallized from 
ethanol (denatured with toluene) to afford (5S)-2-amino-5-(dibenzylamino)-4-oxo-1,6-
diphenylhex-2-ene 240 as white crystals (5.71 g, 92%), !D.p. 101-102 DC (lit.,163 101-102 DC) 
(Found: W-Bn, 369.19646. C32H32N20 requires M-Bn, 369.19669); Vmax (nujol mulllcm·1) 
3433 and 3324 (NH2) and 1597 (CO); OH (400 MHz; CDCh) 2.97 and 3.15 (2H, 2 x dd, J=6.3 
and 13 .7 Hz, CH2), 3.49 (3H, In, CH2 and CH), 3.65 (2H, d, J=14.0 Hz, CH2), 3.78 (2H, d, 
J=14.0 Hz, CH2), 4.88 (IH, br s, NH), 5.08 (IH, s, CH), 7.10-7.42 (20H, m, Ar-H) and 9.79 
(lH, br s, NH); oe (100 MHz; CDCh) 32.5 (CH2), 42.4 (CH2), 54.4 (2 x CH2), 66.7 (CH), 
97.0,125.6, 126.7, 127.3, 128.0, 128.1, 128.7, 128.9, 129.3, 129.5, 135.8, 140.1, 140.2 and 
162.8 (Ar-C and CH=C) and 198.1 (C=O). 
(2S,3 S,5S)-5 -Amino-2-( dibenzylamino )-3 -hydroxy-I, 6-diphenylhexane 242 163 
A suspension of sodium borohydride (1.0 g, 27 mmol) in dry TIIF (56 mL) was cooled to -5 
DC. Methanesulfonic acid (4.3 mL, 66 mmol) was added at a rate such that the temperature 
remained below 5 DC. The reaction mixture was cooled to 0 DC, and a solution of the 
enaminone 240 (5.0 g, 11 mmol) in dry THF (10 mL) and isopropyl alcohol (6.0 mL) was 
added, and the resulting mixture was stirred for 14 h at 5 DC. In a separate flask, a dispersion 
of sodium borohydride (1.65 g, 43.4 mmol) in dry TIIF (22 mL) was cooled to 0 DC, and 
trifluoroacetic acid (4.2 mL, 54 mmol) was added slowly. The resulting solution was stirred 
for 45 min at 10 DC, and then added slowly to the enaminone reaction mixture, maintaining 
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the temperature of the mixture below 15°C. The resulting mixture was stirred for 4 h and 
cooled to 10 °C before quenching the reaction with 3M NaOH (35 mL). tert-Butyl methyl 
ether (40 mL) was then, added and the organic layer was separated and washed sequentially 
with 2% aq. NaOH (40 mL), 20% aq. N&CI (40 mL) and 6% aq. NaCI (2 x 40 mL). The 
organic solution was dried over anhydrous Na2S04 and then concentrated in vacuo to afford, 
as a yellow oil, a mixture of diastereomers containing the required hydroxy compound 242 
(5.5 g, ca.lOO%) (Found: M+-Bn, 373.22440. C32H36N20 requires M-Bn, 373.22799); Vmsx 
(nujol mull/em-I) 3400-3000 (hr, OH and NH2); IiH (400 MHz; CDCh) 1.25 (IH, ill, CH), 
1.61 (lH, ill, CH), 2.47 (lH, dd, J=14.0 Hz, CH), 2.66 (2H, ill, CH2), 3.00 (3H, ill, CH2 and 
CH), 3.46 (2H, d, J=13.5 Hz, CH2), 3.65 (lH, ill, CH), 4.16 (2H, d, J=13.6 Hz, CH2) and 
7.07-7.35 (20H, ill, Ar-H) ; lie (100 MHz; CDCb) 30.3 (CH2), 40.5 (CH2), 46.7 (CH2), 53.3 
(CH), 55.1 (2 x CH2), 63.7 (CH), 72.1 (CH), 125.7, 126.3, 126.8, 128.2, 128.3, 128.4, 128.9, 
129.0,129.4, 138.6, 140.3 and 141.0 (Ar-C). 
(2S,3S,5S)-2, 5-Diamino-3-hydroxy-l, 6-diphenylhexane dihydrochloride 243163 
The diastereomeric mixture containing the hydroxy compound 242 (5.0 g, 11 mmol), 
methanol (80 mL), aqueous ammonium formate (3 .4 g in 5.8 mL of water) and 5% 
palladium-on-carbon catalyst (50-60% water by weight; 1.0 g) was boiled under reflux for 6 
h. The cooled suspension was filtered through a bed of diatomaceous earth (Celite 545), and 
the cake was washed with methanol (2 x 50 mL). The filtrate and washings were 
concentrated in vacuo to afford an oily residue, which was dissolved in EtOAc (50 mL) and 
washed sequentially with 4% aq. NaOH (50 mL), 20% aq. NaCI (50 mL) and water (30 mL). 
The organic solution was dried over anhydrous Na2S04, and concentrated in vacuo to give a 
yellow oily residue. Isopropyl alcohol (52 mL) and cone. HCI (4.3 mL) were added to the 
residue, and the resulting suspension was boiled under reflux for 1 h, cooled to 25°C and 
then stirred for 18 h. The solid was filtered off and washed with EtOAc to afford (2S,3S, 58)-
2,5-diamino-3-hydroxy-l,6-diphenylhexane dihydrochloride 243 as a white crystalline solid 
(2.00 g, 68%), m.p. >300 °C (lit./63 >300 DC) (Found: ~-Bn, 193.13469. C18H24N20 
requires M-Bn, 193.13409); Vmax (nujol mu11lcm-l) 3190-2360 (br, OH and NH); IiH (400 
MHz; DMSO-d6)t 1.62 and 1.80 (2H, 2 x ill, 4-H), 2.90 (4H, ill, I-H and 6-H), 3.20 (lH, ill, 
5-H), 3.46 (lH, ill, 2-H), 3.71 (lH, ill, 3-H), 7.18-7.34 (10H, ill, Ar-H) and 8.10 (4H, br s, 2 x 
t The hydroxyl proton was not observed presumably. due to rapid exchange with water present in the DMSO-d6 used as the solvenl 
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NH2); be (100 MHz; DMSO-d6) 34.9 (C-l), 35.2 (C-4), 37.8 (C-6), 50.5 (C-5), 56.4 (C-2), 
66.1 (C-3), 126.6,126.7,128.5,129.3,129.4,136.0 and 136.5 (Ar-C). 
(2S,3S,5S)-2, 5-Diamino-3-hydroxy-l, 6-diphenylhexane 236 
A solution of the dihydrochloride salt 243 (0.50 g, 1.4 mmol) in water (2.0 mL) was basified 
with saturated aq. NaHC03 (monitored by pH indicator paper). The resulting solution was 
extracted with EtOAc (3 x 50 mL). The combined extracts were dried over anhydrous 
Na2S04, and the solvent was evaporated in vacuo to afford (2S,3S,5S)-2,5-diamino-3-
hydroxy-l,6-diphenylhexane 236 as a yellow oil (0.30 g, 77%) (Found: M'-Bn, 193.13404. 
C1sH24N20 requires M-Bn, 193.13409); Vrnax (hexachlorobutadiene/cm,l) 3467-3090 (hr, OH 
and NH2); bH (400 MHz; CDCh) 1.56 and 1.70 (2H, m, 4-H), 2.20 (5H, br s, 3-0H and 2 x 
NH2), 2.54 and 2.85 (5H, m, 2-H and I-H and 6-H), 3.11 (IiI, m, 5-H), 3.72 (lH, m, 3-H), 
and 7.15-7.35 (10H, m, Ar-H); be (100 MHz; CDCh) 39.1 (C-l), 41.3 (C-4), 47.3 (C-6), 54.0 
(C-5), 57.5 (C-2), 74.5 (C-3), 126.1, 126.5, 128.4, 128.6, 129.3, 129.4, 138.3, and 139.7 (Ar-
C). 
3.5.2 Synthesis of chromone-2-carboxylic acid derivatives 
Chromone-2-carboxylic acid 258165,166 
A mixture of diethyl oxalate (15 mL, 0.11 mol) and o-hydroxyacetophenone 244 (12 mL, 
0.10 mol) was added dropwise under N2 to a stirred ethanolic solution ofNaOEt [generated in 
situ by adding Na metal (6.9 g, 0.3 mol) to dry EtOH (200 mL)] . The resulting yellow 
mixture was boiled gently under reflux for 45 min, during which time a thick yellow slurry 
was formed. After cooling, the yellow reaction mixture was poured into Et20 (300 mL). 
After standing for 1 h, the yellow sodium salt was filtered off; washed with Et20 and 
acidified with 2M-HCI (200 mL), and the resulting semi-solid mixture was extracted with 
Et20 (3 x 100 mL). The combined ethereal extracts were dried over anhydrous MgS04, 
filtered and evaporated in vacuo to afford a yellow oily residue [indicated, by 1 H NMR 
spectroscopy, to contain a mixture of ethyl 1-(2-hydroxyphenyl)-1,3-dioxobutanoate (as an 
enol tautomer, formulated as 249) and ethyI2-hydroxychromanone-2-carboxylate 253] which 
was used without further purification. The crude mixture, together with glacial acetic acid (45 
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mL) and cone. HCl (45 mL), was boiled under reflux for 1 h. After cooling, the precipitated 
solid was filtered off, washed with acetic acid and recrystallized from acetic acid to afford 
chromone-2-carboxylic acid 258 as a colourless solid (16 g, 85%), m.p. 249-251 °C 
(decom.p.) (lit.,165 265°C); vmax (KBr)/cm·1 3300-2000 (hr, OH) and 1740 and 1630 (2 x CO); 
OH (400 MHz; DMSO-dd 6.91 (IH, s, 3-H), 7.54 (lH, d, J=7.6 Hz, 6-H), 7.72 (lH, d, J=8.3 
Hz, 8-H), 7.87 (lH, m, 7-H) and 8.05 (IH, m, 5-H); oe (100 MHz; DMSO-d6) 113.3 (C-3), 
118.7 (C-8), 123.6 (C-4a), 124.8 (C-5), 125.9 (C-6), 135.0 (C-7), 153.2 (C-2), 155.3 (C-8a), 
161.3 (COOH) and 177.4 (C=O). 
6-Chlorochromone-2-carboxylic acid 259165.166 
The experimental procedure employed for the synthesis of chromone-2-carboxylic acid 258 
was followed, using the crude mixture of ethyl 1-(5-chloro-2-hydroxyphenyl)-1,3-dioxo-
butanoate 250 and ethyl 6-chloro-2-hydroxychromanone-2-carboxylate 254 {initially 
prepared using 5'-chloro-2'-hydroxyacetophenone 245 (4.5 g, 26 mmol), diethyl oxalate (20 
mL, 0.15 mol) and NaOEt [generated in situ by adding Na metal (2.4 g, 0.11 mol) to dry 
EtOH (44 mL)]}, glacial acetic acid (22 mL) and conc. HCl (11 mL). Work-up afforded 6-
chlorochromone-2-carboxylic acid 259 as a white solid (5.1 g, 88%); m.p. >260 °C 
(decom.p.) (from ethanol) (lit.,1sS 267-269 °C) (Found: M+, 223.98806. ClOH5CI04 requires 
M, 223.98764); Vmax (KBr)/cm-1 3200-2100 (hr, OH) and 1745 and 1657 (2 x CO); OH (400 
MHz; DMSO-~)~ 6.93 (lH, s, 3-H), 7.79 (lH, d, J=8.9 Hz, 8-H), 7.90 (IH, dd, J=2.6 and 
9.0 Hz, 7-H), and 7.96 (lH, d, J=2.5 Hz, 5-H); m/z 223.9 (M'", 100%). 
6-Methoxychromone-2-carboxylic acid 260165.166 
The experimental procedure employed for the synthesis of chromone-2-carboxylic acid 258 
was followed, using the crude mixture of ethyl 1-(2-hydroxy-5-methoxyphenyl)-1,3-
dioxobutanoate 251 and ethyl 2-hydroxy-5-methoxychromanone-2-carboxylate 255 {initially 
prepared using 2'-hydroxy-5'-methoxyacetophenone 246 (4.0 g, 24 mmol), diethyl oxalate 
(5.0 mL, 36 mol) and NaOEt [generated in situ by adding Na metal (1.7 g, 72 mol) to dry 
EtOH (50 mL)]}, glacial acetic acid (60 mL) and conc. HCl (30 mL). Work-up afforded 6-
methoxychromone-2-carboxylic acid 260 as a pale green solid (4.5 g, 85%), m.p. >260 °C 
(decom.p.) (lit., \89 268°C) (Found: M+, 220.03674. C\1HS0 5 requires M, 220.03717); Vrnax 
t The carboxylic acid proton was not observed, presumably, due to rapid exchange with water present in tbe DMSO-d& used as the solvent. 
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(KBr)/cmI3200-2200 (br, OH) and 1730 and 1640 (2 x CO); OH (400 MHz; DMSO-d6)13.87 
(3H, s, OCH3), 6.88 (lH, s, 3-H), 7.40 (lH, d, J=3.1 Hz, 8-H), 7.45 (1H, In, 7-H), and 7.68 
(lH, d, J=9.1 Hz, 5-H); Oc (100 MHz; DMSO-d6) 55.7 (OCH3), 104.5 (C-3), 112.4 (C-8), 
l20.4 (C-4a), 124.2 (C-5), 124.4(C-7), 150.0 (C-6), 152.9 (C-2), 156.9 (C-8a), 161.3 
(COOH) and 177.1 (C=O); m/z 220 (M'", 100%). 
5-Methoxychromone-2-carboxylic acid 261165,166 
The experimental procedure employed for the synthesis of chromone-2-carboxylic acid 258 
was followed, using the crude mixture of ethyl 1-(2-hydroxy-6-methoxyphenyl)-1,3-
dioxobutanoate 252 and ethyl 2-hydroxy-5-methoxychromanone-2-carboxylate 256 {initially 
prepared using 2'-hydroxy-6'-methoxyacetophenone 247 (2.0 g, 12 mmol), diethyl oxalate 
(3.4 mL, 25 mol) and NaOEt [generated in situ by adding Na metal (1.0 g, 43 mol) to dry 
EtOH (25 mL)]), glacial acetic acid (30 mL) and cone. HCI (15 mL). Work-up afforded 5-
methoxychromone-2-carboxylic acid 261 as a cream solid (4.8 g, 87%); m.p. 250-252 °C 
(decom.p.) (lit./9o 252-253 DC) (Found: M+, 220.03717. CllHgOs requires M, 220.03854); 
Vrnax (KBr)/cm'! 3300-2200 (hr, OH) and 1750 and 1650 (2 x CO); OH (400 MHz; DMSO-d6)1 
3.86 (3H, s, OCH3), 6.70 (lH, s, 3-H), 7.02 (lH, d, J=8.2 Hz, 6-H), 7.16 (lH, d, J=8.3 Hz, 8-
R), and 7.72 (lH, t, J=8.4 Hz, 7-H); m/z 220 (M'", 100%). 
7-Hydroxychromone-2-carboxylic acid 262166 
A mixture of2',4'-dihydroxyacetophenone 248 (2.0 g, 13 mmol) and diethyl oxalate (3.5 mL, 
26 mmol) was added to a stirred ethanolic solution ofNaOEt [generated in situ by adding Na 
metal (1.2 g, 52 mmol) to dry EtOH (30 mL)]. The resuhing mixture was boiled under reflux 
for 5 h, and then cone. HCI (7.2 mL) was added and heating was continued for 1 h. Charcoal 
(0.40 g), conc. HCI (6 mL) and H20 (12 mL) were added, and the heating was continued for a 
further 4 h. The resulting hot solution was filtered and evaporated in vacuo to give a brown 
residue, which was washed well with hot water (60°C), and recrystallized from aqueous 
EtOH [EtOH-H20 (2:1)] to afford a brown solid, indicated by IH NMR analysis to be ethyl 
7-hydroxychromone-2-carboxylate 257. A mixture of ethyl 7-hydroxychromanone-2-
carboxylate 257, glacial acetic acid (20 mL) and cone. HCI (20 mL) was boiled under reflux 
for 12 h. After cooling, H20 (40 mL) was added and the resulting precipitate was filtered off 
and washed well with cold H20 to afford 7-hydroxychromone-2-carboxylic acid 262 as a 
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maroon solid (1.9 g, 72%); m.p. >280 °C (decom.p.) (lit./ 66 >300 °C) (Found: M+, 
206.02152. CIO~OS M, 206.02079); Vrnax (KBr)/cm'l 3400-2000 (br, OH) and 1760 and 1640 
(2 x CO); OH (400 MHz; DMSO-d6); 6.79 (lH, s, 3-H), 6.89 (lH, d, J=2.1 Hz, 8-H), 6.96 
(lH, dd, J=2.2and 8.8 Hz, 6-H), and 7.89 (1H, d, J=8.7 Hz, 5-H); m/z 206 (M+, 100%). 
3.5.3 Coupling of the isostere 236 with chromone-2-carboxylic acid 
derivatives using EDC and HOBt 
(2S, 3S, 5S)-2, 5-Bis(benzopyran-4-one-2-carbamoyl)-3-hydroxy-l, 6-diphenylhexane 263 
To a solution of the diamine 236 (90 mg, 0.32 mmol) in dry DMF (5.0 mL) under N2 were 
added I-hydroxybenzotriazole hydrate (HOBt) (171 mg, 1.26 mmol), N-ethyl-N'-(dimethyl-
arninopropyl)carbodiimide hydrochloride (EDC) (241 mg, 1.26 mmol) and chromone-2-
carboxylic acid 258 (120 mg, 0.63 mmol). Triethylamine was then added to adjust the pH of 
the solution to 8.5. The resulting mixture was stirred at room temperature for 24 h, and then 
poured into H20 (6 mL) and extracted with EtOAc (3 x 25 mL). The combined extracts were 
washed sequentially with 10% citric acid, saturated aq. NaHC03 (10 mL) and saturated brine 
(10 mL), and then dried over anhydrous Na2S04. The solvent was evaporated in vacuo give a 
yellow residue, which was chromatographed [flash chromatography on silica gel; elution with 
hexane-EtOAc (1:9)] to afford (2S, 3S, 5S)-2,5-bis(benzopyran-4-one-2-carbamoyl)-3-
hydroxy-l,6-diphenylhexane 263 as a white solid (115 mg, 60%), m.p. 126-128 °c (Found: 
~, 628.22076. C38H32N20 1 requires M, 628.22095); Vrnax (KBr)/cml 3500-3200 (br, OH and 
NH), 1655 and 1649 (2 x CO); OH (400 MHz; CDCb) 1.83 (2H, m, 4-H), 2.01 (2H, d, J=6.7 
Hz, 2 x NH), 2.86-3.00 (4H, m, I-H and 6-H), 3.89 (IH, br s, 3-H), 4.24 (llI, br s, 3-0H), 
4.41 (2H, m, 2-H and 5-H), 6.96 and 7.05 (2H, 2 x s, 2 X 3'-H), 7.10-7.65 (16H, m, Ar-H) 
8.00 and 8.10 (2H, 2 x d, J=8.0, 8.1 Hz, 2 x 5'-H); oe (100 MHz; CDCb) 38.2 (C-l), 39.4 
(C-4), 40.8 (C-6), 49.9 (C-5), 55.6 (C-2), 69.4 (C-3), 111.8, 112.0, 118.0, 118.2, 123.9, 124.1, 
125.7, 125.8, 126.0, 126.7, 127.0, 128.7, 129.2, 129.3, 134.5, 134.6, 136.6, 137.4, 154.5, 
154.7,155.0 and 155.2 (C-2', C-3' and Ar-C), 159.2 and 159.4 (2 x NCO), 178.0 and 178.2 (2 
x C=O); m/z 628 (M+, 2%) and 91 (100). 
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(28, 38, 58)-2, 5-Bis(6-chlorobenzopyran-4-one-2-carbamoyl)-3-hydroxy-l, 6-diphenyl-
hexane 264 
The experimental procedure employed for the synthesis of (28, 38, 5S)-2,5-bis(benzopyran-4-
one-2-carbamoyl)-3-hydroxy-l,6-diphenylhexane 263 was followed, using the diamine 236 
(80 mg, 0.28 mmol), 6-chlorochromone-2-carboxylic acid 259 (126 mg, 0.56 mmol), 1-
hydroxybenzotriazole hydrate (HOBt) (150 mg, 1.12 mmol), N-ethyl-N'-(dimethylamino-
propyl)carbodiimide hydrochloride (EDC) (251 mg, 1.12 mmol) and dry DMF (10 mL). 
Work-up afforded a yellow oily residue. Flash chromatography on silica gel [elution with 
hexane-EtOAc (2:8)] gave (28, 38, 58)-2,5-bis(6-chlorobenzopyran-4-one-2-carbamoyl)-3-
hydroxy-I,6-diphenylhexane 264 as a cream solid (93 mg, 52%), m.p. 226-228 °C (Found: 
M+, 696.14184. C38H3035ChN20 7 requires M, 696.14301); Vrnax (KBr)/cm-1 3500-3200 (br, 
OH and NH), 1654 and 1648 (2 x CO); BH (400 MHz; CDCh) 1.86 (2H, Ill, 4-H), 2.28 (3H, 
br s, 3-0H and 2 x NH), 2.98 (4H, Ill, I-H and 6-H), 3.90 (lH, br s, 3-H), 4.38 (2H, Ill, 2-H 
and 5-H), 6.93 and 7.02 (2H, 2 x s, 2 x 3'-H), 7.10-7.60 (14H, Ill, Ar-H), 7.90 and 8.00 (2H, 2 
x d, J=2.5, 2.5 Hz, 2 x 5'-H); Be (100 MHz; CDCh) 38.2 (C-l), 39.3 (C-4), 40.8 (C-6), 50.0 
(C-5), 55.6 (C-2), 69.4 (C-3), 111.7, 112.0, 119.7, 120.0, 124.7, 125.0, 125.2, 125.3, 126.8, 
127.0, 128.7, 129.2, 129.3, 132.1, 132.2, 134.7, 134.8, 136.5, 137.2, 153.3, 153.4, 154.7 and 
154.9 (C-2', C-3' and Ar-C), 158.8 and 159.0 (2 x NCO), 176.8 and 176.9 (2 x C=O); mlz 696 
(M+, 1%) and 91 (100). 
(28, 38, 58)-3-Hydroxy-2, 5-bis(6-methoxybenzopyran-4-one-2-carbamoyl)-1, 6-dipherryl-
hexane 265 
The experimental procedure employed for the synthesis of (28, 38, 5S)-2,5-bis(benzopyran-4-
one-2-carbamoyl)-3-hydroxy-l,6-diphenylhexane 263 was followed, using the diamine 236 
(80 mg, 0.28 mmol), 6-methoxychromone-2-carboxylic acid 260 (125 mg, 0.56 mmol), 1-
hydroxybenzotriazole hydrate (HOBt) (150 mg, 1.12 mmol), N-ethyl-N'-(dimethylamino-
propyl)carbodiimide hydrochloride (EDC) (251 mg, 1.12 mmol) and dry DMF (10 mL). 
Work-up afforded a yellow oily residue. Flash chromatography on silica gel [elution with 
hexane-EtOAc (2:8)] to gave (28, 38, 58)-3-hydroxy-2,5-bis(6-methoxybenzopyran-4-one-2-
carbamoyl)-1,6-diphenylhexane 265 as a pale yellow solid (98 mg, 56%), m.p. 119-121 °C 
(Found: M +, 688.24222. C4oH36N209 requires M, 688.24208); Vrnax (KBr)/cm-1 3470-3000 (br, 
OH and NH), 1654 and 1638 (2 x CO); BH (400 MHz; CDCh) 1.85 (2H, Ill, 4-H), 2.30 (2H, 
br s, 2 x NH), 2.86-3.06 (4H, Ill, I-H and 6-H), 3.77 and 3.80 (6H, 2 x s, 2 x OCH3), 3.91 
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(IH, br s, 3-H), 4.40 (2H, In, 2-H and 5-H), 4.47 (lH, br s, 3-0H), 6.90 and 7.02 (2H, 2 x s, 2 
x 3'-H) and 7.10-7.40 (16H, In, Ar-H); Be (100 MHz; CDCh) 38.2 (C-l), 39.1 (C-4), 40.7 (C-
6), 50.0 (C-5), 55.6, 55.7 and 55.8 (C-2 and 2 x OCH3), 69.4 (C-3), 104.7, 104.8, 110.7, 
111.0, 119.4, 119.6, 124.4, 124.5, 124.8, 126.7, 126.8, 128.6, 129.2, 129.3, 136.7, 137.4, 
149.7, 149.9, 137.2, 154.3, 154.5, 157.3 and 157.4 (C-2', C-3' and Ar-C), 159.1 and 159.4 (2 
x NCO), 177.8 and 178.0 (2 x C=O); mlz 688 (M+, 1%) and 91 (100). 
(2S, 3S, 5S)-3-Hydroxy-2,5-bis(5-methoxybenzopyran-4-one-2-carbamoyl)-1,6-diphenyl-
hexane 266 
The experimental procedure employed for the synthesis of (28, 38, 5S)-2,5-bis(benzopyran-4-
one-2-carbamoyl)-3-hydroxy-l,6-diphenylhexane 263 was followed, using the diarnine 236 
(150 mg, 0.53 mmol), 5-methoxychromone-2-carboxylic acid 261 (233 mg, 1.06 mmol), 1-
hydroxybenzotriazole hydrate (HOBt) (286 mg, 2.12 mmol), N-ethyl-N'-(dimethylarnino-
propyl)carbodfunide hydrochloride (EDC) (406 mg, 2.12 mmol) and dry DMF (10 mL). 
Work-up afforded a brown residue. Flash chromatography on silica gel [elution with 
CHC!)-MeOH (9:1)] gave (2S, 3S, 5S)-3-hydroxy-2,5-bis(5-methoxybenzopyran-4-one-2-
carbamoyl)-1,6-diphenylhexane 266 as a brown powder (300 mg, 82%), m.p. 143-145 °c 
(Found: M+, 688.24070. C4oH36N20 9 requires M, 688.24208); vmax(KBr)/cm-1 3300-2500 (br, 
OH and NH), 1650 and 1640 (2 x CO); BH (400 MHz; CDCh) 1.72-1.93 (5H, br s, 4-H, 3-0H 
and 2 x NH), 2.86-3.00 (4H, In, 1-H and 6-H), 3.86 and 3.90 (6H, 2 x s, 2 x OCH3), 3.92 
(lH,br s, 3-H), 4.36 (2H, In, 2-H and 5-H) and 6.66-7.50 (18H, In, 2 x 3'-H and Ar-H); Be 
(100 MHz; CDCb) 38.2 (C-l), 39.2 (C-4), 41.0 (C-6), 50.0 (C-5), 55.5 (C-2), 56.3 and 56.4 ( 
2 x OCH3), 69.5 (C-3), 106.9, 107.0, 109.8, 110.0, 113.4, 113.6, 114.6, 114.7, 126.7, 126.9, 
128.6, 128.7, 129.3, 129.4, 134.5, 136.8, 137.4, 152.7, 152.8, 157.1, 157.2, 159.3 and 159.4 
(C-2', C-3' and Ar-C), 159.7 and 159.8 (2 x NCO), 177.7 and 177.8 (2 x C=O); mlz 688 (M'", 
2%) and 377 (100). 
(2S, 3S, 5S)-3-Hydroxy-2,5-bis(7-hydroxybenzopyran-4-one-2-carbamoyl)-1,6-diphenyl-
hexane 267 
The experimental procedure employed for the synthesis of (28, 38, 5S)-2,5-bis(benzopyran-4-
one-2-carbamoyl)-3-hydroxy-l,6-diphenylhexane 263 was followed, using the diarnine 236 
(160 mg, 0.56 mmol), 7-hydroxychromone-2-carboxylic acid 262 (230 mg, 1.12 mmol), 1-
hydroxybenzotriazole hydrate (HOBt) (303 mg, 2.24 mmol), N-ethyl-N'-(dimethylarnino-
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propyl)carbodiimide hydrochloride (EDC) (430 mg, 2.24 romol) and dry DMF (10 rnL). 
Work-up afforded a yellow oily residue. Flash chromatography on silica gel (elution with 
EtOAc) gave (28, 38, 58)-3-hydroxy-2,5-bis(7-hydroxybenzopyran-4-one-2-carbamoyl)-1,6-
diphenylhexane 267 as a yellow solid (290 mg, 78%), m.p. 196-198 °C (Found: W+H, 
661.21755. C3sH32N209 requires M+H, 661.21861); Vrnax (KBr)/cm-1 3500-3000 (br, OH and 
NH), 1660 and 1645 (2 x CO); OH (400 MHz; DM80-d6) 1.76 (2H, m, 4-H), 2.84 (2H, d, 
J=6.6 Hz, I-H), 2.96 (2H, d, J=6.7 Hz, 6-H), 3.32 (2H, br s, 2 x NH), 3.74 (IH, br s, 3-H), 
4.40 (2H, m, 2-H and 5-H), 5.05 (lH, br s, 3-0H), 6.57 and 6.64 (2H, 2 x s, 2 x 3'-H), 6.93-
7 .27 (12H, m, Ar-H), 7.87 (2H, dd, J=4.1 and 8.5 Hz, 2 x 8'-H), 8.39 and 8.73 (2H,2 x d, 
J=9.0 Hz, 2 x S'-H) and 10.90 (2H, br s, Ar-OH); Oc (100 MHz; DM80-d6) 36.5 (C-1), 38.1 
(C-4), 40.1 (C-6), 48.3 (C-5), 54.3 (C-2), 68.1 (C-3), 102.6, 102.7, 110.2, 110.4, 115.6, 116.3, 
125.7, 125.8, 126.5, 127.9, 128.9, 129.0, 138.5, 138.8, 154.9, 155.0, 156.8, and 158.3 (C-2', 
C-3' and Ar-C), 159.0 and 163.1 (2 x NCO), 176.0 and 176.2 (2 x C=O); mlz 661 (M+W, 
56%) and 91 (100). 
3.5.4 Coupling o/the isostere 236 with chromone-2-carboxylic acid 
derivatives using CDI 
The tris-chromone derivative 268 and the bis-chromone derivative 263 
To a solution of the diamine 236 (30 mg, 0.11 romol) in dry DMF (1.0 rnL) was added to a 
stirred solution of chromone-2-carboxylic acid 258 (40 mg, 0.21 romol), 1,1'-
carbonyldiimidazole (CDI) (34 mg, 0.21 romol) in dry DMF (1.0 rnL) under N2. The reaction 
mixture was stirred at room temperature for 48 h, and the reaction was then quenched with 
H20 (3.0 rnL). The mixture was extracted with EtOAc (3 x 10 rnL), and the combined 
extracts were sequentially washed with 10% citric acid (5.0 rnL), saturated aq. NaHC03 (5.0 
mL) and brine (5.0 rnL). The extracts were dried over anhydrous Na2804, and evaporation of 
the solvent in vacuo afforded a yellow oily residue, which was chromatographed (flash 
chromatography on silica gel; elution with EtOAc) to afford the tris-chromone derivative 268 
as a pale yellow oil (45 mg, 54%) [vrnax (KBr)/cm-1 3300 (NH), 1740, 1653 and 1650 (3 x 
CO); OH (400 MHz; CDC!) 2.00 (2H, m, CH2), 2.88-3.02 (4H, m, 2 x CH]Ph), 4.58 (lH, br s, 
5-H), 4.81 (2H, m, 2-H and 3-H), 6.92 (lH, d, N-H), and 7.05-8.30 (26H, m, Ar-H, 3'-H and 
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N-H); FABMS m/z 800 (M', 100%)] and the bis-chromone derivative 263 as a white solid 
(20mg,31%). 
The tris-chromone derivative 269 and the bis-chromone derivative 264 
The experimental procedure employed for the synthesis of the tris-chromone derivative 268 
and bis-chromone derivative 263 was followed, using the diamine 236 (320 mg, 1.13 mmol), 
6-chloro-chromone-2-carboxylic acid 259 (507 mg, 2.26 mmol), CDr (366 mg, 2.26 mmol) 
and dry DMF (10 mL). Work-up afford a yellow oily residue. Flash chromatography on 
silica gel [elution with hexane-EtOAc (1 :3)] gave the tris-chromone derivative 269 as a white 
solid (500 mg, 49%), m.p. 180-183 DC [vmax (KBr)/cm-1 3270 (NH), 1736, 1655 and 1650 (3 x 
CO); BH (400 MHz; CDCh) 2.05 (2H, In, CHz), 2.96 (4H, In, 2 x CH2Ph), 4.61 (IH, br s, 5-
H), 4.93 and 5.32 (2H, In, 2-H and 3-H), 6.91 (!H, d, N-H), and 7.00-8.10 (23H, In, Ar-H, 3'-
Hand N-H); Be (100 MHz; CDCh) 35.9, 38.3 and 41.1 (3 x CHz), 48.3 (C-5), 52.2 (C-2), 
76.0 (C-3), 112.0, 112.3, 114.9, 119.6, 119.9, 120.3, 124.9, 125.0, 125.3, 127.1,127.2, 128.8, 
128.9, 129.0, 129.4, 132.1, 132.3, 132.5, 134.7, 134.9, 135.3, 135.7, 136.1, 151.4, 153.2, 
153.4,153.9,154.3,154.4,158.5, 159.2 and 159.5 (Ar-C and C-3'), 176.6, 176.7 and 177.0 (3 
x C=O); FABMS mlz 902 (M', 100%)] and the bis-chromone derivative 264 as a cream white 
solid (210 mg, 27%). 
The Tris-chromone derivative 270 and the bis-chromone derivative 265 
The experimental procedure employed for the synthesis of the tris-chromone derivative 268 
and the bis-chromone 263 was followed, using the diamine 236 (250 mg, 0.879 mmol), 6-
methoxy-chromone-2-carboxylic acid 260 (390 mg, 1.76 mmol), CDr (290 mg, 1.76 mmol) 
and dry DMF (10 mL). Work-up afford a yellow oily residue. Flash chromatography on 
silica gel [elution with hexane-EtOAc (1:3)] gave the tris-chromone derivative 270 as a 
cream white solid (470 mg, 60%), m.p. 235-237 DC [vrnax (KBr)/cm-1 3300 (NH), 1740, 1653 
and 1650 (3 x CO); BH (400 MHz; CDCh) 2.02 (2H, In, CHz), 2.93 (4H, In, 2 x CH2Ph), 3.86, 
3.89, and 3.91 (9H, 3 x s, 3 X OCH3), 4.59 (1H, br s, 5-H), 4.90 and 5.31 (2H, In, 2-H and 3-
H) and 6.70-7.60 (24H, In, Ar-H, 3'-H and 2 x N-H); FABMS m/z 891 (M+H+, 100%)] and 
the bis-chromone derivative 265 as a pale yellow solid (210 mg, 35%). 
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3.6 Synthesis of chromone-3-carbaldehydes 
Chromone-3-carbaldehyde 2729 
POC!) (9.4 mL, 0.10 mol) was added dropwise, during a period of 30 min, to a stirred 
solution of o-hydroxyacetophenone 43 (3.0 mL, 25 mmol) in dry DMF (25 mL) under N2, 
while maintaining the temperature at -20°C using a dry ice-acetone bath. The resulting 
mixture was stirred overnight at room temperature and then poured into ice-water (50 mL). 
The resulting precipitate was filtered off; and washed successively with water and EtOH. 
Recrystallization from acetone afforded chromone-3-carbaldehyde 27 as a colourless 
crystalline solid (2.6 g, 60%), m.p. 152-154 °c (lit.,29 152-153 °C); VIDIIX (KBr)!cm-1 1649 and 
1690 (2 x CO); OH (400 MHz; CDC!) 7.47 (lH, t, J=7.5 Hz, 6-H), 7.51 (lH, d, .1=8.6 Hz, 8-
H), 7.73 (lH, t, J=7.2 Hz, 7-H), 8.27 (lH, d, J=7.7 Hz, 5-H), 8.52 (lH, s, 2-H) and 10.35 
(lH, s, CHO); Oc (100 MHz; CDCh) 118.6 (C-8), 120.4 (C-3), 125.4 (C-4a), 126.2 (C-5), 
126.6 (C-6), 134.8 (C-7), 156.2 (C-8a), 160.5 (C-2), 175.9 (C=O) and 188.5 (CHO); m/z 174 
(M+, 6%) and 146 (100). 
6-Bromochromone-3-carbaldehyde 28229 
The experimental procedure employed for the synthesis of chromone-3-carbaldehyde 27 was 
followed, using POC!) (8.4 mL, 90 mmol), 5'-bromo-2'-hydroxyacetophenone 277 (5.0 g, 23 
mmol) and dry DMF (25 mL). Work-up afforded 6-bromochromone-3-carbaldehyde 282 as 
a yellow crystalline solid (4.2 g, 72%), m.p. 193-194°C (lit.,191 186-188 0C); Vmax (KBr)!cm-1 
1655 and 1699 (2 x CO); OH (400 MHz; CDCh) 7.42 (lH, d, J=8.8 Hz, 8-H), 7.82 (IH, dd, 
J=2.2 and 8.8 Hz, 7-H), 8.38 (lH, d, J=2.1 Hz, 5-H), 8.51 (lH, s, 2-H) and 10.33 (lH, s, 
CHO); Oc (100 MHz; CDC!) 120.3 (C-3), 120.4 (C-6), 120.5 (C-8), 126.6 (C-4a), 128.8 (C-
5),137.8 (C-7), 155.0 (C-8a), 160.6 (C-2), 174.6 (C=O) and 188.0 (CHO); m/z 252 (M", 4%) 
and 226 (100). 
6-Chlorochromone-3-carbaldehyde 28329 
The experimental procedure employed for the synthesis of chromone-3-carbaldehyde 27 was 
followed, using POC!) (18.7 mL, 200 mmol), 5'-chloro-2'-hydroxyacetophenone 278 (8.53 g, 
50.0 mmol) and dry DMF (50 mL). Work-up afforded 6-chlorochromone-3-carbaldehyde 
283 as a yellow crystalline solid (7.0 g, 67%), m.p. 166-168 °C (lit.,29 166-168 0C); Vmax 
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(KBr)/cm·11655 and 1695 (2 x CO); liH (400 MHz; CDCh) 7.49 (lH, d, J=8 .9 Hz, 8-H), 7.68 
(lH, dd, J=2.6 and 8.9 Hz, 7-H), 8.22 (IH, d, J=2.5 Hz, 5-H), 8.52 (1H, s, 2-H) and 10.33 
(lH, s, CHO); lic (100 MHz; CDCh) 120.2 (C-3), 120.3 (C-8), 125.6 (C-5), 126.3 (C-4a), 
132.8 (C-6), 135.0 (C-7), 154.5 (C-8a), 160.6 (C-2), 174.8 (C=O) and 188.0 (CHO); mlz208 
(M", 4%) and 180 (100). 
6-Fluorochromone-3-carbaldehyde 28429 
The experimental procedure employed for the synthesis of chromone-3-carbaldehyde 27 was 
followed, using POCh (8.40 mL, 90.0 mmol), 5'-fluoro-2'-hydroxyacetophenone 279 (5.0 g, 
32 mmol) and dry DMF (25 mL). Work-up afforded 6-fluorochromone-3-carbaldehyde 284 
as a yellow crystalline solid (3.6 g, 58%), m.p. 157-159 DC (lit.,176 158 DC); Vmax (KBr)/cm·1 
1657 and 1701 (2 x CO); liH (400 MHz; CDCh) 7.44 (lH, m, 7-H), 7.56 (lH, m, 8-H), 7.91 
(lH, dd, J=2.2 and 7.7 Hz, 5-H), 8.52 (1H, s, 2-H) and 10.34 (lH, s, CHO); lic (100 MHz; 
CDC!)) 111 .3 (JCF =23 Hz, C-5), 119.7 (C-4a), 120.8 (JCF =8.2 Hz, C-8), 123.0 (JCF =25 Hz, 
C-7), 126.7 and 126.8 (C-3 and C-6), 152.4 (C-8a), 160.6 (C-2), 175.2 (C=O) and 188.1 
(CHO); mlz 192 (M'", 4%) and 164 (100). 
6-Methoxychromone-3-carbaldehyde 28529 
The experimental procedure employed for the synthesis of chromone-3-carbaldehyde 27 was 
followed, using POCh (13.5 mL, 144 mmol), 5'-methoxy-2'-hydroxyacetophenone 280 (6.0 
g, 36 mmol) and dry DMF (25 mL). Work-up afforded 6-methoxychromone-3-carbaldehyde 
285 as a yellow crystalline solid (3 .88 g, 62%), m.p. 163-165 DC (lit.,29 164-166 DC); Vmax 
(KBr)/cm·11650 and 1690 (2 x CO); liH (400 MHz; CDCh) 3.90 (3H, s, OCH3), 7.30 (lH, dd, 
J=2.9 and 9.1 Hz, 7-H), 7.45 (lH, d, J=9.1 Hz, 8-H), 7.62 (IH, d, J=3.0 Hz, 5-H), 8.51 (lH, 
s, 2-H) and 10.37 (1H, s, CHO); lic (100 MHz; CDCh) 56.0 (OCH3), 105.4 (C-5), 119.5 (C-
3), 120.0 (C-8), 124.4 (C-7), 126.1 (C-4a), 151.0 (C-6), 157.9 (C-8a), 160.2 (C-2), 175.8 
(C=O) and 188.7 (CHO); mlz 204 (M'", 1%) and 176 (100). 
5-Methoxychromone-3-carbaldehyde 28629 
The experimental procedure employed for the synthesis of chromone-3-carbaldehyde 27 was 
followed, using POC!) (11.2 mL, 120 mmol), 6'-methoxy-2'-hydroxyacetophenone 281 (5.0 
g, 30 mmol) and dry DMF (25 mL). Work-up afforded 5-methoxychromone-3-carbaldehyde 
187 
Experimental 
286 as a yellow crystalline solid (3.2 g, 52%), m.p. 113-115 °c (lit.,29 115-116 0C); Vmax 
(KBr)/cm,lI650 and 1697 (2 x CO); OH (400 MHz; CDCh) 3.99 (3H, s, OCH3), 6.87 (lH, eI, 
.J.=8.3 Hz, 6-H), 7.05 (1H, del, J=0.7 and 8.3 Hz, 8-H), 7.60 (lH, t, J=8.4 Hz, 7-H), 8.36 (lH, 
s, 2-H) and 10.32 (IH, s, CHO); oe (100 MHz; CDCh) 56.5 (OCH3), 107.9 (C-6), 110.4 (C-
8), 115.5 (C-4a), 121.2 (C-3), 134.9 (C-7), 158.0 (C-8a), 158.7 (C-2), 160.3 (C-5), 175.8 
(C=O) and 189.1 (CHO); mlz 204 (M" 2%) and 176 (100). 
3.7 Morita-Baylis-Hillman reactions of chromone-3-carbaldehydes 
3.7.1 Reactions of chromone-3-carbaldehydes with acrylonitrile 
3-(3-Hydroxy-2-cyanopropen-3-yl)-4H-I-benzopyran-4-one 287 
Acrylonitrile (0.56 mL, 8.6 mmol) and 3-hydroxyquinuclidine (3.63 g, 28.8 mmol) were 
added to a stirred solution of chromone-3-carbaldehyde 27 (1.0 g, 5.7 mmol) dissolved in a 
minimum volume ofCHCh (8.0 mL). The resulting intense red mixture was stirred at room 
temperature for 25 h. Flash chromatography on silica gel [elution with hexane-EtOAc (2:3)] 
afforded 3-(3-hydroxy-2-cyanopropen-3-yl)-4H-l-benzopyran-4-one 287 as a yellow 
crystalline solid (0.83 g, 64%), m.p. 69-71 °C (lit. ,176 68-70 °C); (Found: M+, 227.0570. 
C13H9N03 requires M, 227.0582); vmax' (thin film)/cm,1 3430 (br, OH), 2225 (CN) and 1630 
(CO); OH (400 MHz; CDCh) 4.41 (lH,br s, 3'-OH), 5.30 (lH, s, 3'-H), 6.13 and 6.32 (2H, 2 x 
s, 1'-H), 7.45 (1H, m, 6-H), 7.50 (lH, eI, J=8.3 Hz, 8-H), 7.71 (IH, t, J=7.0 Hz, 7-H), 8.08 
(lH, s, 2-H) and 8.18 (lH, dd, .J.=1.4 and 8.0 Hz, 5-H); Oe (100 MHz; CDCh) 69.2 (C-3'), 
116.8 and 124.1 (C-2' or CN), 118.4 (C-8), 121.2 (C-3), 123.7 (C-4a), 125.6 (C-6), 125.8 (C-
5), 131.3 (C-l'), 134.5 (C-7), 153.9 (C-2), 156,3 (C-8a) and 177.7 (C=O); mlz 227 (M", 46%) 
and 210 (100). 
6-Bromo-3-(3-hydroxy-2-cyanopropen-3-ylj-4H-I-benzopyran-4-one 288 
The experimental procedure employed for the synthesis of 3-(3-hydroxy-2-cyanopropen-3-
yl)-4H-l-benzopyran-4-one 287 was followed, using 6-bromochromone-3-carbaldehyde 282 
(0.5 g, 2.0 mmol), acrylonitrile (0.20 mL, 3.0 mmol), 3-hydroxyquinuclidine (1.27 g, 10.0 
mmol) and CHCh (6.0 mL). Work-up afforded 6-bromo-3-(3-hydroxy-2-cyanopropen-3-yl)-
4H-l-benzopyran-4-one 288 as an orange-yellow solid (0.40 g, 67%), m.p. 123-125 °c 
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(lit.,176 122-125 0C); (Found: M", 304.9724. CI3HS79BrN03 requires M, 304.9688); Vmax (thin 
film)/cm-13420 (br, OH), 2225 (CN) and 1648 (CO); OH (400 MHz; CDCb) 4.10 (lH,br s, 3'-
OH), 5.33 (lH, s, 3'-H), 6.14 and 6.32 (2H, 2 x s, 1'-H), 7.40 (lH, d, .1=8.8 Hz, 8-H), 7.80 
(lH, dd, J=2.3 and 8.8 Hz, 7-H), 8.09 (lH, s, 2-H) and 8.28 (lH, d, J=2.3 Hz, 5-H); oe (100 
MHz; CDC!]) 68.8 (C-3'), 116.6 (CN), 119.3 (C-6), 120.3 (C-8), 121.6 (C-2'), 123.9 (C-3), 
124.9 (C-4a), 128.2 (C-5), 131.6 (C-l'), 137.5 (C-7), 154.l (C-2), 155.1 (C-8a) and 176.l 
(C=O); m/z 305 (M", 44%) and 253 (100). 
6-Chloro-3-(3-hydroxy-2-cyanopropen-3-yl)-4H-I-benzopyran-4-one 289 
The experimental procedure employed for the synthesis of 3-(3-hydroxy-2-cyanopropen-3-
yl)-4H-l-benzopyran-4-one 287 was followed, using 6-chlorochromone-3-carbaldehyde 283 
(0.50 g, 2.4 mmol), acrylonitrile (0.24 mL, 3.6 mmol), 3-hydroxyquinuclidine (1.53 g, 12.0 
rnmo1) and CHCb (7.0 mL). Work-up afforded 6-chloro-3-(3-hydroxy-2-cyanopropen-3-yl)-
4H-l-benzopyran-4-one 289 as a yellow crystalline solid (0.37 g, 59%), m.p. 133-134 °C 
(lit.,176 131-133 0C); (Found: M+, 261.0196. CI3HlsCIN03 requires M, 261.0193); Vrnax (thin 
film)/cm-1 3440 (hr, OH), 2300 (CN) and 1653 (CO); OH (400 MHz; CDCb) 4.16 (lH, d, 
.1=6.8 Hz, 3'-OH), 5.34 (1H, d, .1=6.5 Hz, 3'-H), 6.l3 and 6.32 (2H, 2 x s, l'-H), 7.47 (lH, d, 
.1=8.9 Hz, 8-H), 7.66 (lH, dd, J=2.5 and 8.9 Hz, 7-H), 8.09 (lH, s, 2-H) and 8.11 (lH, d, 
J=2.4 Hz, 5-H); oe (100 MHz; CDCb) 68.7 (C-3'), 116.6 and 123.9 (C-2' or CN), 120.1 (C-
8),121.7 (C-3), 124.5 (C-4a), 125.0 (C-5), 131.6 (C-1'), 131.8 (C-6), 134.7 (C-7), 154.l (C-
2), 154.6 (C-8a) and 176.3 (C=O); m/z 261 (M", 52%) and 209 (100). 
6-Fluoro-3-(3-hydroxy-2-cyanopropen-3-yl)-4H-I-benzopyran-4-one 290 
The experimental procedure employed for the synthesis of 3-(3-hydroxy-2-cyanopropen-3-
yl)-4H-l-benzopyran-4-one 287 was followed, using 6-fluorochromone-3-carbaldehyde 284 
(0.50 g, 2.6 mmo1), acrylonitrile (0.26 mL, 3.9 mmol), 3-hydroxyquinuclidine (1.66 g, 13.0 
mmol) and CHCb (6.0 mL). Work-up afforded 6-fluoro-3-(3-hydroxy-2-cyanopropen-3-yl)-
4H-1-benzopyran-4-one 290 as a yellow solid (0.34 g, 53%), m.p. 60-62 °C (lit./76 58-60 
0C); (Found: M +, 245.0490. C13HsFN03 requires M, 245.0488); Vrnax (thin film)/cm-1 3200 (hr, 
OH), 2235 (CN) and 1640 (CO); OH (400 MHz; CDCb) 4.16 (1H, d, .1=6.0 Hz, 3'-OH), 5.34 
(lH, d, J=4.0 Hz, 3'-H), 6.13 and 6.32 (2H, 2 x s, 1'-H), 7.46 (lH, m, 7-H), 7.52 (lH, m, 8-
H), 7.80 (lH, dd, J=2.9 and 8.0 Hz, 5-H) and 8.l0 (IH, s, 2-H); oe (100 MHz; CDCb) 68.8 
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(C-3'), 110.5 (JeF =23 Hz, C-5), 116.6 and 124.0 (C-2' or CN), 120.6 (JeF =8.1 Hz, C-8), 
120.9 (C-3), 122.8 (JeF = 25.4 Hz, C-7), 124.8 (JeF =7.5 Hz, C-4a), 131.4 (C-1'), 152.6 (C-
8a), 154.1 (C-2), 159.7 (JeF =246.8 Hz, C-6) and 176.7 (C=O); mlz 245 (M+, 57%) and 193 
(100). 
3-(3-Hydroxy-2-cyanopropen-3-yl)-6-methoxy-4H-l-benzopyran-4-one 291 
The experimental procedure employed for the synthesis of 3-(3-hydroxy-2-cyanopropen-3-
yl)-4H-1-benzopyran-4-one 287 was followed, using 6-methoxychromone-3-carbaldehyde 
285 (0.50 g, 2.5 mmol), acrylonitrile (0.24 mL, 3.7 mmol), 3-hydroxyquinuclidine (1.56 g, 
12.3 mmol) and CHCh (6.0 mL). Work-up afforded 3-(3-hydroxy-2-cyanopropen-3-yl)-6-
methoxy-4H-1-benzopyran-4-one 291 as a yellow solid (0.34 g, 54%), mp. 113-115 DC 
(lit.,176 114-117 DC); (Found: M+, 257.0686. C14Hl1N04 requires M, 257.0688); Vrnax (thin 
fIlm)/cm·l 3400 (hr, OH), 2225 (CN) and 1650 (CO); liH (400 MHz; CDCh) 3.89 (3H, s, 
OCH3), 4.50 (IH, s, J=4.0 Hz, 3'-OH), 5.33 (lH, d, J=3.8Hz, 3'-H), 6.10 and 6.30 (2H, 2 x s, 
I'-H), 7.27 (lH, dd, J=2.9 and 9.0 Hz, 7-H), 7.41 (lH, d, J=9.0 Hz, 8-H), 7.49 (lH, d, J=3.0 
Hz, 5-H) and 8.08 (lH, s, 2-H); lie (100 MHz; CDCh) 55.9 (OCH3), 68.8 (C-3'), 104.4 (C-5), 
116.8 (C-3), 119.8 (C-8), 120.7 (C-4a), 124.2 and 124.3 (C-2' or CN), 124.6 (C-7), 131.2 (C-
I'), 151.2 (C-8a), 153.7 (C-2), 157.3 (C-6) and 177.3 (C=O); mlz 257 (M.., 75%) and 205 
(100). 
3-(3-Hydroxy-2-cyanopropen-3-yl)-5-methoxy-4H-l-benzopyran-4-one 292 
The experimental procedure employed for the synthesis of 3-(3-hydroxy-2-cyanopropen-3-
yl)-4H-1-benzopyran-4-one 287 was followed, using 5-methoxychromone-3-carbaldehyde 
286 (0.50 g, 2.5 mmol), acrylonitrile (0.24 mL, 3.7 mmol), 3-hydroxyquinuc1idine (1.56 g, 
12.3 mmol) and CHCh (6.0 mL). Work-up afforded 3-(3-hydroxy-2-cyanopropen-3-y1)-5-
methoxy-4H-1-benzopyran-4-one 292 as a yellow solid (0.38 g, 60%), mp. 99-102 DC 
(lit.,176 97-100 DC) (Found: M+W, 258.0766. C14Hl1N04 requires M+H, 258.0766); Vmax 
(thin film)/cm" 1 3400 (hr, OH), 2355 (CN) and 1650 (CO); liH (400 MHz; CDCh) 3.99 (3H, s, 
OCH3), 4.60 (lH, s, J=7.2 Hz, 3'-OH), 5.18 (lH, d, )=5.6 Hz, 3'-H), 6.10 and 6.31 (2H, 2 x s, 
I'-H), 6.84 (lH, d, J=8.3 Hz, 6-H), 7.15 (1R, d, J=8.4 Hz, SoH), 7.60 (lH, t, )=8.4 Hz, 7-H) 
and 7.92 (lH, s, 2-H); lie (100 MHz; CDCh) 55.6 (OCH3), 69.6 (C-3'), 106.8 (C-6), 110.3 
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(C-8), 114.4 (C-4a), 117.0 (CN), 121.9 (C-3), 124.1 (C-2'), 131.2 (C-l'), 134.7 (C-7), 152.1 
(C-2), 158.3 (C-8a), 160.0 (C-5) and 177.7 (C=O); m/z257 (M", 19%) and 239 (100). 
3.7.2 Reactions of chromone-3-carbaldehydes with methyl acrylate 
3-(3-Hydroxy-2-methoxycarbonylpropen-3-yl)-4H-l-benzopyran-4-one 293 and the 
corresponding dimer 299 
Methyl acrylate (0.40 mL, .4.3 mmol) and 3-hydroxyquinuclidine (1.83 g, 14.4 mmol) were 
added to a stirred solution of chromone-3-carbaldehyde 27 (0.50 g, 2.9 mmol) dissolved in a 
minimum volume ofCHCh (6.0 mL). The resulting intense red mixture was stirred at room 
temperature for 24 h. Evaporation of the solvent gave, in vacuo an intense red oily residue. 
Flash chromatography on silica gel {elution with a mixture ofhexane-EtOAc-petroleum ether 
[b.p. 80-100oq-toluene (1:1:1:1)} afforded two fractions:-
i) 3-(3-hydroxy-2-methoxycarbonylpropen-3-yl)-4H-l-benzo-pyran-4-one 293 as a yellow 
solid (0.49 g, 66%), m.p. 108-110°C (lit.,176 109-112 °C); (Found: M", 260.0690. CI4HIZOS 
requires M, 260.0685); vmax(thin film)/cm'13420 (br, OR), 1720 and 1640 (2 x CO); 8H (400 
MHz; CDC!) 3.74 (3H, s, OCH3), 4.58 (lH,br s, 3'-OH), 5.59 (lH, s, 3'-H), 6.14 and 6.42 
(2H, 2 x s, 1'-H), 7.40 (lH, In, 6-H), 7.45 (lH, d, .1=8.3 Hz, 8-H), 7.68 (lH, In, 7-H), 8.D2 
(lH, s, 2-H) and 8.18 (lH, dd, J=1.4 and 8.0 Hz, 5-H); 8c (100 MHz; CDC!) 52.0 
(CO.OCH3), 67.6 (C-3'), 118.2 (C-8), 123.0 (C-3), 124.0 (C-4a), 125.4 (C-6), 125.6 (C-5), 
126.8 (C-l'), 134,0 (C-7), 139.5 (C-2'), 154.3 (C-2), 156,3 (C-8a), 166.5 (CO.O) and 177.9 
(C=O); m/z 260 (M", 7%) and 200 (100); and 
ii) The corresponding dimer 299 as a pale yellow solid (0 .. 25 g, 34%), m.p. 192-195 °C 
(lit.,176 193-194 °C) (Found: M+, 502.1250. Cz8Hzz09 requires M, 502.1257); Vrnax (thin 
fIlm)/cm"171O, 1705, 1650 and 1631 (4 x CO); 8H (400 MHz; CDC!) 3.12 and 3.38 (2H, 
dd, 13H), 3.61 (3H, s, 12-H), 3.65 (3H, s, 16-H), 4.50 (2H, dd, J=2.0 and 17.0 Hz, 2-Ha and 
2-Hb), 5.05 (lH, s, 9a-H), 6.90 (lH, t, J=7.8 Hz, 6-H), 6.97(lH, d, J=8.4Hz,5-H), 7.30 (lH, 
s, 4-H), 7.35(IH, t, J=8.4 Hz, 7-H), 7.40 (2H, In, 7'-H and 8'-H), 7.50 (lH, s, 17-H), 7.69 
(lH, t, J=7.2 Hz, 6'-H), 7.72 (Ill, dd, 8-H), 7.90 (lH, s, 2'-H) and 8.16 (lH, d, J= 7.2 Hz, 5'-
H); oe (100 MHz; CDC!) 28.4 (C-13), 50.3 (C-4a), 51.8 (C-12), 52.1 (C-16), 65.8 (C-2), 
99.9 (C-9a), 117.7 (C-8), 117.9 (C-8'), 119.9 (C-I0a), 120.5 (C-4a'), 122.7 (C-6), 123.9 (C-
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3'), 125.5 (C-6'), 126.2 (C-5), 127.7 (C-5'), 129.1 (C-3), 130.8 (C-14), 133.1 (C-17), 133.9 
(C-7'), 136.0 (C-7), 136.1 (C-4), 154.9 (C-2'), 155.8 (C-8a'), 157.1 (C-8a), 163.8 (C-11), 
167.3 (C-15), 174.9 (C-4') and 191.4 (C-I0); mlz 502 (M" 24%) and 243 (100). 
6-Bromo-3-(3-hydroxy-2-methoxycarbonylpropen-3-yl)-4H-l-benzopyran-4-one 294 and the 
corresponding dimer 300 
The experimental procedure employed for the synthesis of 3-(3-hydroxy-2-methoxycarbonyl-
propen-3-yl)-4H-l-benzopyran-4-one 293 and the corresponding dimer 299 was followed, 
using 6-bromochromone-3-carbaldehyde 282 (0.50 g, 2.0 romol), methyl acrylate (0.27 mL, 
3.0 romol), 3-hydroxyquinuclidine (1.26 g, 9.92 romol) and CHCh (3.0 mL). Work-up and 
flash chromatography afforded two fractions:-
i) 6-bromo-3-(3-hydroxy-2-methoxycarbonylpropen-3-yl)-4H-l-benzopyran-4-one 294 as a 
yellow solid (0.42 g, 63%), m.p. 114-116°C (lit.,l76 114-116 DC); (Found: ~, 337.9790. 
Cl4H1l79BrOs requires M, 337.9789); vmax(thin fIlm)/cm-1 3440 (br, OH), 1716 and 1642 (2 x 
CO); liH (400 MHz; CDCh) 3.75 (3H, s, OCH3), 4.38 (lH, d, J=7.8 Hz, 3'-OH), 5.59 (1H, d, 
J= 7.8 Hz, 3'-H), 6.11 and 6.42 (2H, 2 x s, I'-H), 7.37 (lH, d, .1=8.9 Hz, 8-H), 7.75 (1H, dd, 
J=2.5 and 9.0 Hz, 7-H), 8.02 (lH, s, 2-H) and 8.28 (IH, d, .1=2.5 Hz, 5-H); lie (100 MHz; 
CDCh) 52.0 (CO.OCH3), 67.5 (C-3'), 118.8 (C-8), 120.2 (C-6), 123.3 (C-3), 125.2 (C-4a), 
127.0 (C-l'), 128.3 (C-5), 137.0 (C-7), 139.2 (C-2'), 154.5 (C-2), 155.0 (C-8a), 166.5 (CO.O) 
and 176.5 (C=O); mlz 338 (M" 17%) and 280 (100); and 
i) The corresponding dimer 300 as a yellow solid (0.23 g, 37%), m.p. 222-224 DC (lit.,176 
223-225 DC) (Found: ~, 657.9471. C2sH2079Br209 requires M, 657.9474); Vmax (thin 
fJ.lm)/cm-1 1715, 1705,1650 and 1646 (4 x CO); liH (400 MHz; CDCh) 3.11 and 3.33 (2H, 
dd, 13H), 3.65 (3H, s, 12-H), 3.69 (3H, s, 16-H), 4.51 (2H, dd, J=2.0 and 17.0 Hz, 2-H. and 
2-Hb), 5.02 (m, s, 9a-H), 6.88 (lH, d, J=8.8 Hz, 8-H), 7.27(1H, In, 4-H), 7.35 (1H, d, J=8.9 
Hz, 7'-H), 7.41 (IH, dd, J=2.5 and 9.0 Hz, 7-H), 7.48 (lH, s, 17-H), 7.78 (IH, dd, J=2.5 and 
9.0 Hz, 8'-H), 7.81 (lH, d, J =2.5 Hz, 5-H), 7.88 (lH, d, J=l.O Hz, 2'-H) and 8.26 (lH, d, J= 
2.5 Hz, 5'-H); lie (100 MHz; CDCh) 28.4 (C-13), 50.3 (C-4a), 52.0 (C-12), 52.2 (C-I6), 66.0 
(C-2), 100.0 (C-9a), 115.7 (C-8), 119.2 (C-4a'), 119.8 (C-8~, 120.1 (C-I0a), 120.6 (C-6), 
121.3 (C-6'), 125.0 (C-3'), 128.8 (C-5'), 129.3 (C-3), 130.1 (C-5), 131.2 (C-14), 132.8 (C-17), 
135.4 (C-n 137.0 (C-7), 138.8 (C-4), 154.4 (C-2'), 155.0 (C-8a'), 156.0 (C-8a), 163.8 (C-
11),167.1 (C-15), 173.5 (C-4') and 190.2 (C-I0); mlz 658 (M"10%}'and 323 (100). 
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6-Chloro-3-(3-hydroxy-2-methoxycarbonylpropen-3-yl)-4H-I-benzopyran-4-one 295 and the 
corresponding dimer 301 
The experimental procedure employed for the synthesis of 3-(3-hydroxy-2-methoxycarbonyl-
propen-3-yl)-4H-l-benzopyran-4-one 293 and the corresponding dimer 299 was followed, 
using 6-chlorochromone-3-carbaldehyde 283 (0.50 g, 2.4 mmol), methyl acrylate (0.33 mL, 
3.6 mmol), 3-hydroxyquinuclidine (1.53 g, 12.0 mmol) and CHCh (3.0 mL). Work-up and 
flash chromatography afforded two fractions:-
i) 6-chloro-3-(3-hydroxy-2-methoxycarbonylpropen-3-yl)-4H-l-benzopyran-4-one 295 as a 
cream white solid (0.35 g, 50%), !D.p. 110-112 °C (lit.,m 108-110 0C); (Found: M+W, 
295.0373. Cl4HllsCIOs requires M+H, 295.0373); vrnax(thin film)/cm·1 3423 (br, OH), 1718 
and 1640 (2 x CO); BH (400 MHz; CDCh) 3.75 (3H, s, OCH3), 4.48 (lH, br s, 3'-OH), 5.60 
(JH, s, 3'-H), 6.12 and 6.44 (2H, 2 x s, 1'-H), 7.42 (lH, d, J=9.0 Hz, 8-H), 7.61 (lH, dd, 
J=2.5 and 9.0 Hz, 7-H), 8.04 (IH, s, 2-H) and 8.13 (lH, d, J=2.5 Hz, 5-H); Be (100 MHz; 
CDCh) 52.0 (CO.oCH3), 67.5 (C-3'), 120.0 (C-8), 123.2 (C-3), 124.8 (C-6), 125.1 (C-4a), 
127.0 (C- l'), 131.4 (C-5), 134.2 (C-7), 139.2 (C-2'), 154.5 (C-2), 154.6 (C-8a), 166.5 (CO.O) 
and 176.6 (C=O); mlz 294 cW, 3%) and 234 (100); and 
ii) The corresponding dimer 301 as a yellow solid (0.25 g, 50%), !D.p. 210-213 °C (lit., 176 
210-212 0C) (Found: M+W, 572.0636. C28H203SCh09 requires M+H, 572.0641); Vmsx (thin 
fJlm)/cm·1 1715, 1710, 1650 and 1646 (4 x CO); BH (400 MHz; CDCh) 3.10 and 3.35 (2H, 
dd, 13H), 3.67 (3H, s, 12-H), 3.69 (3H, s, 16-H), 4.52 (2H, dd, 2-H. and 2-Hb), 5.04 (lH, s, 
9a-H), 6.93 (lH, d, J=8.9 Hz, 8-H), 7.27(lH, m, 4-H), 7.29 (lH, m, 7-H), 7.42 (lH, d, J= 9.0 
Hz, 8'-H), 7.48 (IH, s, 17-H), 7.61 (lH, m, 7'-H), 7.65 (1H, d, J=2.4 Hz, 5-H), 8.00 (lH, s, 
2'-H) and 8.10 (lH, d, J= 2.5 Hz, 5'-H); Be (100 MHz; CDCh) 28.4 (C-13), 50.3 (C-4a), 5l.9 
(C-12), 52.2 (C-16), 66.0 (C-2), 100.0 (C-9a), 119.5 (C-8), 119.8 (C-8'), 120.5 (C-4a'), 120.8 
(C-3'), 125.5 (C-5'), 127.0 (C-5), 128.5 (C-IOa), 129.4 (C-3), 131.2 (C-14), 131.7 (C-6'), 
132.3 (C-I7), 134.3 (C-7'), 135.4 (C-7), 136.0 (C-4), 154.0 (C-8a'), 155.1 (C-2'), 155.6 (C-
8a), 163.8 (C-6), 167.1 (C-ll), 173.6 (C-15), 175.7 (C-4') and 190.3 (C-IO); mlz 571 (M'", 
38%) and 277 (100). 
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6-Fluoro-3-(3-hydroxy-2-methoxycarbonylpropen-3-yl)-4H-l-benzopyran-4-one 296 and the 
corresponding dimer 302 
The experimental procedure employed for the synthesis of 3-(3-hYdroXY-2-methoxycarbonYI-
propen-3-yl)-4H-l-benzopyran-4-one 293 and the corresponding dimer 299 was followed, 
using 6-fluorochromone-3-carbaldehyde 284 (0.50 g, 2.6 mrnol), methyl acrylate (0.35 mL, 
3.9 mrnol), 3-hydroxyquinuclidine (1.66 g, 13.0 mrnol) and CHCh (3 .0 mL). Work-up and 
flask chromatography afforded two fractions:-
i) 6-fluoro-3-(3-hydroxy-2-methoxycarbonylpropen-3-yl)-4H-l-benzopyran-4-one 296 as a 
yellow crystalline solid (0.50 g, 70%), m.p. 138-141 °C (lit.,176 140-142 0C); (Found: M', 
278.0596. C14HllFOs requires M, 278.0591); Vrnax (thin film)/cm·l 3420 (br, OH), 1710 and 
1637 (2 x CO); IiH (400 MHz; CDCh) 3.75 (3H, s, OCH3), 4.43 (lH, d, J=7.8 Hz, 3'-OH), 
5.60 (lH, d, J=8.0 Hz, 3'-H), 6.12 and 6.46 (2H, 2 x s, 1'-H), 7.40 (lH, Ill, 7-H), 7.48 (IH, 
dd, J=4.2 and 9.1 Hz, 8-H), 7.81 (lH, dd, J=3.0 and 8.3 Hz, 5-H) and 8.05 (lH, s, 2-H); lie 
(100 MHz; CDCh) 52.0 (CO.oCH3), 67.6 (C-3'), 110.5 (C-5), 120.4 (C-8), 122.3 (C-7), 
122.5 (C-3), 125.8 (C-4a), 126.9 (C-l'), 139.2 (C-2'), 152.5 (C-8a), 154.6 (C-2), 159.6 (C-6), 
166.5 (CO.O) and 177.1 (C=O); mlz 278 (M+, 34%) and 193 (100); and 
ii) The corresponding dimer 302 as a yellow solid (0.20 g, 30%), m.p. 200-202 °C (lit.,176 
198-200 0c) (Found: ~, 538.1074. C28H20F209 requires M, 538.1075); Vrnax (thin film)/cm-1 
1725,1713,1650 and 1646 (4 x CO); IiH (400 MHz; CDCh) 3.10 and 3.35 (2H, dd, 13H), 
3.64 (3H, s, 12-H), 3.70 (3H, s, 16-H), 4.51 (2H, dd, 2-Ha and 2-Hb), 5.01 (lH, s, 9a-H), 6.97 
(lH, dd, J=4.0 and 9.0 Hz, 5-H), 7.05 (lH, Ill, 7-H), 7.25 (IH, s, 4-H), 7j3 1{lH, d, J= 3.0 
and 7.8 Hz, 8-H), 7.38-7.48 (2H, m, 5'-H and 7'-H), 7.50 (lH, s, 17-H), 7.78 (lH, dd, J=2.8 
and 8.3 Hz, 8'-H) and 7.90 (IH, s, 2'-H); lie (100 MHz; CDCh) 28.4 (C-13), 50.2 (C-4a), 51.9 
(C-12), 52.2 (C-16), 65.9 (C-2), 100.1 (C-9a), 111.0 (C-8'), 112.7 (C-8), 119.5 (C-5), 119.8 
(C-3'), 120.2 (C-5'), 120.6 (C-I0a), 122.3 (C-7'), 123.6 (C-7), 124.9 (C-4a'), 129.4 (C-3), 
131.1 (C-14), 132.8 (C-17), 135.4 (C-4), 151.9 (C-8a'), 153.3 and 157.8 (C-8a and C-6~, 
155.1 (C-2'), 159.7 (C-6), 163.8 (C-l1), 167.1 (C-15), 174.0 (C-4') and 190.6 (C-I0); mlz 538 
(M', 21 %) and 261 (100). 
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3-(3-Hydroxy-2-methoxycarbonylpropen-3-yl)-6-methoxy-4H-I-benzopyran-4-one 297 and 
the corresponding dimer 303 
The experimental procedure employed for the synthesis of 3-(3-hydroxy-2-methoxycarbonyl-
propen-3-yl)-4H-l-benzopyran-4-one 293 and the corresponding dimer 299 was followed, 
using 6-methoxychromone-3-carbaldehyde 285 (0.50 g, 2.5 mmol), methyl acrylate (0.33 
mL, 3.7 mmol), 3-hydroxyquinuclidine (1.56 g, 12.3 mmol) and CHCh (3.0 mL). Work-up 
and flash chromatography afforded two fractions:-
i) 3-(3-hydroxy-2-methoxycarbonylpropen-3-yl)-6-methoxy-4H-l-benzopyran-4-one 297 as a 
pale yellow oil (0.42 g, 60%) (Found: M+, 290.0780. ClsH1406 requires M, 290.0790); Vrnax 
(thin film)/cm-1 3425 (br, OH), 1720 and 1640 (2 x CO); <>H (400 MHz; CDCh) 3.70 (3H, s, 
CO.OCH3), 3.81 (3H, s, 6-0CH3), 4.68 (lH, d, J=4.5 Hz, 3'-OH), 5.60 (lH, d, J=2.5 Hz, 3'-
H), 6.10 and 6.39 (2H, 2 x s, l'-H), 7.18 (Ill, dd, J=3.0 and 9.1 Hz, 7-H), 7.30 (Ill, d, J=9.1 
Hz, 8-H), 7.44 (lH, d, J=3.0 Hz, 5-H) and 7.98 (lH, s, 2-H); <>c (100 MHz; CDCh) 51.7 
(CO.OCH3), 55.6 (6-0CH3), 67.1 (C-3'), 104.3 (C-5), 119.4 (C-8), 122.2 (C-3), 123.9 (C-7), 
124.3 (C-4a), 126.3 (C-l'), 139.7 (C-2'), 150.9 (C-8a), 154.0 (C-2), 156.8 (C-6), 166.3 
(CO.O) and 177.4 (C=O); mlz 290 (M" 26%) and 151 (100); and 
ii) the corresponding dimer 303 as a pale yellow viscous oil (0.26 g, 40%) (Found: M+, 
562.1467. C30H26011 requires M, 562.1475); vmax(thin film)/cm-11722, 1715, 1650 and 1646 
(4 x CO); <>H (400 MHz; CDCb) 3.11 and 3.35 (2H, dd, 13H), 3.60 (3H, s, 12-H), 3.70 (3-H, 
S, 6-0CH3), 3.78 (3H, s, 16-H), 3.89 (3H, S, 6'-OCH3), 4 .39-4.53 (2H, dd, 2-H. and 2-Hb), 
5.45 (IH, s, 9a-H), 6.70 (lH, s, 4-H), 6.73 (lH, d, J=9.0 Hz, 8-H), 7.00 (lH, m, 7-H), 7.10 
(lH, d, J= 3.0 Hz, 5-H), 7.26 (lH, dd, J=3 .0 and 9.0 Hz, 7'-H), 7.38 (lH, d, J=9.1Hz, 8'-H), 
7.50 (Ill, d, J=3.2 Hz, 5'-H), 7.55 (lH, s, 17-H) and 7.91 (IH, s, 2'-H); <>c (100 MHz; CDCh) 
31.2 (C-13), 51.0 (C-4a), 51.7 (C-12), 52.2 (C-16), 55.7 (6-0CH3), 55.9 (6'-OCH3), 62.9 (C-
2),99.2 (C-9a), 105.3 (C-5'), 107.6 (C-5), 119.0 (C-I0a), 119.2 (C-8), 119.4 (C-8'), 119.6 (C-
3'), 123.9 (C-T), 124.5 (C-4a~, 125.6 (C-7), 129.9 (C-3), 130.6 (C-14), 133.3 (C-I7), 135.0 
(C-4), 150.7 (C-8a'), 151.8 (C-8a), 154.3 (C-2'), 154.7 (C-6), 157.1 (C-6'), 163.9 (C-11), 
167.8 (C-15), 175.1 (C-4') and 192.4 (C-I0); mlz 562 (M" 37%) and 289 (100). 
3 -(3-Hydroxy-2-methoxycarbonylpropen-3-yl)-5-methoxy-4H-l-benzopyran-4-one 298 
The experimental procedure employed for the synthesis of 3-(3-hydroxy-2-methoxycarbonyl-
propen-3-yl)-4H-l -benzopyran-4-one 293 and the corresponding dimer 299 was followed, 
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using 5-methoxychromone-3-carbaldehyde 285 (0.50 g, 2.5 mmol), methyl acrylate (0.33 
mL, 3.7 mmol), 3-hydroxyquinuclidine (1.56 g, 12.3 mmol) and CHCh (3.0 mL). Work-up 
and flash chromatography afforded 3-(3-hydroxy-2-methoxycarbonylpropen-3-yl)-5-
methoxy-4H-l-benzopyran-4-one 298 as a yellow viscous oil (0.56 g, 79%) (Found: M+W, 
291.0869. C1sHl406 requires M+H, 291.0869); Vrnax (thin film)!cm-1 3420 (br, OH), 1722 and 
1653 (2 x CO); liH (400 MHz; CDCI3) 3.71 (3H, s, CO.OCH3), 3.95 (3H, s, 5-0CH3), 4.78 
(lH, d, J=7.1 Hz, 3'-OH), 5.51 (lH, br s, 3'-H), 6.19 and 6.43 (2H, 2 x s, 1'-H), 6.80 (lH, d, 
J=8.2 Hz, 6-H), 7.00 (lH, d, J=8.4 Hz, 8-H), 7.54 (lH, t, J=8.3 Hz, 7-H) and 7.87 (lH, s, 2-
H); lie (100 MHz; CDCh) 51.8 (CO.OCH3), 56.4 (5-0CH3), 68.0 (C-3'), 106.3 (C-6), 110.2 
(C-8), 114.6 (C-4a), 123.5 (C-3), 127.0 (C-1'), 134.1 (C-7), 139.2 (C-2'), 152.5 (C-2), 158.2 
(C-8a), 160.0 (C-5), 166.5 (CO.O) and 178.2 (C=O); m/z 290 (M'", 41%) and 230 (100). 
3.7.3 Formation of the chromone dimers 
The chromone dimer 299 
A mixture of 3-(3-hydroxy-2-methoxycarbonylpropen-3-yl)-4H-1-benzopyran-4-one 293 
(50.0 mg, 0.192 mmol) and DABCO (50.0 mg, 0.446 mmol) was heated at 80°C in an oil 
bath for 3 h (the reaction being monitored by TLC). Chromatography of the reaction mixture 
on chromatotron [elution with hexane-EtOAc-toluene (1:1:1)] afforded the chromone dimer 
299 (30 mg, 62%). 
The chromone dimer 300 
The experimental procedure employed for the synthesis of the chromone dimer 299 was 
followed, using 6-bromo-3-(3-hydroxy-2-methoxycarbonylpropen-3-yl)-4H-1-benzopyran-4-
one 294 (50.0 mg, 0.148 mmol) and DABCO (50.0 mg, 0.446 mmol). Work-up and 
chromatography afforded the chromone dimer 300 (28 mg, 59%). 
The chromone dimer 301 
The experimental procedure employed for the synthesis of the chromone dimer 299 was 
fo llowed, using 6-chloro-3 -(3-hydroxy-2-methoxycarbonylpropen-3 -yl)-4H-1-benzopyran-4-
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one 295 (50.0 mg, 0.169 mmol) and DABCO (50.0 mg, 0.446 mmol). Work-up and 
chromatography afforded the chromone dimer 301 (22 mg, 68%). 
The chromone dimer 302 
The experimental procedure employed for the synthesis of the chromone dimer 299 was 
fo llowed, using 6-fluoro-3-(3 -hydroxy-2-methoxycarbonylpropen-3-yl)-4 H-l-benzopyran-4-
one 296 (50.0 mg, 0.180 mmol) and DABCO (50.0 mg, 0.446 mmol). Work-up and 
chromatography afforded the chromone dimer 302 (24 mg, 49%). 
The chromone dimer 303 
The experimental procedure employed for the synthesis of the chromone dimer 299 was 
foHowed, using 3-(3-hydroxy-2-methoxycarbonylpropen-3-yl)-6-methoxy-4H-l-benzopyran-
4-one 297 (50.0 mg, 0.172 mmol) and DAB CO (50.0 mg, 0.446 mmol). Work-up and 
chromatography afforded the chromone dimer 303 (25 mg, 51 %). 
The chromone dimer 304 
The experimental procedure employed for the synthesis of the chromone dimer 299 was 
followed, using 3-(3-hydroxy-2-methoxycarbonylpropen-3-yl)-5-methoxy-4H-l-benzopyran-
4-one 298 (50.0 mg, 0.172 mmol) and DABCO (50.0 mg, 0.446 mmol). Work-up and 
chromatography afforded the chromone dimer 304 as a yellow viscous oil (27 mg, 55%), 
(Found: M+, 562.1461. C30R260 11 requires M, 562.1469); Vrnax (thin fiIm)/cm-1 1725, 1719, 
1647 and 1644 (4 x CO); IiH (400 MHz; CDCh) 3.09 and 3.37 (2R, dd, 13H), 3.62 (3H, s, 12-
H), 3.76 (3-R, s, 5-0CR3), 3.79 (3H, s, 16-H), 4.00 (3R, s, 5'-OCR3), 4.42-4.60 (2R, In, 2-R. 
and 2-Rb), 5.47 (lH, s, 9a-H), 6.75 (lR, s, 4-H), 6.83 (1H, d, J=8.0 Hz, 6-H), 7.03 (lH, d, 
J=8.3 Hz, 8-H), 7.07 (lH, dd, 7-H)' 7.09 (IR, d, J= 8.5 Hz, 6'-H), 7.15 (lH, d, J=9.0 Hz, 8'-
H), 7.20 (IR, dd, 7'-H), 7.53 (lH, s, 17-H) and 7.93 (lH, s, 2'-H); Be (100 MHz; CDCh) 31.0 
(C-13), 51.3 (C-4a), 51.9 (C-12), 52.1 (C-I6), 56.4 (5-0CH3), 56.6 (5'-OCR3), 63.1 (C-2), 
100.0 (C-9a), 106.1 (C-6'), 107.0 (C-6), 120.1 (C-I0a), 120.2 (C-8), 120.4 (C-8'), 120.5 (C-
3'), 124.2 (C-7~, 124.6 (C-4a'), 125.0 (C-7), 130.0 (C-3), 130.1 (C-14), 133.8 (C-I7), 135.2 
(C-4), 151.3 (C-8a'), 152.0 and 157.4 (C-8a and C-5'), 154.9 (C-2'), 155.5 (C-5), 163.7 (C-
11),168.0 (C-15), 175.4 (C-4') and 192.8 (C-IO); m/z 562 (M+, 32%) and 289 (100). 
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3.7.4 Attempted/ormation o/the bischromone-acrylonitrile adduct 
Method 1 
3-(3-Hydroxy-2-cyanopropen-3-yl)-4H-l-benzopyran-4-one 287 (260 mg, 1.15 mmol), 
chromone-3-carbaldehyde 27 (200 mg, 1.15 mmol) and 3-hydroxyquinuclidine (292 mg, 2.30 
mmol) were dissolved in a minimum volume of CHCh (3 .0 mL). The mixture was stirred at 
room temperature for 7 days, after which IH NMR analysis indicated that the starting 
materials were eventually unchanged. 
Method 2 
3-(3-Hydroxy-2-cyanopropen-3-yl)-4H-I-benzopyran-4-one 287 (260 mg, 1.15 mmol), 
chromone-3-carbaldehyde 27 (200 mg, 1.15 mmol) and DABCO (258 mg, 2.30 mmol) were 
dissolved in a minimum volume of CHCiJ (2.0 mL). The mixture was stirred at room 
temperature for 7 days, after which IH NMR analysis indicated that the starting materials 
were eventually unchanged. 
Method 3 
3-(3-Hydroxy-2-cyanopropen-3-yl)-4H-l-benzopyran-4-one 287 (0.26 g, 0.68 mmol), 
chromone-3-carbaldehyde 27 (0.10 g, 0.68 mmol) and DAB CO (130 mg, 1.15 mmol) were 
dissolved in a mixture of dioxane-H20 (2:1) (3.0 mL). The mixture was stirred at room 
temperature for 2 days, after which 1 H NMR analysis indicated that the starting materials 
were eventually unchanged. 
3.8 Synthesis of chromone-2-carbaldehydes 
1-[2-HydroxyphenylJ-I,3-butanedione 30648,50 
A mixture of o-hydroxyacetophenone 43 (10 mL, 83 mmol) and dry EtOAc (35 mL, 0.36 
mol) was added dropwise to a stirred suspension ofNaOEt [generated in situ by adding Na 
metal (8.0 g, 0.35 mol) to dry EtOH (40 mL)]. The resulting yellow mixture was boiled 
198 
Experimental 
gently under reflux for 8 h, during which time a thick yellow slurry was formed. After 
cooling, the reaction mixture was poured into EhO (200 mL) and, after standing for 1 h, the 
yellow sodium salt was filtered off, washed with EhO and dissolved in ice-cold water 
(100mL). The resulting solution was acidified with acetic acid, and the resulting precipitate 
filtered off and recrystallized from petroleum-ether (b.p. 60-80 DC) to afforded 1-[2-
hydroxyphenyl]-1,3-butanedione 306 as a colourless solid (9.1 g, 63%), which was used 
immediately without further purification. 
1-[2-Hydroxy-5-j[uorophenyl}-1,3-butanedione 30748,50 
The experimental procedure employed for the synthesis of 1-[2-hydroxyphenyl]-1,3-
butanedione 306 was followed, using S'-fluoro-2'-hydroxyacetophenone 175 (2.0 g, 13 
romol), dry EtOAc (8.0 mL, 82 romol) and NaOEt [generated in situ by adding Na metal 
(1.84 g, 79.8 romol) to dry EtOH (9.0 mL)]. Worked-up afforded 1-[2-hydroxy-S-
fluorophenyl]-1,3-butanedione 307 as a yellow solid (1.5 g, 60%), which was used 
immediately without further purification. 
1-[2-Hydroxy-5-methoxyphenyl}-1,3-butanedione 30848 ,50 
. The experimental procedure employed for the synthesis of 1-[2-hydroxyphenyl]-1,3-
butanedione 306 was followed, using S'-methoxy-2'-hydroxyacetophenone 305 (10 g, 60 
romol), dry EtOAc (26 mL, 0.26 mol) and NaOEt [generated in situ by adding Na metal (S.83 
g, 2S2 romol) to dry EtOH (29 mL)]. Worked-tip afforded 1-[2-hydroxy-S-methoxyphenyl]-
1,3-butanedione 308 as a yellow solid (6.3 g, 51%), which was used immediately without 
further purification. 
2-Methylchromone 1948,50 
A mixture of 1-[2-hydroxyphenyl]-1,3-butanedione 306 (5.0 g, 28 romol), glacial acetic acid 
(25 mL) and conc. H2S04 (1.0 mL) was boiled under reflux for 4 h (until the solution 
becomes brick red). The hot solution was poured into ice-cold water (100 mL), the resulting 
mixture basified with 10% aq. NaHCOJ , and the precipitated solid filtered off and washed 
with ice-cold water. Recrystallization from hexane afforded 2-methylchromone 19 as a 
yellow solid (3.6 g, 80%), m.p. 70-71 DC (lit.,49 69-70 DC) (Found: M+, 160.05326. CIOH802 
requires M. 160.0S243); OH (400 MHz; CDCb) 2.36 (3H, s, CHJ), 6.1S (IH, s, 3-H), 7.33-
7.40 (2H, In, 6-H and 8-H), 7.62 (lB, In, 7-H) and 8.16 (1H, dd, J=1.6 and 8.0 Hz, SoH); oe 
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(100 MHz; CDCh) 20.5 (CH3), 110.5 (C-3), 117.7 (C-8), 123.5 (C-4a), 124.9 (C-6), 125.6 
(C-5), 133.4 (C-7), 156.5 (C-8a), 166.2 (C-2) and 178.2 (C=O); m/z 160 (M', 100%). 
6-Fluoro-2-methylchromone 30948•50 
The experimental procedure employed for the synthesis of 2-methylchromone 19 was 
followed, using 1-[2-hydroxy-5-fluorophenyl]-1,3-butanedione 307 (3.5 g, 18 mmol), glacial 
acetic acid (20 mL) and cone. H2S04 (0.8 mL). Work-up afforded 6-fluoro-2-
methylchromone 309 as a yellow solid (2.25 g, 71%), m.p. 101-102 DC (lit.,m 101-102 DC) 
(Found: M" 178.04377. C1OH7F02 requires M, 178.04301); IiH (400 MHz; CDCh) 2.37 (3H, 
s, CH3), 6.14 (1H, s, 3-H), 7.31-7.42 (2H, m, 7-H and 8-H) and 7.78 (1H, dd, J=3.1 and 8.2 
Hz, 5-H); lie (100 MHz; CDCh) 20.5 (CH3), 109.9 (C-3), 110.6 (C-5), 119.8 (C-7), 119.9 (C-
6), 121.4 (C-8), 121.6 (C-4a), 160.6 (C-8a), 166.4 (C-2) and 177.3 (C=O); m/z 178 (M', 
100%). 
6-Methoxy-2-methylchromone 31048,50 
The experimental procedure employed for the synthesis of 2-methylchromone 19 was 
followed using 1-[2-hydroxy-5-methoxyphenyl]-1,3-butanedione 308 (5.0 g, 24 mmol), 
glacial acetic acid (25 mL) and cone. H2S04 (1.0 mL). Work-up afforded 6-methoxy-2-
methylchromone 310 as a yellow solid (4.0 g, 88%), m.p. 105-106 DC (lit.,193 107-108 DC) 
(Found: M+, 190.06296. CIlH100 3 requires M, 190.06299); IiH (400 MHz; CDCh) 2.35 (3H, 
s, CH3), 3.86 (3H, s, OCH3), 6.14 (lH, s, 3-H), 7.20 (lH, m, 8-H), 7.72 (lH, d, J=9.1Hz, 7-H) 
and 7.53 (IH, d, J=3 .0Hz, 5-H); lie (100 MHz; CDC!]) 20.5 (CH3), 55.9 (OCH3), 104.9 (C-5), 
109.8 (C-3), 119.1 (C-7), 123.4 (C-8), 124.1 (C-4a), 151.3 (C-6), 156.8 (C-8a), 165.9 (C-2) 
and 178.0 (C=O); m/z 190 (M', 100%). 
Chromone-2-carbaldehyde 2675,102 
A stirred solution of2-methylchromone 19 (0.50 g, 3.0 mmol) and Se02 powder (1.7 g, 15 
mmol) in xylene (10 mL) was boiled under reflux on an oil bath at 160-165 DC for 12 h. The 
reaction mixture was filtered while hot to remove the black selenium, and the filtrate 
concentrated in vacuo. Flash chromatography of the residue on silica gel (elution with 
chloroform) afforded chromone-2-carbaldehyde 26 as a yellow solid (0.20 g, 40%), m.p. 160-
200 
Experimental 
162°C (lit.,16 162-163 °C) (Found: M., 174.03178. CIO~03 requires M, 174.03169); Vmax 
(KBr)/cm'l 1653 and 1701 (2 x CO); OH (400 MHz; CDCh) 6.90 (1H, s, 3-H), 7.47 (lH, t, 
J=7.4 Hz, 6-H), 7.60 (1H, d, J=8.4 Hz, 8-H), 7.78 (lH, m, 7-H), 8.20 (lH, d, J=8.0 Hz, 5-H) 
and 9.79 (lH, s, CHO); oe (100 MHz; CDCh) 117.0 (C-3), 118.8 (C-8), 124.9 (C-4a), 125.9 
(C-6), 126.2 (C-5), 135.2 (C-7), 155.6 (C-8a), 156.0 (C-2), 178.3 (C=O) and 185.5 (CHO); 
mlz 174 (M., 100%). 
6-Fluorochromone-2-carbaldehyde 311 
The experimental procedure employed for the synthesis of chromone-2-carbaldehyde 26 was 
followed, using 6-fluoro-2-methylchromone 309 (0.50 g, 2.8 mmol), Se02 powder (1.7 g, 15 
mmol) and xylene (10 mL). Work-up afforded 6-jluorochromone-2-carbaldehyde 311 as a 
yellow solid (0.21 g, 38%), !D.p. 156-158 °C (Found: M., 192.02299. ClOHSF03 requires M, 
192.02227); Vrnax (KBr)/cm'l 1655 and 1704 (2 x CO); OH (400 MHz; CDCh) 6.89 (1H, s, 3-
H), 7.50 (lH, m, 7-H), 7.63 (lH, m, 8-H), 7.84 (lH, m, 5-H), and 9.79 (lH, s, CHO); oe (100 
MHz; CDCh) 110.8 (C-3), 111.0 (C-5), 115.8 (C-7), 121.0 (C-6), 121.1 (C-8), 123.7 (C-4a), 
155.0 (C-8a), 156.1 (C-2), 177.5 (C=O) and 185.1 (CHO); mlz 192 (M" 100%). 
6-Methoxychromone-2-carbaldehyde 312 
The experimental procedure employed for the synthesis of chromone-2-carbaldehyde 26 was 
followed using, 6-methoxy-2-methylchromone 310 (0.50 g, 2.8 mmol), Se02 powder (0.5 g, 
4;0 mmol) and xylene (10 mL). Work-up afforded 6-methoxychromone-2-carbaldehyde 312 
as a yellow solid (0.20 g, 35%), m.p. 174-176 °C (Found: M", 204.04304. CllHs04 requires 
M, 204.04226); vrnax (KBr)/cm,11652 and 1699 (2 x CO); OH (400 MHz; CDCh) 3.91 (3H, s, 
OCH3), 6.88 (lH, s, 3-H), 7.36 (lH, m, 8-H), 7.53-7.56 (2H, m, 5-H and 7-H), and 9.78 (1H, 
s, CHO); oe (100 MHz; CDCh) 56.0 (OCH3), 104.9 (C-5), 115.8 (C-3), 120.2 (C-7), 124.5 
(C-8), 125.7 (C-4a), 152.0 (C-6), 156.0 (C-8a), 157.8 (C-2), 178.1 (C=O) and 185.5 (CHO); 
mlz 204 (M" 100%). 
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